

**Funding Opportunities Monthly Edition
March 2021 Due Dates**

Introduction

This funding opportunity packet contains information on funding opportunities with deadlines in March 2021. The opportunities are organized in the following order:

1. [National Institutes of Health \(NIH\)](#)
2. [National Science Foundation \(NSF\)](#)
3. [Other Federal](#)
4. [Non Federal](#)

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
077911	Mechanisms of Disparities in Etiology and Outcomes of Lung Cancer in the U.S.: The Role of Risk and Protective Factors (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PA-19-019	04-Feb-2021 [Optional][LOI/Pre-App]	275,000 USD
	<p>Contact Name Crystal Wolfrey</p> <p>Contact Telephone 240-276-6277</p> <p>Contact Email Crystal.wolfrey@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 04-Feb-2021 [Optional][LOI/Pre-App], 04-Mar-2021</p> <p>Synopsis National Cancer Institute (NCI) invites applications that will support exploratory and developmental multidisciplinary research to understand the underlying causal factors and mechanisms that result in lung cancer disparities in U.S. health disparity populations. This FOA will use the NIH Exploratory/Development Research Grant (R21) award mechanism. The purpose of this initiative is to promote multidisciplinary research to understand the underlying causal factors and mechanisms that result in lung cancer disparities in U.S. health disparity populations.</p>				
077905	Mechanisms of Disparities in Etiology and Outcomes of Lung Cancer in the U.S.: The Role of Risk and Protective Factors (R01 - Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PA-19-018	04-Feb-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Crystal Wolfrey</p> <p>Contact Telephone 240-276-6277</p> <p>Contact Email Crystal.wolfrey@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 04-Feb-2021 [Optional][LOI/Pre-App], 04-Mar-2021</p> <p>Synopsis National Cancer Institute (NCI) invites applications that will support multidisciplinary research to understand the underlying causal factors and mechanisms that result in lung cancer disparities in U.S. health disparity populations. This FOA will use the NIH Research Project (R01) award mechanism. The purpose of this initiative is to promote multidisciplinary research to understand the underlying causal factors and mechanisms that result in lung cancer disparities in U.S. health disparity populations.</p>				
099847	RFA-CA-20-051 -- Social and Behavioral Intervention Research to Address	National Cancer Institute/NIH/DHHS	RFA-	15-Mar-2021	3,500,000

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Modifiable Risk Factors for Cancer in Rural Populations (R01 Clinical Trial Required)			CA-20-051	USD
	<p>Contact Name Kelly D. Blake, ScD</p> <p>Contact Telephone 240-281-5934</p> <p>Contact Email kelly.blake@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Mar-2021 , 18-Jan-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to develop, adapt, and test individual-, community- or multilevel interventions to address modifiable risk factors for cancer in rural populations. Applications should focus on primary prevention and assess and address one or more of the social and behavioral risk factors that contribute to cancer disparities in rural populations: tobacco use; diet, physical activity and weight; alcohol use; UV exposure; and HPV vaccination. Applications should also assess and address myriad social determinants of health, cultural factors, and health care and technology access barriers that may contribute to rural cancer disparities. This FOA also encourages implementation science research, to incorporate efficacious cancer control interventions in a coordinated way, into broader, sustainable health programs that are designed to reach rural populations and allow local customization and adaptation.</p>				
085349	Small Cell Lung Cancer (SCLC) Consortium: Biology, Therapy and Resistance (U01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-19-361	11-Mar-2021	2,250,000 USD
	<p>Contact Name Suzanne Forry, PhD</p> <p>Contact Telephone 240-276-5922</p> <p>Contact Email forryscs@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Mar-2021 , 12-Nov-2021 , 11-Mar-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications for research projects to join the Small-Cell Lung Cancer (SCLC) Consortium. Goals of the SCLC Consortium pertinent to this FOA are: 1) to learn the mechanistic and biological underpinnings of SCLC formation, progression and heterogeneity; 2) to investigate how molecular vulnerabilities could be used to develop targeted agents or combinations; and 3) to understand clinical resistance to drug and radiation therapy and its rapid development.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
045115	Short-Term Scientist Exchange Program	National Cancer Institute/NIH/DHHS		01-Mar-2021	Not Specified
	<p>Contact Name Dr. Vidya Vedham</p> <p>Contact Telephone 240-276-7272</p> <p>Contact Email NCICenterforGlobalHe@mail.nih.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL</p> <p>Deadline Dates (ALL) 01-Mar-2021 , 01-Jul-2021 , 01-Oct-2021</p> <p>Synopsis The Short-Term Scientist Exchange Program (STSEP) promotes collaborative research between researchers at the National Cancer Institute (NCI) and scientists from low-, middle-, and upper-middle income countries.</p>				
101090	RFA-RM-20-022 -- NIH Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Program: FIRST Cohort (U54 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA- 30-Jan-2021 RM-20- [Optional][LOI/Pre-App]		3,695,000 USD
	<p>Contact Name Sanya A. Springfield, Ph.D.</p> <p>Contact Telephone 240-276-6170</p> <p>Contact Email FIRSTNIH@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 30-Jan-2021 [Optional][LOI/Pre-App], 01-Mar-2021</p> <p>Synopsis The purpose of the FIRST Cohort is to transform culture at NIH-funded extramural institutions by building a self-reinforcing community of scientists committed to diversity and inclusive excellence (defined below). Implementing and sustaining cultures of inclusive excellence within the program has the potential to be transformational for biomedical research at the awardee institutions and beyond. This community will be built through recruitment of a diverse group of early-career faculty who are competitive for an advertised research tenure-track or equivalent faculty position and who have demonstrated strong commitment to promoting diversity and inclusive excellence. This Funding Opportunity Announcement (FOA) is developed as a Common Fund initiative (https://commonfund.nih.gov/) through the Office of the NIH Director, Office of Strategic Coordination. All NIH Institutes and Centers participate in Common Fund initiatives. The FOA will be administered by a trans-NIH team, which will be led by the National Cancer Institute (NCI) on behalf of the NIH.</p>				
076438	Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial)	National Cancer Institute/NIH/DHHS	PAR-	08-Mar-2021	1,250,000

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Optional)		18-869		USD
	Contact Name	Scott Rogers, MPH			
	Contact Telephone	240-276-6932			
	Contact Email	rogerssc@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	08-Mar-2021			
	Synopsis	National Cancer Institute (NCI) invites applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, and implementation science. This FOA will use the NIH Research Project (R01) award mechanism.			
077749	Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-18-947	15-Mar-2021	1,250,000 USD
	Contact Name	Abhi Rao, Ph.D.			
	Contact Telephone	240-276-5715			
	Contact Email	abhi.rao@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Mar-2021 , 11-Jul-2021			
	Synopsis	This Funding Opportunity Announcement (FOA) will support extramural research to investigate and mitigate challenges facing clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies, blood biospecimens utilized as “liquid biopsies, or other biospecimens as described in this FOA. Extramural research funded under this FOA may include investigations of preanalytical variability associated with the procurement and study of small biopsies (core biopsies, small excision samples), blood utilized for liquid biopsies, tissue swabs, tissue secretions, pleural and esophageal aspirates, feces, or bodily fluids like sweat, urine, CSF, breast milk and saliva. Investigator-designed experiments will explore how different biospecimen preanalytical conditions affect emerging and clinically relevant biomarkers quantified by a variety of testing platforms. The results from this research program will improve the understanding of how analytical quantification of clinically relevant biomarkers is affected by variation in biospecimen			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
					collection, processing, and storage procedures. The overall goal is to expedite biomarker clinical assay development through evidence-based standardization of biopsy handling practices.
101128	RFA-CA-21-002 -- Cellular Cancer Biology Imaging Research (CCBIR) Program (U54, Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA-21-002	16-Feb-2021 [Optional][LOI/Pre-App]	6,250,000 USD
	<p>Contact Name: Nastaran Zahir, Ph.D.</p> <p>Contact Telephone: 240-276-6333</p> <p>Contact Email: nas.zahir@nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 16-Feb-2021 [Optional][LOI/Pre-App], 18-Mar-2021</p> <p>Synopsis: The National Cancer Institute (NCI) invites applications for Cellular Cancer Biology Imaging Research (CCBIR) Centers. The Centers will develop and test enabling imaging technologies at the cellular and organ scales driven by specific fundamental questions in cancer biology. The overall purpose of the CCBIR initiative is to facilitate innovation in advanced imaging technologies that could be applied to fundamental basic and pre-clinical research problems in cancer biology. CCBIR Centers are structured to operate collaboratively between technology developers and cancer biologists at the forefront of their respective fields. CCBIR Centers will increase in experimental sophistication over time to ultimately produce an interoperable suite of state-of-the-art imaging technologies with transformative potential to study the cancer biology process(es) that defines the Center. The cadre of CCBIR Centers will form a consortium that will be expected to engage with the broader cancer research community.</p>				
098641	NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-20-292	19-Feb-2021	275,000 USD
	<p>Contact Name: William C. Timmer, Ph.D</p> <p>Contact Telephone: 240-276-6130</p> <p>Contact Email: william.timmer@nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 19-Feb-2021 , 19-Mar-2021 , 21-Jun-2021 , 20-Jul-2021 , 20-Oct-2021 , 17-Dec-2021 , 22-Feb-2022 , 21-Jun-2022 , 21-Jun-2022 , 20-Jul-2022</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	Synopsis	<p>This Funding Opportunity Announcement (FOA) supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, symptom management, or reduction of cancer health disparities. This includes (but is not limited to) development and testing of the following: new molecular agents or biologics for cancer treatment; management strategies for cancer-related symptoms or treatment-related toxicity; cancer screening or diagnostic tools, such as imaging techniques; cancer preventive agents or approaches; predictive and prognostic biomarkers for patient selection or stratification; clinically relevant in vivo or in vitro tumor models (including genetically engineered mouse models, patient-derived xenograft models, organoids, and cell lines); and strategies to address therapeutic outcome disparities among diverse racial/ethnic populations. In addition to novel agents, new treatment strategies may involve repurposed agents or novel combinations of interventions (including radiation), based on established mechanisms of action. Comparative oncology studies in dogs investigating strategies for treatment and diagnosis of human disease are supported as well. This FOA does not support research that focuses on basic cancer biology (such as studies of cancer-related pathways or molecular mechanisms), late-stage clinical trials, risk assessment studies, epidemiological studies, or studies of behavioral interventions. These applications will be deemed not responsive to this FOA and will not be reviewed (see below for a more detailed description of studies that are not responsive for this FOA). The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to breakthroughs in particular areas, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on cancer research (preclinical or clinical).</p>			
--	----------	--	--	--	--

083856	RFA-OD-19-022 -- Secondary Analyses of Existing Datasets of Tobacco Use and Health (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-OD-19-022	08-Mar-2021	275,000 USD
--------	---	------------------------------------	---------------	-------------	-------------

	Contact Name	Rachel Grana Mayne, PhD			
	Contact Telephone	240-276-5899			
	Contact Email	granar@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	08-Mar-2021			
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to invite R21 applications proposing the innovative analysis of existing (publicly available) nationally representative U.S. cross-sectional and longitudinal data, to investigate novel scientific ideas and/or to generate new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the Food and Drug Administration (FDA) -</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Center for Tobacco Products (CTP). Other publicly available data sets would be considered depending on the analyses to be conducted; however, nationally representative analyses will receive priority. Applications not using nationally representative data sets will need to provide justification why the data set is unique, and why the research questions cannot be answered from a (publicly available) nationally representative data set. This FOA encourages the analyses of public use datasets that may inform tobacco regulatory actions in the United States (U.S.). The awards under this FOA will be administered by NIH using funds that have been made available through FDA-CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP).

083834	RFA-OD-19-021 -- Maximizing the Scientific Value of Existing Biospecimen Collections (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-OD-19-021	08-Mar-2021	275,000 USD
--------	---	------------------------------------	---------------	-------------	-------------

Contact Name Rachel Grana Mayne, PhD
 Contact Telephone 240-276-5899
 Contact Email granar@nih.gov
 Sponsor Website
 Program URL [Link to program URL](#)
 Deadline Dates (ALL) 08-Mar-2021

Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to invite R21 applications to stimulate exploratory research relevant to the mission of the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP) using existing (publicly available) biospecimens currently stored in repositories in the United States. This will include, but not be limited to, collections associated with the Population Assessment of Tobacco and Health (PATH) Study, the National Health and Nutrition Examination Survey (NHANES), the National Heart, Lung and Blood Institute's (NHLBI) Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC), and the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Proposed research should seek to maximize the scientific value of these stored collections and to provide researchers with an opportunity to generate preliminary data for subsequent research proposals. While other publicly available repositories would be considered, depending on analyses to be conducted, nationally representative analyses will receive priority. These applications need to provide justification why the data set is unique, and the research questions cannot be answered from a publicly available, nationally representative, data set. The awards under this FOA will be administered by NIH using funds that have been made available through FDA-CTP and the Family Smoking Prevention and

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP).

101535	RFA-RM-21-009 -- Cellular Senescence Network: Technology Development and Application (UG3/UH3 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA- RM-21-009	08-Feb-2021 [Optional][LOI/Pre-App]	Not Specified
--------	---	------------------------------------	----------------	-------------------------------------	---------------

Contact Name	T. Kevin Howcroft, Ph.D.
Contact Telephone	240-276-6229
Contact Email	howcrofk@exchange.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	08-Feb-2021 [Optional][LOI/Pre-App], 08-Mar-2021
Synopsis	<p>The purpose of this Funding Opportunity Announcement is to solicit novel analytics and technologies to identify senescent cells in human tissues This FOA supports the accelerated proof-of-principle demonstration and validation of promising tools, techniques and methods that can be integrated, scaled and applied to multiple human tissues. The initial two-year UG3 phase will support the development and demonstration of feasibility of these emerging technologies in the identification and mapping of senescent cells in mammalian tissues. The subsequent UH3 phase is to support initial validation in human tissues, optimization and scale-up, and generation of production level data. Investigators responding to this FOA must submit both UG3 and UH3 projects as part of a single application. UG3 projects that have met their quantifiable milestones will be administratively considered by NIH staff and prioritized for transition to the UH3 phase, depending on the availability of funds. This Funding Opportunity Announcement (FOA) is developed as a Common Fund initiative (http://commonfund.nih.gov/) through the NIH Office of the NIH Director, Office of Strategic Coordination (https://dpcpsi.nih.gov/). All NIH Institutes and Centers participate in Common Fund initiatives. The FOA will be administered by the National Cancer Institute(NCI), (https://www.cancer.gov) on behalf of the Common Fund.</p>

101537	RFA-RM-21-010 -- Cellular Senescence Network: Consortium Organization and Data Coordinating Center (U24 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA- RM-21-010	08-Feb-2021 [Optional][LOI/Pre-App]	Not Specified
--------	---	------------------------------------	----------------	-------------------------------------	---------------

Contact Name	T. Kevin Howcroft, Ph.D.
Contact Telephone	240-276-6229

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email Howcrofk@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Feb-2021 [Optional][LOI/Pre-App], 08-Mar-2021</p> <p>Synopsis This funding opportunity announcement (FOA) invites applications for the Consortium Organization and Data Coordinating Center (CODCC) of the Cellular Senescence Network (SenNet) consortium. The goal of SenNet is to identify and functionally characterize the heterogeneity of senescent cells across multiple tissues in human health, and lifespan at single-cell resolution. The CODCC will serve as the organizational hub for SenNet collecting, storing, curating, and disseminating all data, metadata, analysis and visualization tools, computational models, and aggregate data across the Network into a searchable Atlas of Cellular Senescence; ensure the utility of the database; and promote collaboration through Network engagement with the research community. This Funding Opportunity Announcement (FOA) is developed as a Common Fund initiative (https://commonfund.nih.gov/) through the NIH Office of the NIH Director, Office of Strategic Coordination (https://commonfund.nih.gov/). All NIH Institutes and Centers participate in Common Fund initiatives. This FOA will be administered by the National Cancer Institute (NCI), (https://www.cancer.gov) on behalf of the Common Fund.</p>				
092824	<p>RFA-HL-22-006 -- Implementation Research to Improve Case Finding, Cascade Screening, and Treatment for Familial Hypercholesterolemia (FH) (R61/R33 Clinical Trial Required)</p>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-22-006	08-Feb-2021 [Optional][LOI/Pre-App]	2,060,000 USD
	<p>Contact Name Cheryl Anne Boyce, Ph.D.</p> <p>Contact Telephone 301-496-1051</p> <p>Contact Email cheryl.boyce@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Feb-2021 [Optional][LOI/Pre-App], 08-Mar-2021 , 07-May-2021</p> <p>Synopsis This milestone-driven Funding Opportunity Announcement (FOA) invites applications for single site clinical trials to: (1) address barriers that impede population-level implementation of case finding and cascade screening (i.e., blood relatives of familial hypercholesterolemia (FH) index cases are systematically contacted based on their risk according to the pattern of inheritance); (2) explore implementation science methodologies to assess the uptake, cost-effectiveness, feasibility, and scalability of family-based cascade screening programs for FH; (3) develop or improve machine learning algorithms and data mining techniques to find high-risk individuals using Electronic Health Records (EHRs); and (4) optimize treatment strategies and health outcomes.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
085482	RFA-HL-20-024 -- Catalyze: Product Definition – Device Prototype Design and Testing, Diagnostic Disease Target Identification and Assay Development, and Research Tool Development (R61/R33 - Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-20-024	09-Feb-2021 [Optional][LOI/Pre-App]	500,000 USD
	<p>Contact Name Kathleen Rousche, Ph.D.</p> <p>Contact Telephone 301-827-7981</p> <p>Contact Email kathleen.rousche@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Feb-2021 [Optional][LOI/Pre-App], 09-Mar-2021 , 11-May-2021 , 09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-Aug-2021</p> <p>Synopsis This Catalyze Product Definition Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to develop and test device prototype designs, identify diagnostic disease targets and develop associated assays, and develop research tools for use in the treatment of HLBS diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.</p>				
085480	RFA-HL-20-022 -- Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-20-022	09-Feb-2021 [Optional][LOI/Pre-App]	600,000 USD
	<p>Contact Name Margaret Ochocinska, PhD</p> <p>Contact Telephone 301-827-8285</p> <p>Contact Email ochocinm@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Feb-2021 [Optional][LOI/Pre-App], 09-Mar-2021 , 11-May-2021 , 09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-Aug-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) solicits grant applications to further develop enabling technologies and transformative platforms to catalyze next-generation predictive, diagnostic and therapeutic products to address heart, lung,</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>blood, and sleep (HLBS)-related disorders and diseases. This FOA solicits R33 applications where major feasibility gaps for the enabling technology or transformative platform have already been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage downstream demonstration, utilization and adoption.</p>			
085481	RFA-HL-20-023 -- Catalyze: Product Definition for Small Molecules and Biologics - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 – Clinical Trials Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-20-023	09-Feb-2021 [Optional][LOI/Pre-App]	700,000 USD
	<p>Contact Name Kathleen Rousche, Ph.D.</p> <p>Contact Telephone 301-827-7981</p> <p>Contact Email kathleen.rousche@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Feb-2021 [Optional][LOI/Pre-App], 09-Mar-2021 , 11-May-2021 , 09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-Aug-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify and characterize potential therapeutic candidates (compound and lead series) to treat heart, lung, blood, and sleep diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic candidates.</p>				
085485	RFA-HL-20-028 -- Catalyze: Product Definition – Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation (R33 - Clinical Trials Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-20-028	09-Feb-2021 [Optional][LOI/Pre-App]	500,000 USD
	<p>Contact Name Kathleen Rousche, Ph.D.</p> <p>Contact Telephone 301-827-7981</p> <p>Contact Email kathleen.rousche@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Feb-2021 [Optional][LOI/Pre-App], 09-Mar-2021 , 11-May-2021 , 09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	Aug-2021 This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed for prototype testing/design modification, assay development for diagnostic disease targets, and development of research tools for use in the treatment of HLBS diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.			
085483	RFA-HL-20-027 -- Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-20-027	09-Feb-2021 [Optional][LOI/Pre-App]	700,000 USD
	Contact Name	Kathleen Rousche, Ph.D.			
	Contact Telephone	301-827-7981			
	Contact Email	kathleen.rousche@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	09-Feb-2021 [Optional][LOI/Pre-App], 09-Mar-2021 , 11-May-2021 , 09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-Aug-2021			
	Synopsis	This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify a lead compound series toward development of potential therapeutic agents to treat heart, lung, blood, and sleep diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic agents.			
093741	RFA-HL-21-013 -- Disease Modifying Therapies for Chronic Lung Disease (R61/R33 Clinical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-21-013	17-Feb-2021 [Optional][LOI/Pre-App]	1,000,000 USD
	Contact Name	Antonello Punturieri, MD, PhD			
	Contact Telephone	301-435-0233			
	Contact Email	punturiera@nhlbi.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 17-Feb-2021 [Optional][LOI/Pre-App], 19-Mar-2021 , 02-May-2022 [Optional][LOI/Pre-App], 01-Jun-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support multiple Protocol Leadership Groups (PLGs) that will conduct phase II trials within the NHLBI Pulmonary Trials Cooperative (PTC) clinical trials network. The PTC will include multiple Protocol Leadership Groups (PLGs) and a single Network Management Core (NEMO) and will conduct multiple simultaneous phase II clinical trials that test innovative disease modifying therapies (DMT) for chronic lung diseases. A companion FOA (RFA-HL-21-012) seeks applications for the Network Management Core (NEMO).</p>				
101652	NHLBI Hope for Sickle Cell Disease Challenge	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-21-001	26-Mar-2021	25,000 USD
	<p>Contact Name Joyonna Gamble-George, Ph.D.</p> <p>Contact Telephone 301-496-1051</p> <p>Contact Email SCDChallenge@nhlbi.nih.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 26-Mar-2021</p> <p>Synopsis The National Heart, Lung, and Blood Institute (NHLBI), an institute of the National Institutes of Health (NIH), announces the NHLBI “Hope for Sickle Cell Disease Challenge” to help increase awareness about sickle cell disease and its associated complications. A total of \$50,000 in prizes will be awarded.</p>				
090720	RFA-HG-20-016 -- Novel Synthetic Nucleic Acid Technology Development (R43/R44) (Clinical Trial Not Allowed)	National Human Genome Research Institute/NIH/DHHS	RFA-HG-20-016	07-Feb-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Michael W. Smith, Ph.D.</p> <p>Contact Telephone 301-480-3413</p> <p>Contact Email smithmw@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Feb-2021 [Optional][LOI/Pre-App], 09-Mar-2021 , 05-Jan-2022 [Optional][LOI/Pre-App], 04-Feb-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) solicits R43/R44 grant applications to develop novel technologies that will</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		enable substantive (no less than one order of magnitude) improvement in commercial synthetic nucleic acids. The goal is to improve the quality, capabilities and efficiency of commercial nucleic acid synthesis and synthetic constructs at reasonable and decreased costs. Applicants may propose to develop novel complete synthesis and/or synthetic constructs systems, investigate challenges underlying key novel system components, or propose substantive improvements of at least an order of magnitude improvement to existing commercial systems. Exploration of methods other than those currently commercially in use is highly encouraged.			
090708	RFA-HG-20-014 -- Novel Synthetic Nucleic Acid Technology Development (R01 Clinical Trial not allowed)	National Human Genome Research Institute/NIH/DHHS	RFA-HG-20-014	07-Feb-2021 [Optional][LOI/Pre-App]	2,100,000 USD
	Contact Name	Michael W. Smith, Ph.D.			
	Contact Telephone	301-480-3413			
	Contact Email	smithmw@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Feb-2021 [Optional][LOI/Pre-App], 09-Mar-2021 , 05-Jan-2022 [Optional][LOI/Pre-App], 04-Feb-2022			
	Synopsis	This Funding Opportunity Announcement (FOA) solicits R01 grant applications to develop novel technologies that will enable substantive (no less than one order of magnitude) improvement in synthetic nucleic acids. The goal is to improve the quality, capabilities and efficiency of nucleic acid synthesis and synthetic constructs at reasonable and decreased costs. Large progress in this area has the potential to catalyze scientific advances relevant to the mission of NIH, NHGRI and the field of genomics.			
090719	RFA-HG-20-015 -- Novel Synthetic Nucleic Acid Technology Development (R21) (Clinical Trial not allowed)	National Human Genome Research Institute/NIH/DHHS	RFA-HG-20-015	07-Feb-2021 [Optional][LOI/Pre-App]	400,000 USD
	Contact Name	Michael W. Smith, Ph.D.			
	Contact Telephone	301-480-3413			
	Contact Email	smithmw@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Feb-2021 [Optional][LOI/Pre-App], 09-Mar-2021 , 05-Jan-2022 [Optional][LOI/Pre-App], 04-Feb-2022			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>This Funding Opportunity Announcement (FOA) solicits R21 grant applications to develop novel technologies that will enable substantive (no less than one order of magnitude) improvement in synthetic nucleic acids. The goal is to improve the quality, capabilities and efficiency of nucleic acid synthesis and synthetic constructs at reasonable and decreased costs. Applicants may propose to develop novel complete synthesis and/or synthetic constructs systems, investigate challenges underlying key novel system components, or propose substantive improvements of at least an order of magnitude improvement to existing systems. Exploration of methods other than those currently in use is highly encouraged. High-risk/high-payoff applications are appropriate to achieve the goals of this FOA.</p>			
095566	RFA-HG-20-037 -- Advancing Genomic Medicine Research (R21 Clinical Trial Optional)	National Human Genome Research Institute/NIH/DHHS	RFA-HG-20-037	06-Feb-2021 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Ms. Christine Chang			
	Contact Telephone	301-480-2255			
	Contact Email	christine.chang2@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	06-Feb-2021 [Optional][LOI/Pre-App], 08-Mar-2021 , 03-Oct-2021 [Optional][LOI/Pre-App], 02-Nov-2021 , 02-Jul-2022 [Optional][LOI/Pre-App], 01-Aug-2022 , 11-Feb-2023 [Optional][LOI/Pre-App], 13-Aug-2023			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) encourages applications that stimulate innovation and advance understanding of when, where, and how best to implement the use of genomic information and technologies in clinical care. Proposed projects should be broadly applicable to genomic medicine as a field, and yield findings of significance beyond a single disease, gene, or setting. Projects are strongly encouraged to include ancestrally diverse and underrepresented participants and populations.</p>			
095564	RFA-HG-20-036 -- Advancing Genomic Medicine Research (R01 Clinical Trial Optional)	National Human Genome Research Institute/NIH/DHHS	RFA-HG-20-036	06-Feb-2021 [Optional][LOI/Pre-App]	3,000,000 USD
	Contact Name	Ms. Christine Chang			
	Contact Telephone	301-480-2255			
	Contact Email	christine.chang2@nih.gov			
	Sponsor Website				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 06-Feb-2021 [Optional][LOI/Pre-App], 08-Mar-2021 , 03-Oct-2021 [Optional][LOI/Pre-App], 02-Nov-2021 , 02-Jul-2022 [Optional][LOI/Pre-App], 01-Aug-2022 , 11-Feb-2023 [Optional][LOI/Pre-App], 13-Aug-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages applications that stimulate innovation and advance understanding of when, where, and how best to implement the use of genomic information and technologies in clinical care. Proposed projects should be broadly applicable to genomic medicine as a field, and yield findings of significance beyond a single disease, gene, or setting. Projects are strongly encouraged to include ancestrally diverse and underrepresented participants and populations.</p>				
099483	HIV Vaccine Research and Design (HIVRAD) Program (P01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-21-024	15-Mar-2021	12,500,000 USD
	<p>Contact Name Bruce Sundstrom, Ph.D.</p> <p>Contact Telephone 240-669-5045</p> <p>Contact Email sundstromj@niaid.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Mar-2021 , 15-Mar-2022 , 15-Mar-2023</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support multi-component, multi-disciplinary projects that address scientific questions relevant to AIDS prophylactic vaccine discovery research. Extensive evaluation of vaccine concepts in non-human primate models may be included.</p>				
090030	Integrated Preclinical / Clinical AIDS Vaccine Development Program (IPCAVD) (U19 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-20-120	09-Mar-2021	15,000,000 USD
	<p>Contact Name Sujata Vijh, Ph.D.</p> <p>Contact Telephone 301-761-7713</p> <p>Contact Email vijhs@niaid.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Mar-2021 , 09-Mar-2022</p> <p>Synopsis The purpose of the Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) Funding Opportunity</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Announcement (FOA) is to facilitate the translation of vaccine candidates into early clinical testing. The IPCAVD program is designed to enable a multi-disciplinary team to complete necessary steps from final down-selection of an advanced HIV-1 vaccine candidate through regulatory submissions needed for clinical trial(s). These steps include technology transfer, process development, optimization studies, assay development and qualification, analytical testing, Current Good Manufacturing Practice (CGMP) manufacture, quality assurance oversight, safety testing, product release and storage, drug substance and drug product stability testing program, IND-enabling studies, and regulatory submissions. This FOA will not provide funds for conducting the clinical studies; applicants are encouraged to collaborate with NIAID-supported clinical trial networks or to develop other relationships to support the clinical studies.

100727	Detection of HIV for Self-Testing (R61/R33 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-21-070	17-Mar-2021	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name	Diane Lawrence, Ph.D.
Contact Telephone	240-627-3202
Contact Email	lawrencedi@niaid.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	17-Mar-2021 , 17-Mar-2022 , 17-Mar-2023
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative, interdisciplinary early-stage research to inform the development of innovative rapid, sensitive, simple, and cost-effective diagnostic technologies that will enable HIV self-testing during the earliest phases of acute infection or during viral rebound.

098066	Notice of Special Interest (NOSI): Availability of Emergency Awards for Limited Clinical Trials to Evaluate Therapeutic and Vaccine Candidates Against SARS-CoV-2	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-20-065	14-Feb-2021	Not Specified
--------	---	--	---------------	-------------	---------------

Contact Name	Diane Post, Ph.D.
Contact Telephone	240-627-3348
Contact Email	NIAIDCOVIDIICTNOSI@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	14-Feb-2021 , 14-Mar-2021 , 14-Apr-2021 , 14-May-2021 , 14-Jun-2021 , 14-Jul-2021 , 14-Aug-2021 , 14-Sep-2021

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>This Notice of Special Interest encourages cooperative agreement applications for implementation of investigator-initiated high-risk clinical trials, as defined by NIAID in PAR-18-633 and NOT-AI-16-084, that will augment ongoing and planned clinical trials of therapeutic and vaccine candidates directed against SARS-CoV-2 to evaluate: SARS-CoV-2 candidate vaccines non-vaccine biomedical prevention of SARS-CoV-2 infection and/or COVID-19 therapeutic approaches to treat COVID-19</p>			
100388	Mechanistic Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PAR-21-055	18-Feb-2021 [Optional][LOI/Pre-App]	1,200,000 USD
	Contact Name	Heiyoung Park, Ph.D.			
	Contact Telephone	301-594-5032			
	Contact Email	parkh1@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	18-Feb-2021 [Optional][LOI/Pre-App], 18-Mar-2021 , 20-Jun-2021 [Optional][LOI/Pre-App], 20-Jul-2021 , 18-Oct-2021 [Optional][LOI/Pre-App], 18-Nov-2021 , 18-Feb-2022 [Optional][LOI/Pre-App], 18-Mar-2022 , 20-Jun-2022 [Optional][LOI/Pre-App], 20-Jul-2022 , 18-Oct-2022 [Optional][LOI/Pre-App], 18-Nov-2022			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) solicits applications that propose to conduct time-sensitive mechanistic ancillary studies related to the NIAMS mission in conjunction with privately or publicly funded, ongoing clinical projects. The ongoing “parent” clinical project can be an interventional clinical trial, or a clinical study such as an observational study that will be actively collecting patient samples or clinical data. The “parent” project(s) should provide a cohort of well-characterized patients, infrastructure, data, and biological samples for the ancillary study. Applications submitted in response to this FOA will undergo an accelerated review and award process. The objective of this FOA is to provide a flexible mechanism to leverage established resources and maximize the return on existing investments in parent projects. Successful ancillary studies will enhance the scientific content and value of the parent projects, improve the research community’s understanding of a disease or organ system in the NIAMS portfolio, and thus may identify novel targets for diagnosis, treatment, and prevention of disease.</p>			
100720	Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PAR-21-053	04-Mar-2021	475,000 USD
	Contact Name	Yan Wang, M.D., Ph.D.			
	Contact Telephone	301-594-5032			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email wangy1@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 04-Mar-2021 , 02-Jul-2021 , 02-Nov-2021 , 04-Mar-2022 , 01-Jul-2022 , 04-Nov-2022 , 03-Mar-2023 , 02-Jul-2023 , 03-Nov-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) is to encourage Research Project Grant (R01) applications to pursue clinical observational (CO) studies to obtain data necessary for designing clinical studies for musculoskeletal, rheumatic, or skin diseases or conditions. A future clinical study may include a clinical trial or an observational study. Research data from observational studies supported by this FOA can enhance clinical study design by providing essential information about disease symptoms, stages, and timing of disease progression; comorbid conditions; availability of potential research participants; and outcomes that are important to patients. They also can facilitate efforts to develop and/or validate objective biomarkers or subjective outcome measures for use in a future clinical study. Applicants to this FOA are encouraged to propose studies that address significant obstacles or questions in the design of a clinical project, such as determining the appropriate primary or secondary outcome measures or identifying the stages of disease during which patients are most likely to respond to an intervention. Only observational studies will be supported through this FOA.</p>				
100718	NIAMS Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PAR-21-036	04-Mar-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email NIAMSclinicaltrials@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 04-Mar-2021 , 02-Jul-2021 , 02-Nov-2021 , 04-Mar-2022 , 01-Jul-2022 , 04-Nov-2022 , 03-Mar-2023 , 02-Jul-2023 , 03-Nov-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) solicits cooperative agreement (U01) applications for implementation of investigator-initiated interventional clinical trials (all phases). Applications for clinical trials submitted to the NIAMS are normally expected to go through a two-part process, which begins with an R34 planning phase (Part 1) followed by an application for the U01 (Part 2). Investigators who have completed all necessary pre-trial planning and preparation through other means may apply for a NIAMS U01 without an awarded R34. The NIAMS expects trials to be hypothesis-driven and</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		have the potential for high impact within the research mission of the NIAMS.			
100719	Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R21 Clinical Trial Required)	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PAR-21-045	04-Mar-2021	400,000 USD
	Contact Name	Yan Wang, M.D., Ph.D.			
	Contact Telephone	301-594-5032			
	Contact Email	wangy1@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	04-Mar-2021 , 02-Jul-2021 , 02-Nov-2021 , 04-Mar-2022 , 01-Jul-2022 , 04-Nov-2022 , 03-Mar-2023 , 02-Jul-2023 , 03-Nov-2023			
	Synopsis	This Funding Opportunity Announcement (FOA) is designed to facilitate clinical trials that can be completed within a limited timeframe and budget. A broad range of types of exploratory studies may be submitted to this FOA. The trials must address research questions related to the mission and goals of the NIAMS and may evaluate interventions with drugs, biologics, devices, or surgical, dietary, behavioral or rehabilitation therapies.			
088239	NIAMS Clinical Trial Planning Grant (R34) - Clinical Trial Not Allowed	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PAR-20-090	01-Mar-2021	300,000 USD
	Contact Name	NIAMS Clinical Research Team			
	Contact Telephone				
	Contact Email	NIAMScinicaltrials@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Mar-2021 , 01-Jul-2021 , 01-Nov-2021 , 01-Mar-2022 , 01-Jul-2022 , 01-Nov-2022			
	Synopsis	This Funding Opportunity Announcement (FOA) will support planning grants for investigator-initiated clinical interventional trials. The R34 planning grant is designed to enable the necessary planning, design, and preparation of documentation prior to implementation of investigator-initiated clinical trials. Completion of the agreed upon milestones of an R34 planning grant or documentation that planning has been addressed is required prior to submission of an application through a NIAMS U01			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

clinical trial implementation application that will support the actual implementation and conduct of the study. The planning should facilitate the launching of a trial that is hypothesis-driven, milestone-defined, and has the potential for high impact within the research mission of the NIAMS.

100387	Mechanistic Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PAR-21-054	18-Feb-2021 [Optional][LOI/Pre-App]	400,000 USD
--------	---	--	------------	-------------------------------------	-------------

Contact Name	Heiyoung Park, Ph.D.
Contact Telephone	301-594-5032
Contact Email	parkh1@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	18-Feb-2021 [Optional][LOI/Pre-App], 18-Mar-2021 , 20-Jun-2021 [Optional][LOI/Pre-App], 20-Jul-2021 , 18-Oct-2021 [Optional][LOI/Pre-App], 18-Nov-2021 , 18-Feb-2022 [Optional][LOI/Pre-App], 18-Mar-2022 , 20-Jun-2022 [Optional][LOI/Pre-App], 20-Jul-2022 , 18-Oct-2022 [Optional][LOI/Pre-App], 18-Nov-2022
Synopsis	This Funding Opportunity Announcement (FOA) solicits applications that propose to conduct time-sensitive mechanistic ancillary studies related to the NIAMS mission in conjunction with privately or publicly funded, ongoing clinical projects. The ongoing “parent” clinical project can be an interventional clinical trial, or a clinical study such as an observational study that will be actively collecting patient samples or clinical data. The “parent” project(s) should provide a cohort of well-characterized patients, infrastructure, data, and biological samples for the ancillary study. Applications submitted in response to this FOA will undergo an accelerated review and award process. The objective of this FOA is to provide a flexible mechanism to leverage established resources and maximize the return on existing investments in parent projects. Successful ancillary studies will enhance the scientific content and value of the parent projects, improve the research community’s understanding of a disease or organ system in the NIAMS portfolio, and thus may identify novel targets for diagnosis, treatment, and prevention of disease.

091824	Catalyzing Innovation in Pediatric Pharmacology Clinical Trial Design and Resource Access (X01 Clinical Trial Not Allowed)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-20-161	17-Mar-2021	Not Specified
--------	--	---	------------	-------------	---------------

Contact Name	Perdita Taylor-Zapata, MD
Contact Telephone	301-496-9584

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email taylorpe@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Mar-2021 , 17-Mar-2022 , 17-Mar-2023</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to provide investigators with access to a consultative resource for planning activities and concept development for single or multi-site investigator initiated clinical trials that address gaps in pediatric drug development and that align with priorities identified in the Best Pharmaceuticals for Children Act (BPCA) Program. The FOA will support the development of clinical trials concepts of future well-designed clinical trials that require non-traditional designs in pediatric therapeutics with the opportunity to expand novelty and/or innovation. Investigators will have access to the expertise in pediatric drug development trial designs by utilizing the consultative services provided by the Pediatric Trials Network (PTN) and the BPCA Data Coordinating Center.</p>				
098158	RFA-HD-21-023 -- NICHD Program Project Grants for HIV Research (P01 Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	RFA-HD-21-023	01-Mar-2021 [Optional][LOI/Pre-App]	3,000,000 USD
	<p>Contact Name Denise Russo, PhD</p> <p>Contact Telephone 301-435-6871</p> <p>Contact Email denise.russo@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Mar-2021 [Optional][LOI/Pre-App], 31-Mar-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites submission of Program Project (P01) applications to support integrated, multi-project research programs that address HIV scientific areas relevant to the NICHD mission as a well-defined, central research focus or objective.</p>				
086715	NCMRR Early Career Research Award (R03 Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-20-042	30-Mar-2021	200,000 USD
	<p>Contact Name Theresa Hayes Cruz, PhD</p> <p>Contact Telephone 301-496-9233</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Email	cruzth@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	30-Mar-2021 , 30-Mar-2022
Synopsis	<p>The National Center for Medical Rehabilitation Research (NCMRR) Early Career Research (ECR) Award (R03) is intended to support both basic and clinical research from rehabilitation scientists who are establishing independent research careers. The research must be focused on one or more of the areas within the biomedical and behavioral mission of NCMRR: pathophysiology and management of chronically injured nervous and musculoskeletal systems (including stroke, traumatic brain injury, spinal cord injury, and orthopedic conditions); repair and recovery of motor and cognitive function; functional plasticity, adaptation, and windows of opportunity for rehabilitative interventions; rehabilitative strategies involving pharmaceutical, stimulation, and neuroengineering approaches, exercise, motor training, and behavioral modifications; pediatric rehabilitation; secondary conditions associated with chronic disabilities; improved diagnosis, assessment, and outcome measures; and development of orthotics, prosthetics, and other assistive technologies and devices. The NCMRR ECR Award R03 grant mechanism supports different types of projects including secondary analysis of existing data; small, self-contained research projects; development of research methodology; translational research; outcomes research; and development of new technology. Irrespective of the type of project, the intent of the NCMRR ECR Award R03 is for the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) to obtain sufficient preliminary data for a subsequent R01 application.</p>

101575	RFA-HD-21-032 -- HEAL Initiative: Data Coordinating Center for the Neonatal Opioid Withdrawal Syndrome Pharmacological Treatments Comparative Effectiveness Trial (U24 Clinical Trial Required)	National Institute of Child Health and Human Development/NIH/DHHS	RFA- HD-21-032	28-Feb-2021 [Optional][LOI/Pre-App]	Not Specified
--------	---	---	----------------	-------------------------------------	---------------

Contact Name	Andrew A. Bremer, MD, PhD
Contact Telephone	301-402-7886
Contact Email	andrew.bremer@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	28-Feb-2021 [Optional][LOI/Pre-App], 30-Mar-2021
Synopsis	<p>This FOA invites applications for a Data Coordinating Center (DCC) to design and implement a multi-center, comparative effectiveness, randomized controlled trial (RCT) to assess the optimal pharmacological treatment for Neonatal Opioid Withdrawal Syndrome (NOWS). A separate FOA (RFA-HD-21-031) will invite applications for Clinical Sites. Information</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		obtained from this study is expected to inform clinical practice guidelines and the care of infants with NOWS. The funding for this initiative is provided from the Helping to End Addiction Long-term (HEAL) initiative (https://heal.nih.gov/).			
101574	RFA-HD-21-031 -- HEAL Initiative: Neonatal Opioid Withdrawal Syndrome Pharmacological Treatments Comparative Effectiveness Trial - Clinical Sites (UG1 Clinical Trial Required)	National Institute of Child Health and Human Development/NIH/DHHS	RFA-HD-21-031	28-Feb-2021 [Optional][LOI/Pre-App]	750,000 USD
	<p>Contact Name Andrew A. Bremer, MD, PhD</p> <p>Contact Telephone 301-402-7886</p> <p>Contact Email andrew.bremer@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 28-Feb-2021 [Optional][LOI/Pre-App], 30-Mar-2021</p> <p>Synopsis This FOA invites applications for Clinical Centers to design and implement a multi-center, comparative effectiveness, randomized controlled trial (RCT) to assess the optimal pharmacological treatment for Neonatal Opioid Withdrawal Syndrome (NOWS). A separate FOA (RFA-HD-21-032) will invite applications for Data Coordinating Center (DCC). Information obtained from this study is expected to inform clinical practice guidelines and the care of infants with NOWS. The funding for this initiative is provided from the Helping to End Addiction Long-term (HEAL) initiative (https://heal.nih.gov/).</p>				
100782	RFA-DK-20-033 -- Exploratory Centers for Interdisciplinary Research in Benign Urology (P20 Clinical Trial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-20-033	18-Feb-2021 [Optional][LOI/Pre-App]	400,000 USD
	<p>Contact Name Tamara G. Bavendam, MD, MS</p> <p>Contact Telephone 301-594-4733</p> <p>Contact Email tamara.bavendam@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 18-Feb-2021 [Optional][LOI/Pre-App], 18-Mar-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to seek applications for Exploratory Centers for Interdisciplinary Research in Benign Urology (P20). A major goal of this program is to build interdisciplinary research teams. The program seeks innovative, high-risk–high-reward Research Projects that utilize integrative approaches to address</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>questions relevant to benign genitourinary diseases or disorders bringing together investigators with complementary expertise. Studies involving human subjects or tissues and small, innovative, pilot and feasibility clinical studies are encouraged. The following expertise must be included in the proposed Research Project: 1) researchers new to the investigation of benign genitourinary diseases or disorders and 2) clinical urology expertise. Additional expertise may also be included, as needed. In addition to the scientific Research Project, each Exploratory Center must include an Administrative Core with an Educational Enrichment Program. As part of the NIDDK's efforts to expand and enhance benign urology research and the base of urologic researchers, the Exploratory Centers Program will work in partnership with the George M. O'Brien Urology Cooperative Research Centers Program (U54), the Urology Centers Program Interactions Core (U24), and the Multidisciplinary K12 Urologic Research (KURe and UroEpi) Career Development Programs.</p>			
100737	RFA-DK-20-030 -- Understanding the Cellular and Molecular Mechanisms of Gastroparesis in Adults and Children (R01 Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-20-030	03-Feb-2021 [Optional][LOI/Pre-App]	1,250,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Frank A. Hamilton, M.D., MPH</p> <p>301-594-8877</p> <p>hamiltonf@mail.nih.gov</p> <p></p> <p></p> <p>03-Feb-2021 [Optional][LOI/Pre-App], 03-Mar-2021</p> <p>Since its establishment in 2006, the Gastroparesis Clinical Research Consortium (GpCRC), a multi-center coalition created and funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has made major advances to our understanding of the pathophysiology of Gastroparesis (Gp). Through the establishment of the largest gastroparesis tissue repository in the United States, combined with detailed phenotypic data, the GpCRC is ideally suited to accelerate insights into the underlying cellular and molecular pathophysiology of the gastroparesis with the ultimate goal of developing therapeutic target(s). This RFA invites investigators from several disciplines, including basic and translational research in areas of neurosciences, immunology, microbiology and physiology, to contribute new insights into the cellular and molecular mechanisms of Gastroparesis.</p>			
098645	RFA-DK-20-022 -- Toward Elucidating Mechanisms of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS) (R01 Clinical Trial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-20-022	03-Feb-2021 [Optional][LOI/Pre-App]	2,500,000 USD
	<p>Contact Name</p>	<p>Peter J. Perrin, Ph.D.</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-451-3759</p> <p>Contact Email Peter.Perrin@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-Feb-2021 [Optional][LOI/Pre-App], 03-Mar-2021 , 17-Oct-2021 [Optional][LOI/Pre-App], 17-Nov-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support multidisciplinary research teams with complementary expertise in HIV and pathobiology, pathophysiology, and/or metabolism in organs, tissues, and/or biological systems of specific interest to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). These teams will comprehensively interrogate fundamental mechanisms underlying HIV-associated comorbidities, coinfections, and complications relevant to the mission of the NIDDK and advance progress toward alleviating them.</p>				
088332	<p>RFA-DK-19-032 -- The KUH Predoctoral to Postdoctoral Fellow Transition Award (F99/K00 Independent Clinical Trial Not Allowed)</p>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-19-032	02-Mar-2021	Not Specified
	<p>Contact Name Christine Maric-Bilkan, Ph.D</p> <p>Contact Telephone 301-435-0486</p> <p>Contact Email christine.maric-bilkan@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 02-Mar-2021</p> <p>Synopsis The purpose of the Kidney, Urology or Hematology (KUH) Predoctoral to Postdoctoral Fellow Transition Awards (F99/K00) is to recruit exceptional graduate students from diverse research fields to pursue postdoctoral training focused on Kidney, Urology or Hematology (K, U, or H) research. Talented graduate students from disciplines including, but not limited to, engineering, statistics, data science, imaging, biochemistry and genetics are invited to apply to this opportunity. Graduate students who are already involved in K, U, or H research are not eligible for the F99/K00 award and are instead encouraged to apply for the Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31, PA-19-195). Prospective applicants are strongly encouraged to contact the NIDDK Program Official prior to initiating plans for application submission. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
084473	NIDDK Central Repositories Non-renewable Sample Access (X01 Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-19-319	02-Mar-2021	Not Specified
	<p>Contact Name Lisa M. Spain, Ph.D</p> <p>Contact Telephone 301-451-9871</p> <p>Contact Email SpainL@niddk.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 02-Mar-2021 , 29-Jun-2021 , 26-Oct-2021 , 01-Mar-2022 , 28-Jun-2022</p> <p>Synopsis National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites investigators to apply for access to non-renewable samples from one or more of these studies. Information about the samples available can be found at www.niddkrepository.org. Applicants must provide information from the NIDDK Central Repositories documenting sample availability. This FOA will utilize the NIH X01 Resource Access Award mechanism.</p>				
076166	Time-Sensitive Obesity Policy and Program Evaluation (R01 Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-18-854	10-Feb-2021	Not Specified
	<p>Contact Name Mary Evans, Ph.D.</p> <p>Contact Telephone 301-594-4578</p> <p>Contact Email evansmary@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Feb-2021 , 10-Mar-2021 , 09-Apr-2021 , 10-May-2021 , 11-Jun-2021 , 09-Jul-2021 , 10-Aug-2021 , 10-Sep-2021</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding. All applications submitted to this FOA must demonstrate that the evaluation of an obesity related policy and /or program offers an uncommon and scientifically compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications submitted to this time-sensitive FOA are not eligible for re-</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

submission. It is intended that eligible applications selected for funding will be awarded within 4 months of the application due date. However, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline. This FOA will utilize the NIH R01 Research Project Grant award mechanism.

088600	RFA-ES-20-006 -- Environmental Health Sciences Core Centers (EHSCC) (P30 Clinical Trial Optional)	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES-20-006	16-Mar-2021 [Optional][LOI/Pre-App]	3,400,000 USD
--------	---	--	---------------	-------------------------------------	---------------

Contact Name	Claudia Thompson, Ph.D.
Contact Telephone	984-287-3330
Contact Email	thomps14@niehs.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	16-Mar-2021 [Optional][LOI/Pre-App], 16-Apr-2021 , 14-Mar-2022 [Optional][LOI/Pre-App], 14-Apr-2022
Synopsis	This Funding Opportunity Announcement (FOA) invites grant applications for Environmental Health Sciences Core Centers (EHS CC). As intellectual hubs for environmental health science research, the EHS CC is expected to be the thought leaders for the field and advance the goals of the NIEHS Strategic Plan (http://www.niehs.nih.gov/about/strategicplan/). The Core Centers provide critical research infrastructure, shared facilities, services and/or resources, to groups of investigators conducting environmental health sciences research. An EHS CC enables researchers to conduct their independently-funded individual and/or collaborative research projects more efficiently and/or more effectively. The overall goal of an EHS CC is to identify and capitalize on emerging issues that advance improving the understanding of the relationships among environmental exposures, human biology, and disease. The EHS CC supports community engagement and translational research as key approaches to improving public health.

081424	Environmental Influences on Aging: Effects of Extreme Weather and Disaster Events on Aging Populations (R01 Clinical Trial Optional)	National Institute of Environmental Health Sciences/NIH/DHHS	PAR-19-250	08-Mar-2021	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name	Symma Finn, PhD
Contact Telephone	984-287-3259
Contact Email	finns@niehs.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	08-Mar-2021

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The purpose of this funding opportunity announcement is to advance our understanding of the impact of extreme weather and disaster events in aging human populations. Together with the companion FOA (PAR- 19-XXX) that focuses on underlying mechanisms of aging utilizing animal models, these two FOAs will help to explicate the behavioral, biological, and socioecological processes that occur during extreme weather or disaster events and that affect aging processes. Through the integration of the population studies and the companion mechanistic studies FOA, the ultimate goal is to improve the health and well-being of older adults via increased knowledge about extreme weather and disaster preparedness, response, and recovery.</p>			
101131	RFA-ES-21-002 -- Application of Artificial Intelligence and Machine Learning for Advancing Environmental Health Sciences (R43 Clinical Trial Not Allowed)	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES-21-002	28-Feb-2021 [Optional][LOI/Pre-App]	256,580 USD
	Contact Name	Lingamanaidu Ravichandran, PhD			
	Contact Telephone	948-287-3309			
	Contact Email	lingamanaidu.ravichandran@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	28-Feb-2021 [Optional][LOI/Pre-App], 29-Mar-2021			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) solicits Phase I (R43) SBIR grant applications from small business concerns (SBCs) to develop promising methodologies using Artificial Intelligence (AI) and Machine Learning (ML) approaches to advance environmental health research and decisions. When further developed and validated, these methodologies or approaches should improve the accuracy of toxicity prediction, help in prioritizing chemicals for more relevant or targeted testing, identify and/or fill data or knowledge gaps in toxicity assessment, and promote more comprehensive understanding of human exposure effects, susceptibility and adverse health outcomes.</p>			
101133	RFA-ES-21-003 -- Application of Artificial Intelligence and Machine Learning for Advancing Environmental Health Sciences (R41 Clinical Trial Not Allowed)	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES-21-003	28-Feb-2021 [Optional][LOI/Pre-App]	256,580 USD
	Contact Name	Lingamanaidu Ravichandran, PhD			
	Contact Telephone	948-287-3309			
	Contact Email	lingamanaidu.ravichandran@nih.gov			
	Sponsor Website				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 28-Feb-2021 [Optional][LOI/Pre-App], 29-Mar-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) solicits Phase I (R41) STTR grant applications from small business concerns (SBCs) to develop promising methodologies using Artificial Intelligence (AI) and Machine Learning (ML) approaches to advance environmental health research and decisions. When further developed and validated, these methodologies or approaches should improve the accuracy of toxicity prediction, help in prioritizing chemicals for more relevant or targeted testing, identify and/or fill data or knowledge gaps in toxicity assessment, and promote more comprehensive understanding of human exposure effects, susceptibility and adverse health outcomes.</p>				
084593	RFA-ES-19-011 -- Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed)	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES-19-011	01-Feb-2021	275,000 USD
	<p>Contact Name Martha I. Barnes, MS</p> <p>Contact Telephone 919-541-3335</p> <p>Contact Email barnes@niehs.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2021 , 01-Mar-2021 , 01-Apr-2021 , 03-May-2021 , 01-Jun-2021 , 01-Jul-2021 , 02-Aug-2021 , 01-Sep-2021 , 01-Oct-2021 , 01-Nov-2021 , 01-Dec-2021 , 03-Jan-2022 , 01-Feb-2022 , 01-Mar-2022 , 01-Apr-2022 , 02-May-2022 , 01-Jun-2022 , 01-Jul-2022 , 01-Aug-2022 , 01-Sep-2022 , 03-Oct-2022</p> <p>Synopsis This funding opportunity announcement (FOA) is intended to support novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. The primary motivation of the FOA is to understand the consequences of natural and human-made disasters, emerging environmental public health threats, and policy changes in the U.S. and abroad. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented. The shortened timeframe will be achieved by more frequent application due dates and expediting peer review, council concurrence and award issuance. The entire cycle, from submission to award, is expected to be within 3-4 months.</p>				
100252	Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)	National Institute of Environmental Health Sciences/NIH/DHHS	NOT-ES-20-020	01-Feb-2021	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Anika Dzierlenga, Ph.D.</p> <p>Contact Telephone 984-287-3125</p> <p>Contact Email anika.dzierlenga@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2021 , 01-Mar-2021 , 01-Apr-2021 , 03-May-2021</p> <p>Synopsis NIEHS is issuing this Notice of Special Interest (NOSI) to address the urgent need for mission-relevant research to understand the impact of environmental exposures on Coronavirus Disease 2019 (COVID-19) and its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). NIEHS is particularly interested in applications that will provide insight into the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies.</p>				
100259	Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)	National Institute of Environmental Health Sciences/NIH/DHHS	NOT-ES-20-015	01-Feb-2021	Not Specified
	<p>Contact Name Anika Dzierlenga, Ph.D.</p> <p>Contact Telephone 984-287-3125</p> <p>Contact Email anika.dzierlenga@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2021 , 01-Mar-2021 , 01-Apr-2021 , 03-May-2021</p> <p>Synopsis NIEHS is issuing this Notice of Special Interest (NOSI) to address the urgent need for mission-relevant research to understand the impact of environmental exposures on Coronavirus Disease 2019 (COVID-19) and its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). NIEHS is particularly interested in applications that will provide insight into the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies.</p>				
084867	Explainable Artificial Intelligence for Decoding and Modulating Neural Circuit Activity Linked to Behavior (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-19-344	10-Mar-2021	Not Specified
	Contact Name Michele Ferrante				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-435-6782</p> <p>Contact Email michele.ferrante@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Mar-2021 , 10-Mar-2022</p> <p>Synopsis Explainable Artificial Intelligence (XAI) aims to provide strong predictive value along with mechanistic understanding of AI by combining machine learning techniques with effective explanatory techniques. This Funding Opportunity Announcement (FOA) solicits applications in the area of XAI applied to neuroscientific questions of encoding, decoding, and modulation of neural circuits linked to behavior. This FOA encourages collaborations between computationally and experimentally-focused investigators. This FOA seeks the development of machine learning algorithms that are able to mechanistically explain how experimental manipulations affect cognitive, affective, or social processing in humans or animals. Proof-of-concept applications aimed at improving the current state of the technology that uses XAI to provide unbiased, hierarchical explanations of causal relationships between complex neural and behavioral data are also appropriate .</p>				
076230	RFA-MH-19-147 -- BRAIN Initiative: Integration and Analysis of BRAIN Initiative Data (R01 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	RFA-MH-19-147	02-Feb-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Ming Zhan, Ph.D.</p> <p>Contact Telephone 301-827-3678</p> <p>Contact Email ming.zhan@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 02-Feb-2021 [Optional][LOI/Pre-App], 04-Mar-2021</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to develop informatics tools for analyzing, visualizing, and integrating data related to the BRAIN Initiative or to enhance our understanding of the brain This FOA will use the NIH R01 Research Project Grant award mechanism.</p>				
100293	RFA-MH-21-165 -- From Genomic -Association to Causation: A Convergent Neuroscience Approach for Integrating Levels of Analysis to Delineate Brain Function in Neuropsychiatric Disorders (U19 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	RFA-MH-21-165	15-Feb-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name David M. Panchision, Ph.D.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone	301-443-5288
Contact Email	panchisiond@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	15-Feb-2021 [Optional][LOI/Pre-App], 17-Mar-2021
Synopsis	<p>This Funding Opportunity Announcement (FOA) supports research to understand causal linkages across different scales (e.g., molecular, cellular, circuit, behavioral, clinical) relevant to neuropsychiatric disorders. The Convergent Neuroscience (CN) program goal is to establish theoretical models to show how specific constituent processes at one level of analysis contribute to quantifiable properties at other levels, either directly or as emergent phenomenon. Studies should incorporate four key features: (1) a premise on identifying the causal and disease-relevant relationships between objective genetic/biological/clinical criteria at two or more contiguous levels of analysis, whether involving human subjects or experimentally tractable in vivo or in vitro paradigms (genetic variation can be one of the contiguous levels of analysis or can be the context in which other, higher levels of analysis are linked); (2) use of the large and diverse datasets existing or generated at these levels of analysis to develop testable theoretical models within three years of award; (3) experimental testing of the model-based predictions to confirm or reject their validity, (4) preferential utilization of scalable approaches to maximize analytic throughput, content, sensitivity, selectivity, spatiotemporal resolution and robustness. Results should yield causal linkages between levels of analysis and mechanistically explain key functional dimension(s) relevant to mental illness pathophysiology. Leadership of research teams will include expertise in experimental neurobiology or clinical research paired with orthogonal theoretical disciplines (e.g., mathematics, computation, physics). This endeavor will be facilitated by active participation in a community-driven manner through the CN Consortium. Groups will manage their data and analysis methods using a harmonized framework with other U19 awardees through a CN Consortium Data Commons structure.</p>

100788	RFA-MH-21-160 -- Social Drivers of Mental Illnesses in Low- & Middle-Income Countries: Mechanisms and Pathways of Interventions for Youth (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	RFA-MH-21-160	18-Feb-2021 [Optional][LOI/Pre-App]	2,500,000 USD
--------	---	--	---------------	-------------------------------------	---------------

Contact Name	Stacia Friedman-Hill, PhD
Contact Telephone	301-443-8458
Contact Email	friedmans@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	18-Feb-2021 [Optional][LOI/Pre-App], 18-Mar-2021

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to solicit research that will help to identify and explain the mechanisms and pathways by which interventions targeting social drivers of mental illnesses affect the mental health and functioning of children and/or adolescents (ages 5-24 years) living in World Bank designated low- and middle-income countries (LMICs) and previously designated LMICs re-categorized as high income on or after January 1, 2021. Studies should use innovative approaches to capture as much real-world complexity as possible in identifying and elucidating mechanisms and pathways that reduce risk for mental illnesses or improve mental health in children and/or adolescents. NIMH welcomes applicants from LMICs and strongly encourages applicants from the United States or upper middle income countries to partner with sites in LMICs.</p>			
101117	RFA-MH-21-116 -- Mood Disorders in People Living with HIV: Mechanisms and Pathways (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	RFA-MH-21-116	10-Feb-2021 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Vasudev R Rao, MBBS, MS.			
	Contact Telephone	301-825-3259			
	Contact Email	vasudev.rao@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	10-Feb-2021 [Optional][LOI/Pre-App], 10-Mar-2021			
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to support studies to better understand the underlying mechanisms and interplay of biological, psychosocial and structural factors contributing to mood disorders in people living with HIV. Applications testing a fully conceptualized and hypothesis-based solid premise founded with adequate preliminary data are appropriate for this FOA. Exploratory and high-risk research projects should consider applying to the companion R21 announcement RFA-MH-21-117. Basic and preclinical research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.</p>			
101119	RFA-MH-21-117 -- Mood Disorders in People Living with HIV: Mechanisms and Pathways (R21 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	RFA-MH-21-117	10-Feb-2021 [Optional][LOI/Pre-App]	275,000 USD
	Contact Name	Vasudev R Rao, MBBS, MS.			
	Contact Telephone	301-825-3259			
	Contact Email	vasudev.rao@nih.gov			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Feb-2021 [Optional][LOI/Pre-App], 10-Mar-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support studies to better understand the underlying mechanisms and interplay of biological, psychosocial and structural factors contributing to mood disorders in people living with HIV. Exploratory and high-risk research projects are appropriate for this FOA. Applications testing a fully conceptualized and hypothesis-based solid premise founded with adequate preliminary data should consider applying to the companion R01 announcement RFA-MH-21-116. Basic and preclinical research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.</p>				
100375	<p>RFA-MH-21-140 -- BRAIN Initiative Cell Census Network (BICCN) Scalable Technologies and Tools for Brain Cell Census (R01 Clinical Trial Not Allowed)</p>	National Institute of Mental Health/NIH/DHHS	RFA-MH-21-140	10-Feb-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Yong Yao, Ph.D.</p> <p>Contact Telephone 301-443-6102</p> <p>Contact Email yyao@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Feb-2021 [Optional][LOI/Pre-App], 10-Mar-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) intends to accelerate the use of scalable technologies and tools to enhance brain cell census research, including the development of technology platforms and/or resources and the generation of spatiotemporal cell census data and/or resources. Applications are expected to address limitations and gaps of existing technologies/tools as a benchmark against which the improvements or competitive advantages of the proposed ones will be measured. The improvements include throughput, sensitivity, selectivity, scalability, spatiotemporal resolution and reproducibility in cell atlas analyses. The projects funded under this FOA will align with the overarching goals of the BRAIN Initiative Cell Census Network (BICCN) and are expected to enable the generation of a large amount of cell census data using the proposed technologies or via collaboration with the BICCN.</p>				
077849	<p>RFA-NS-19-011--NIH Blueprint Diversity Specialized Predoctoral to Postdoctoral Advancement in Neuroscience (D-SPAN) Award (F99/K00 Independent Clinical Trial Not Allowed)</p>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-19-011	16-Mar-2021 [Optional][LOI/Pre-App]	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Michelle Jones-London, PhD</p> <p>Contact Telephone 301-451-7966</p> <p>Contact Email jonesmiche@ninds.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Mar-2021 [Optional][LOI/Pre-App], 15-Apr-2021</p> <p>Synopsis The purpose of the NIH Blueprint Diversity Specialized Predoctoral to Postdoctoral Advancement in Neuroscience (D-SPAN) Award is to support a defined pathway across career stages for outstanding graduate students from diverse backgrounds, including those from groups underrepresented in biomedical and behavioral sciences. This two-phase award will facilitate completion of the doctoral dissertation and transition of talented graduate students to strong neuroscience research postdoctoral positions, and will provide career development opportunities relevant to their long-term career goal of becoming independent neuroscience researchers. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor</p>				
101493	<p>RFA-NS-21-017 -- Next Generation Sequencing in Post Mortem Tissue from Patients with Parkinson's Disease (U01 Clinical Trial Not Allowed)</p>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-21-017	15-Mar-2021	Not Specified
	<p>Contact Name Debra Babcock, PhD, MD</p> <p>Contact Telephone 301-496-9964</p> <p>Contact Email dbabcock@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Mar-2021</p> <p>Synopsis This FOA seeks applications to perform single nucleus RNA sequencing (snRNA seq) and whole genome sequencing (WGS) in post-mortem brain tissue from 100 patients with Parkinson's Disease (PD) and normal controls. Applicants will be expected to have access to high quality brain tissue and perform sequencing in four separate brain regions, including some regions known to be affected by PD pathology and at least one region known to be relatively unaffected. All sequencing data and any available pre-mortem clinical data will be broadly shared with the research community through the Accelerating Medicine Partnership in Parkinson's Disease (AMP PD) Knowledge Portal.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
085884	Patient Activation for Self-Management of Chronic Conditions (R21 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-19-382	16-Feb-2021	400,000 USD
	Contact Name	Karen Huss, PhD, RN, APRN-BC, FAAN, FAAAAI			
	Contact Telephone	301-594-5970			
	Contact Email	hussk@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Feb-2021 , 16-Mar-2021 , 07-May-2021 , 16-Jun-2021 , 16-Jul-2021 , 07-Sep-2021 , 16-Feb-2022 , 16-Mar-2022 , 07-May-2022 , 16-Jun-2022 , 16-Jul-2022 , 07-Sep-2022 , 16-Feb-2023 , 16-Mar-2023 , 07-May-2023			
	Synopsis	The purpose of this Funding Opportunity Announcement is to encourage grant applications that address the influence of patient activation on self-management of chronic conditions.			
085882	Patient Activation for Self-Management of Chronic Conditions (R01 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-19-381	05-Feb-2021	Not Specified
	Contact Name	Karen Huss, PhD, RN, APRN-BC, FAAN, FAAAAI			
	Contact Telephone	301-594-5970			
	Contact Email	hussk@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021 , 05-Mar-2021 , 07-May-2021 , 05-Jun-2021 , 05-Jul-2021 , 07-Sep-2021 , 05-Feb-2022 , 05-Mar-2022 , 07-May-2022 , 05-Jun-2022 , 05-Jul-2022 , 07-Sep-2022 , 05-Feb-2023 , 05-Mar-2023 , 07-May-2023			
	Synopsis	The purpose of this Funding Opportunity Announcement is to encourage grant applications that address the influence of patient activation on self-management of chronic conditions.			
097721	Notice of Special Interest (NOSI): Sex and Gender Differences in Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD)	National Institute on Aging/NIH/DHHS	NOT-AG-20-038	11-Mar-2021	Not Specified
	Contact Name	Amelia Karraker, Ph.D.			
	Contact Telephone	301-496-3131			
	Contact Email	amelia.karraker@nih.gov			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Mar-2021 , 09-Jul-2021 , 12-Nov-2021</p> <p>Synopsis This Notice of Special Interest (NOSI) is intended to promote multidisciplinary research to clarify sex and gender differences in the risk, development, progression, diagnosis, and clinical presentation of Alzheimer's disease or Alzheimer's disease-related dementias (AD/ADRD). Studies that examine sex and gender differences in outcomes (e.g., clinical, functional, well-being) among people living with AD/ADRD are also relevant. Broad areas of interest include biological (e.g., hormonal, genetic, metabolic, comorbidity-related), neuroscientific (e.g., neural systems and functions), behavioral (e.g., physical activity, substance use, social engagement), social (e.g., history of maltreatment or adversity, child rearing, marital status, education, employment), psychological (e.g., depression, cognitive ability, emotional function, stress reactivity, personality), and healthcare profession (e.g., provider knowledge and attitudes about dementia) and healthcare system-level (e.g., access to care) factors and processes that separately or together may drive observed differences by sex and gender and/or may operate differently by sex and gender. Studies that account for methodological and measurement issues that may drive sex and gender differences are also of interest.</p>				
078596	Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-19-071	11-Mar-2021	275,000 USD
	<p>Contact Name Robin A. Barr, D.Phil.</p> <p>Contact Telephone 301-402-7715</p> <p>Contact Email BarrR@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Mar-2021 , 09-Jul-2021 , 12-Nov-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing new tests, animal models, techniques, etc. to advance research on Alzheimer's disease and its related dementias and which need additional preliminary data with broader dissemination to establish them for more general use in this research field. The priority topics will be announced through a series of Notices published subsequent to this FOA.</p>				
081422	Environmental Influences on Aging: Effects of Extreme Weather and Disaster Events on Aging Processes (R01 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-19-249	08-Mar-2021	Not Specified
	<p>Contact Name Ronald A. Kohanski, Ph.D.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-496-6402</p> <p>Contact Email kohanskir@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Mar-2021</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to support research to explore the impacts of extreme weather and disaster events on the basic biology of aging. Together with the companion FOA (PAR-19-250) that focuses on how extreme weather and disaster events impact older adults, these complementary FOAs will help to explicate the behavioral, biological, epigenetic, genetic, neurological and socioecological processes that affect the aging process. Through integration of this and the companion population studies FOA, the ultimate goal is to improve the health and well-being of older adults via increased knowledge about extreme weather and disaster preparedness, response, and recovery.</p>				
101208	Notice of Special Interest (NOSI): Sensory and Motor System Changes as Predictors of Preclinical Alzheimer's Disease	National Institute on Aging/NIH/DHHS	NOT-AG-20-053	11-Mar-2021	Not Specified
	<p>Contact Name Coryse St. Hillaire-Clarke, Ph.D.</p> <p>Contact Telephone 301-827-6944</p> <p>Contact Email sthillaireclacn@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Mar-2021 , 09-Jul-2021 , 12-Nov-2021</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to encourage applications that propose either basic, clinical, or a combination of basic and clinical studies to investigate how functional changes in the sensory and/or motor systems impact the development and progression of Alzheimer's disease. Studies may include older adults and/or animal models and may employ a variety of approaches, including but not limited to cellular, molecular, imaging, physiological, and genetic, to address this need. For clinical studies, leveraging of existing longitudinal cohorts already collecting sensory and motor assessments is highly encouraged.</p>				
101533	RFA-RM-21-008 -- Cellular Senescence Network: Tissue Mapping Centers (U54 - Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	RFA-RM-21-008	08-Feb-2021 [Optional][LOI/Pre-App]	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Felipe Sierra, Ph.D. 240-338-9544 sierraf@nia.nih.gov Link to program URL 08-Feb-2021 [Optional][LOI/Pre-App], 08-Mar-2021 Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to establish state-of-the-art Tissue Mapping Centers (TMCs) to work within the Cellular Senescence Network (SenNet). The goal of the SenNet consortium is to identify and functionally characterize the heterogeneity of senescent cells across multiple tissues in human health, disease, and lifespan at single-cell resolution. Through collaborative efforts, the consortium will generate a multimodal, multidimensional Atlas of senescent cells in various human tissues; develop innovative tools and technologies to identify and characterize senescent cells; and aggregate data across the Network into a searchable Atlas of Cellular Senescence, ensure the utility of the database, and promote collaboration through Network engagement with the research community. The TMCs solicited through this RFA will generate the high-resolution, high-content, multiscale biomarkers and maps of cellular senescence across the lifespan and physiological states necessary to generate the Senescence Atlas. The SenNet is focused on healthy human tissues, and work in diseased tissue or animal models is acceptable only as long as it is used to support this overall goal. TMCs will be expected to integrate and optimize all parts of the data generation pipeline, from tissue collection and preservation through analyses at organ, tissue and single cell level using omics, imaging and other approaches, to data integration, analysis and interpretation. This Funding Opportunity Announcement (FOA) is developed as a Common Fund initiative (http://commonfund.nih.gov/) through the NIH Office of the NIH Director, Office of Strategic Coordination (https://dpcpsi.nih.gov/). All NIH Institutes and Centers participate in Common Fund initiatives. The FOA will be administered by the National Institute on Aging (NIA) (https://www.nia.nih.gov) on behalf of the NIH.
--	---

101540	RFA-AG-20-042 -- Regulation of Brain Regional and Cell Type Specific Proteome Dynamics in Aging and Alzheimer's Disease (R01 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	RFA-AG-21-033	18-Feb-2021 [Optional][LOI/Pre-App]	3,750,000 USD
--------	--	--------------------------------------	---------------	-------------------------------------	---------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL	J. Austin Yang, Ph.D. 301-496-9350 austin.yang@nih.gov Link to program URL
--	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 18-Feb-2021 [Optional][LOI/Pre-App], 18-Mar-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites innovative research focused on understanding the regulation of brain regional and cell-type-specific proteome dynamics in Alzheimer’s disease (AD). Specifically, this FOA encourages collaborative approaches to design and implement novel, single-cell-based proteomic platforms to comprehensively characterize the dynamics of neuronal proteomes during the course of aging and AD.</p>				
101705	RFA-AG-21-034 -- Infectious Etiology of Alzheimer's Disease (R01 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	RFA-AG-21-034	28-Feb-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Mirosław ‘Mack’ Mackiewicz, Ph.D.</p> <p>Contact Telephone 301-594-7636</p> <p>Contact Email miroslaw.mackiewicz@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 28-Feb-2021 [Optional][LOI/Pre-App], 31-Mar-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will support applications aimed at: (1) determining whether microbial pathogens represent a causal component of Alzheimer’s disease (AD), (2) establishing mechanisms by which microbial pathogens impact neurodegenerative processes in AD, and (3) informing aspects of future translational studies in AD, including the discovery of candidate therapeutics aimed at regulating pathogen-associated networks and molecules in AD.</p>				
080217	Summer Research Education Experience Program (R25 Clinical Trial Not Allowed)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-19-197	17-Mar-2021	500,000 USD
	<p>Contact Name L Lynn Morin</p> <p>Contact Telephone 301-402-0176</p> <p>Contact Email Lynn.Morin@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Mar-2021 , 07-May-2021</p> <p>Synopsis The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

workforce to meet the nation's biomedical, behavioral and clinical research needs.

071939	Supplements to Advance Research (STAR) from Projects to Programs (Admin Supp Clinical Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-18-647	01-Mar-2021	300,000 USD
--------	---	---	-----------	-------------	-------------

Contact Name	Abraham P. Bautista, Ph.D.
Contact Telephone	301-443-9737
Contact Email	bautista@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	01-Mar-2021
Synopsis	National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites administrative supplement applications to promote innovation and novel high-risk projects by early established investigators (EIs). The supplement will allow EIs to expand and explore new opportunities within the scope of the currently funded R01 grant, and to facilitate the transition from a single, structured research project to a research program. This FOA will use the NIH Administrative Supplement award mechanism.

080374	Alcohol and Other Substance Use Research Education Programs for Health Professionals (R25 Clinical Trial Not Allowed)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-19-207	15-Mar-2021	1,000,000 USD
--------	---	---	------------	-------------	---------------

Contact Name	Lori Ducharme, PhD
Contact Telephone	301-451-8507
Contact Email	ducharmel@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	15-Mar-2021 , 10-Aug-2021 , 15-Nov-2021 , 15-Mar-2022 , 10-Aug-2022
Synopsis	The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this IC Name R25 program is to support educational activities that complement and/or foster a better understanding of biomedical, behavioral and clinical research and its implications. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Outreach. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIAAA/NIDA R25 program is to support educational activities that foster a better understanding of biomedical, behavioral, and clinical research on alcohol and other substance use disorders and their implications. To accomplish the stated over-

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

arching goal, this FOA will support creative educational activities with a primary focus on Outreach. Specifically, this FOA will support projects designed to engage practicing health care professionals in education about current and emerging knowledge derived from scientific research on the neurobiology, epidemiology, prevention, and/or treatment of alcohol and other substance use disorders and related health conditions.

070958	Investigational New Drug (IND)-enabling Development of Medications to Treat Alcohol Use Disorder and Alcohol-related disorders (U44 - Clinical Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-18-578	25-Mar-2021	Not Specified
--------	--	---	------------	-------------	---------------

Contact Name	Raye Z. Litten, Ph.D.
Contact Telephone	301-443-0636
Contact Email	rlitten@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	25-Mar-2021
Synopsis	National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications for Small Business Innovation Research (SBIR) from small business concerns (SBCs) that propose the development of therapeutic agents for disorders that fall under the mission of NIAAA. An identified candidate, having sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application, is required prior to application. The FOA supports Investigational New Drug (IND)-enabling studies for the therapeutic candidate. At the end of the funding period, a successful project should have, at a minimum, an IND application submitted to the U.S. Food and Drug Administration (FDA). The program supports early-phase clinical trials, although these are not required. This FOA will utilize the NIH U44 Small Business Innovation Research (SBIR) Cooperative Agreement – Fast-Track mechanism.

070962	Investigational New Drug (IND)-enabling Development of Medications to Treat Alcohol Use disorder and Alcohol-related disorders (UT2 Clinical Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-18-580	25-Mar-2021	Not Specified
--------	--	---	------------	-------------	---------------

Contact Name	Raye Z. Litten, Ph.D.
Contact Telephone	301-443-0636
Contact Email	rlitten@mail.nih.gov
Sponsor Website	

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-Mar-2021</p> <p>Synopsis National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites Small Business Technology Transfer (STTR) applications from small business concerns (SBCs) that propose the development of therapeutic agents for disorders that fall under the mission of NIAAA. An identified candidate, having sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application, is required prior to application. The FOA supports Investigational New Drug (IND)-enabling studies for the therapeutic candidate. At the end of the funding period, a successful project should have, at a minimum, an IND application submitted to the U.S. Food and Drug Administration (FDA). The program supports early-phase clinical trials, although these are not required. This FOA will utilize the NIH UT2 Small Business Technology Transfer (STTR) Cooperative Agreement – Fast-Track mechanism.</p>				
082413	Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-19-282	10-Mar-2021	Not Specified
	<p>Contact Name Vani Pariyadath, Ph.D.</p> <p>Contact Telephone 301-443-3209</p> <p>Contact Email vani.pariyadath@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Mar-2021 , 07-May-2021 , 13-Oct-2021 , 07-Jan-2022 , 11-Jul-2022 , 07-Sep-2022 , 10-Mar-2023 , 07-May-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) uses a R61/R33 Phased Innovation Award mechanism to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying Substance Use Disorders (SUD), including fundamental brain function relevant to substance use. For projects not requiring a phased research approach, applicants are encouraged to apply under a different funding mechanism (e.g., Neuroscience Research on Drug Abuse (R01 Clinical Trial Optional)).</p>				
078920	HEAL Initiative: America's Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44 - Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-19-019	10-Mar-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Elena Koustova, PhD, MBA</p> <p>Contact Telephone 301-496-8768</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email NIDASBIR@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Mar-2021 [Optional][LOI/Pre-App], 09-Apr-2021 , 09-Aug-2021 [Optional][LOI/Pre-App], 08-Sep-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA), issued by the National Institute on Drug Abuse (NIDA), invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications to develop technologies to provide science- and research-based solutions to the national opioid emergency and offer new hope for individuals, families, and communities affected by this devastating crisis. United States SBCs that have the research capabilities and technological expertise to contribute to NIDA R&D mission identified in this FOA are encouraged to submit SBIR grant applications in response to the FOA topics.</p>				
078921	HEAL Initiative: America's Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R41/R42 - Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-19-020	10-Mar-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Elena Koustova, PhD, MBA</p> <p>Contact Telephone 301-496-8768</p> <p>Contact Email NIDASBIR@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Mar-2021 [Optional][LOI/Pre-App], 09-Apr-2021 , 09-Aug-2021 [Optional][LOI/Pre-App], 08-Sep-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA), issued by the National Institutes on Drug Abuse (NIDA), invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications to develop technologies to provide science- and research-based solutions to the national opioid emergency and offer new hope for individuals, families, and communities affected by this devastating crisis. United States SBCs that have the research capabilities and technological expertise to contribute to NIDA R&D mission identified in this FOA are encouraged to submit STTR grant applications in response to the FOA topics.</p>				
074734	Genetic Analysis of Non-Human Animal Models to Understand the Genomic Architecture of Substance Use Disorders and Addictive Behaviors (U01 Clinical Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	PAR-18-789	19-Mar-2021	Not Specified
	Contact Name Da-Yu Wu, PhD				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-435-4649</p> <p>Contact Email wudy@nida.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 19-Mar-2021</p> <p>Synopsis National Institute on Drug Abuse (NIDA) invites applications to discover allelic variants, genomic alterations, and functional changes associated with addictive behaviors in non-human animals through systems studies that employ genetic and genomics strategies. We also encourage applications that take genetic and/or genomics approaches to integrate data, delineate gene networks, and uncover the function of known or newly discovered genetic or epigenetic variants. This program will use the NIH U01 Research Project Cooperative Agreements award mechanism.</p>				
096665	<p>NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional)</p>	National Institute on Drug Abuse/NIH/DHHS	PAR-20-249	01-Mar-2021	2,500,000 USD
	<p>Contact Name Aria Davis Crump, Sc.D.</p> <p>Contact Telephone 301-435-0881</p> <p>Contact Email acrump@nida.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Mar-2021 , 02-Aug-2021 , 15-Nov-2021 , 01-Mar-2022 , 02-Aug-2022 , 15-Nov-2022 , 01-Mar-2023 , 02-Aug-2023 , 15-Nov-2023</p> <p>Synopsis This funding opportunity announcement (FOA) encourages applications for institutional research career development (K12) programs that propose to support intensive supervised research and career development experiences for clinician scientists (Scholars) leading to research independence in the area of substance use and substance use disorder research. For this FOA, clinician scientists may include (but are not limited to) physicians, clinical psychologists, epidemiologists, doctoral level social workers, pharmacists, and behavioral scientists. Scholars are expected to be supported for 3-5 years on consecutive 12-month appointments. Candidates selected for support as scholars must hold a doctorate and commit a minimum of 9 person months (equivalent to 75% of full-time professional effort) to conducting clinical research and career development activities associated with the proposed program This FOA allows appointment of scholars proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary study to an existing trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
080453	Behavioral & Integrative Treatment Development Program (R01 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-19-212	23-Mar-2021	Not Specified
	<p>Contact Name Will M. Aklin, Ph.D.</p> <p>Contact Telephone 301-827-5909</p> <p>Contact Email aklinwm@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 23-Mar-2021 , 23-Jul-2021 , 23-Mar-2022</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to encourage behavioral intervention development research. Specifically, test efficacy, conduct clinical trials, examine mechanisms of behavior change, determine dose-response, treatment optimization, and/or ascertain best sequencing of behavioral, combined, sequential, or integrated behavioral and pharmacological treatments. Research of interest includes but is not limited to Stage II and Stage III efficacy research, including: (1) drug abuse treatment interventions, including interventions for patients with comorbidities; (2) drug abuse treatment and adherence interventions; (3) drug abuse treatment and adherence interventions that utilize technologies to boost effects and increase implementability and sustainability; (4) interventions to prevent the acquisition or transmission of HIV infection among individuals in drug abuse treatment; (5) interventions to promote adherence to drug abuse treatment, HIV and addiction medications; and (6) interventions to treat substance misuse and chronic pain</p>				
080458	Behavioral & Integrative Treatment Development Program (R34 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-19-213	23-Mar-2021	450,000 USD
	<p>Contact Name Will M. Aklin, Ph.D.</p> <p>Contact Telephone 301-827-5909</p> <p>Contact Email aklinwm@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 23-Mar-2021 , 23-Jul-2021 , 23-Mar-2022</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to encourage behavioral intervention development research. Specifically, test efficacy, conduct clinical trials, examine mechanisms of behavior change, determine dose-response, treatment optimization, and/or ascertain best sequencing of behavioral, combined, sequential, or integrated behavioral and pharmacological treatments. Research of interest includes but is not limited to Stage I research, including: (1) drug abuse</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		treatment interventions, including interventions for patients with comorbidities; (2) drug abuse treatment and adherence interventions; (3) drug abuse treatment and adherence interventions that utilize technologies to boost effects and increase implementability and sustainability; (4) interventions to prevent the acquisition or transmission of HIV infection among individuals in drug abuse treatment; (5) interventions to promote adherence to drug abuse treatment, HIV and addiction medications; and (6) interventions to treat substance misuse and chronic pain.			
091068	Extracellular RNA Carrier Subclasses in Processes Relevant to Substance Use Disorders or HIV infection (R01- Clinical Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	PAR-20-147	15-Mar-2021	Not Specified
	Contact Name	John Satterlee, Ph.D			
	Contact Telephone	301-435-1020			
	Contact Email	satterleej@nida.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Mar-2021 , 07-May-2021 , 13-Oct-2021 , 07-Jan-2022 , 15-Mar-2022 , 07-May-2022 , 13-Oct-2022 , 07-Jan-2023 , 15-Mar-2023 , 07-May-2023			
	Synopsis	The purpose of this FOA is to encourage research investigating the roles of extracellular RNA (exRNA) carrier subclasses in biological processes relevant to substance use disorders (SUDs) and/or HIV infection, latency, or pathogenesis in the CNS. Applicants may propose to investigate biological mechanisms involving exRNA carrier subclasses, or propose to develop improved technologies to investigate extracellular vesicles or other exRNA carriers.			
091070	Extracellular RNA Carrier Subclasses in Processes Relevant to Substance Use Disorders or HIV infection (R21- Clinical Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	PAR-20-148	15-Mar-2021	275,000 USD
	Contact Name	John Satterlee, Ph.D			
	Contact Telephone	301-435-1020			
	Contact Email	satterleej@nida.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Mar-2021 , 07-May-2021 , 13-Oct-2021 , 07-Jan-2022 , 15-Mar-2022 , 07-May-2022 , 13-Oct-2022 , 07-Jan-2023 , 15-Mar-2023 , 07-May-2023			
	Synopsis	The purpose of this FOA is to encourage research investigating the roles of extracellular RNA (exRNA) carrier subclasses in			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		biological processes relevant to substance use disorders (SUDs) and/or HIV infection, latency, or pathogenesis in the CNS. Applicants may propose to investigate biological mechanisms involving exRNA carrier subclasses, or propose to develop improved technologies to investigate extracellular vesicles or other exRNA carriers.			
077954	Mechanisms of Disparities in Etiology and Outcomes of Lung Cancer in the U.S.: The Role of Risk and Protective Factors (R01 Clinical Trial Not Allowed)	National Institute on Minority Health and Health Disparities/NIH/DHHS	PAR-19-018	04-Mar-2021	Not Specified
	Contact Name	Rina Das, PhD, Program Director			
	Contact Telephone	301-496-3996			
	Contact Email	dasr2@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	04-Mar-2021			
	Synopsis	This initiative will support multidisciplinary research to understand the underlying causal factors and mechanisms that result in lung cancer disparities in U.S. health disparity populations.			
078762	Leveraging Health Information Technology (Health IT) to Address Minority Health and Health Disparities (R01 Clinical Trial Optional)	National Institute on Minority Health and Health Disparities/NIH/DHHS	PAR-19-093	04-Mar-2021	Not Specified
	Contact Name	Beda Jean-Francois, Ph.D.			
	Contact Telephone	301-594-9764			
	Contact Email	beda.jean-francois@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	04-Mar-2021			
	Synopsis	This funding opportunity announcement (FOA) seeks to support research that examines how health information technology adoption impacts minority health and health disparity populations in access to care, quality of care, patient engagement, and health outcomes.			
101093	RFA-RM-20-023 -- NIH Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Program: FIRST Coordination and Evaluation Center	National Institute on Minority Health and Health	RFA-RM-20-	30-Jan-2021 [Optional][LOI/Pre-	6,840,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	(U24 Clinical Trial Not Allowed)		Disparities/NIH/DHHS	023 App]	
	<p>Contact Name Dr. Rina Das</p> <p>Contact Telephone 301-496-3996</p> <p>Contact Email FIRSTNIH@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 30-Jan-2021 [Optional][LOI/Pre-App], 01-Mar-2021</p> <p>Synopsis The purpose of the NIH Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Coordination and Evaluation Center (CEC), is to coordinate and facilitate the development of strategies with FIRST Cohort awardees to conduct a comprehensive evaluation of the FIRST program.</p>				
077956	Mechanisms of Disparities in Etiology and Outcomes of Lung Cancer in the U.S.: The Role of Risk and Protective Factors (R21 Clinical Trial Not Allowed)		National Institute on Minority Health and Health Disparities/NIH/DHHS	PAR-19-019 04-Mar-2021	275,000 USD
	<p>Contact Name Rina Das, PhD, Program Director</p> <p>Contact Telephone 301-496-3996</p> <p>Contact Email dasr2@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 04-Mar-2021</p> <p>Synopsis This initiative will support multidisciplinary research to understand the underlying causal factors and mechanisms that result in lung cancer disparities in U.S. health disparity populations.</p>				
095519	Mid-Career Enhancement Awards to Integrate Basic Behavioral, Biomedical, and/or Social Scientific Processes (K18 Basic Experimental Studies with Humans Required)		National Institutes of Health/DHHS	PAR-20-226 17-Mar-2021	Not Specified
	<p>Contact Name William Elwood, PhD</p> <p>Contact Telephone 301-402-0116</p> <p>Contact Email william.elwood@nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Mar-2021 , 17-Mar-2022 , 17-Mar-2023</p> <p>Synopsis</p> <p>This Funding Opportunity Announcement (FOA) invites applications from investigators who strive to expand their research trajectories through the acquisition of new knowledge and skills in the areas of basic psychological processes, sociological processes, and/or biomedical pathways—expertise that is beyond and enhances their current areas of expertise. The program will support career development experiences and a small-scale research project that will provide experienced investigators with the scientific competencies required to conduct independent research projects that more thoroughly investigate interrelationships among behavioral, biological, endocrine, epigenetic, immune, inflammatory, neurological, psychological, and/or social processes. Eligible candidates are independent investigators at mid-career faculty rank or level. Applicants may propose research career development projects that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical and/or behavioral outcomes in humans to understand fundamental aspects of phenomena (see, NOT-OD-18-212). These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants who plan to gain research experience within an existing clinical trial or basic experimental study with humans led by another investigator, or who propose to gain research experience in purely basic human or model animal research, or in data sciences, must apply to companion FOA, PAR--20-211, Independent Clinical Trials Not Allowed. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind.</p>				
078592	Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-19-070	11-Mar-2021	Not Specified
	Contact Name	Robin A. Barr, D.Phil.			
	Contact Telephone	301-402-7715			
	Contact Email	BarrR@mail.nih.gov			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	11-Mar-2021 , 09-Jul-2021 , 12-Nov-2021			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing research on current topics in Alzheimer's disease and its related dementias. Further information on the high-priority topics of interest will be announced through a series of Notices published subsequent to this FOA.			
086488	Integrative Research on Polysubstance Abuse and Disorder (R61/R33 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-20-035	17-Mar-2021	2,100,000 USD
	Contact Name	Shelley Su, Ph.D.			
	Contact Telephone	301-402-3869			
	Contact Email	shelley.su@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	17-Mar-2021 , 19-Jul-2021 , 17-Nov-2021 , 17-Mar-2022 , 19-Jul-2022 , 07-Nov-2022			
	Synopsis	This Funding Opportunity Announcement (FOA) is supported by Collaborative Research on Addiction (CRAN) at the National Institutes of Health (NIH), a trans-NIH partnership composed of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Drug Abuse (NIDA), and the National Cancer Institute (NCI). The intent of this FOA is two-fold: (1) characterize how the neurobiological alterations, associated behaviors, and public health consequences arising from polysubstance use differ from, or are similar to, those observed in single drug use; (2) promote integrative polysubstance research along a translational pipeline, consisting of basic science research in animals, human-based laboratory investigations, and epidemiological studies. These dual objectives will be accomplished with an Exploratory/Developmental Phased Award (R61/R33) mechanism, where polysubstance research can occur in any of these translational stages during the R61 phase and these findings will be rapidly back- or forward-integrated into another stage during the R33 phase, permitting accelerated bi-directional research exchange.			
096383	Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19) in Individuals with Down Syndrome for the INCLUDE Project	National Institutes of Health/DHHS	NOT-OD-20-129	12-Mar-2021	1,000,000 USD
	Contact Name	Ryan Talesnik			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-435-6976</p> <p>Contact Email talesnikr@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Mar-2021 , 12-Jul-2021</p> <p>Synopsis NIH is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) in individuals with Down syndrome in conjunction with the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Project. Because many people with Down syndrome are at increased risk of having co-occurring medical conditions, such as pulmonary disease, cardiac problems, obesity, diabetes, sleep apnea, and altered immune function that may predispose them to more severe infection with SARS-CoV-2, they may be particularly vulnerable to COVID-19 complications. Combined with shared living situations, and reduced access to testing and treatment services due to disparities in provision of resources, the impact of COVID-19 infection in people with Down syndrome is likely to be elevated. The overarching goal of this NOSI is to improve understanding and treatment of COVID-19 infection in individuals with Down syndrome and reduce COVID-19 associated morbidity and mortality for this population, which may be disproportionately affected by, have higher infection rates of, and/or be at elevated risk for adverse outcomes from contracting the virus.</p>				
100888	<p>RFA-NS-21-005 -- Small Vessel VCID Biomarker Validation Consortium Sites (U01)(Clinical Trials Not Allowed)</p>	National Institutes of Health/DHHS	RFA- NS-21-005	09-Feb-2021 [Optional][LOI/Pre-App]	4,000,000 USD
	<p>Contact Name Roderick A. Corriveau, Ph.D.</p> <p>Contact Telephone 301-496-5680</p> <p>Contact Email roderick.corriveau@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Feb-2021 [Optional][LOI/Pre-App], 09-Mar-2021</p> <p>Synopsis The purpose of this funding opportunity announcement is to invite applications to an open competition to be one of up to 7 supported sites in the next phase of the NINDS small vessel vascular contributions to cognitive impairment and dementia (VCID) biomarkers consortium. The original consortium, established under RFA-NS-16-019 and RFA-NS-16-020, pursued initial stages of multi-site validation of 11 candidate imaging-based and fluid-based biomarkers. The primary objective of the next 5 years is to carry out comprehensive multi-site clinical validation of up to six of these 11 biomarkers to be selected by the</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

NINDS in a process separate from this FOA. The focus will be validation in longitudinal studies of diverse all-comers populations that are typical in clinical settings in the United States. The network of sites will provide scientific expertise and experimental infrastructure to pursue these goals synergistically including with the Coordinating Center (RFA-NS-21-004). At the conclusion of clinical validation each biomarker will have a designated category and context of use as defined by the FDA and a finalized public protocol that describes all details needed to utilize the biomarker. The sites will drive the consortium scientifically and contribute administratively to comprehensive rigorous clinical validation of biomarkers for future clinical trials, including in large phase III trials, and for generating scientific breakthroughs in our understanding and treatment of VCID.

100056	Health Services Research on Minority Health and Health Disparities (R01-Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-20-310	17-Mar-2021	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Rada K. Dagher, PhD
Contact Telephone	301-451-2187
Contact Email	rada.dagher@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	17-Mar-2021 , 17-Nov-2021 , 17-Mar-2022 , 17-Nov-2022 , 17-Feb-2023 , 17-Mar-2023
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage innovative health services research that can directly and demonstrably contribute to the improvement of minority health and/or the reduction of health disparities at the health care system-level as well as within clinical settings.

100890	RFA-NS-21-004 -- Small Vessel VCID Biomarkers Validation Consortium Coordinating Center (U24 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-NS-21-004	09-Feb-2021 [Optional][LOI/Pre-App]	Not Specified
--------	--	------------------------------------	---------------	-------------------------------------	---------------

Contact Name	Roderick A. Corriveau, Ph.D.
Contact Telephone	301-496-5680
Contact Email	roderick.corriveau@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	09-Feb-2021 [Optional][LOI/Pre-App], 09-Mar-2021

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
099865	RFA-NS-21-010 -- HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-NS-21-010	22-Feb-2021 [Optional][LOI/Pre-App]	Not Specified

Synopsis | The purpose of this funding opportunity announcement (FOA) is to have an open competition to support a Coordinating Center for the next phase of the NINDS small vessel vascular contributions to cognitive impairment and dementia (VCID) biomarkers consortium. The original consortium was established under RFA-NS-16-019 and RFA-NS-16-020. The goal of the next phase, under RFA-NS-21-004 (Coordinating Center) and RFA-NS-21-005 (sites), is to complete clinical validation of biomarkers initially developed during the first 5-year funding cycle of this program. The Coordinating Center will consist of: (i) an Administrative Core responsible for organizing, coordinating and administratively driving Consortium activities; and (ii) a Data Core that will coordinate, receive, collect, and share data, including de-identified clinical data. The Coordinating Center will drive the consortium administratively and contribute scientifically to validation of biomarkers with specified context of use for future clinical trials, including in large phase III trials, with general and diverse populations, and for generating scientific breakthroughs in our understanding and treatment of VCID.

Contact Name	Michael Oshinsky
Contact Telephone	301-496-9964
Contact Email	michael.oshinsky@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	22-Feb-2021 [Optional][LOI/Pre-App], 24-Mar-2021 , 14-Jun-2021 [Optional][LOI/Pre-App], 14-Jul-2021 , 15-Sep-2021 [Optional][LOI/Pre-App], 15-Oct-2021 , 16-Jan-2022 [Optional][LOI/Pre-App], 15-Feb-2022 , 16-May-2022 [Optional][LOI/Pre-App], 15-Jun-2022
Synopsis	The purpose of this funding opportunity announcement (FOA) is to support preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain. The goal of the program is to accelerate the optimization and development of promising small molecule and biologic hits/leads to Phase I clinical trials and readiness for the Early Phase Pain Investigation Clinical Network (EPPIC-Net) https://heal.nih.gov/research/clinical-research/eppic-net or other Phase II clinical studies. Applicants must have a promising biologic or small molecule hit/lead, robust biological rationale for the intended approach, and identified assays for optimization of the agent. The scope of this program includes optimization and early development activities, IND-enabling studies, development of a pharmacodynamic/target engagement biomarker, assembly and filing of an Investigational New Drug (IND) application and Phase I clinical testing. This is a milestone-driven phased cooperative agreement program involving participation of NIH program staff in the development of the project plan and monitoring of research progress.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
100941	RFA-CA-21-001 -- Small Business Transition Grant For Early Career Scientists (R42 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-CA-21-001	08-Feb-2021 [Optional][LOI/Pre-App]	Not Specified

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Kory Hallett, Ph.D. 240-276-5882 kory.hallett@nih.gov Link to program URL 08-Feb-2021 [Optional][LOI/Pre-App], 10-Mar-2021
Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to support early career academic scientists interested in transitioning to entrepreneurship while also supporting the transfer of technology from academic laboratories into small businesses. Both small businesses and universities are drivers of technological innovation in the United States (U.S.), often working together to advance innovative ideas into products that can benefit the U.S. population. While most NIH funding supports basic research in university laboratories, the NIH also supports innovative technology development in U.S. small businesses through its SBIR&STTR programs. As technologies transition from academic discovery to small businesses, two common challenges arise, identifying the right team with the right expertise to take the product into a small business, and funding for early stage technology development. This FOA seeks to address both challenges simultaneously by having two equally important goals: entrepreneurial mentoring support, and product development support. This FOA proposes a new and unique Fast-Track only award structure comprised of a Phase I STTR that transitions to a Phase II SBIR. An STTR award is a collaborative award made to small businesses that are working closely with a university. While both SBIR and STTR grants are only awarded to small businesses, the STTR program allows a significant amount of STTR-funded work to be conducted at a partner university site and allows the Principal Investigator (PI) to maintain his or her employment at a university during the phase I period. Therefore, awards made under this FOA will begin as a Phase I STTR to allow the candidate to complete proof of concept studies at the academic site and prepare the technology to move into the small business. After completion of the STTR phase I activities, transition to a Phase II SBIR award will only occur after demonstration that stringent criteria have been met that include a demonstration of ongoing mentoring as well as having achieved technical milestones (more information under Section V. Application Review Information). A key component of the small business transition grant is mentoring. Mentoring is not traditionally a factor in SBIR/STTR funding decisions, however here mentoring is critical to facilitate the transition from junior academic scientist to entrepreneur. Therefore, the mentoring team that supports the candidate will be a critical factor in peer review. The ideal candidate for this small business transition grant is a postdoctoral researcher who participated in technology discovery during their academic work and is now ready to move to a small</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

business with the help of some key mentors and advisors. To be responsive to this FOA, proposed projects MUST pertain to one of the participating Organizations/Institutes listed above, and propose the development of a technology that fits into at least one of the following categories: (1) Therapeutics and Preventative Agents; (2) Imaging Technologies, Interventional Devices, and In Vivo Diagnostics; or (3) In Vitro and Ex Vivo Diagnostics and Prognostics.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
095511	Mid-Career Enhancement Awards to Integrate Basic Behavioral, Biomedical, and/or Social Scientific Processes (K18 No Independent Clinical Trials)	National Institutes of Health/DHHS	PAR-20-211	17-Mar-2021	Not Specified

Contact Name | William Elwood, PhD
 Contact Telephone | 301-402-0116
 Contact Email | william.elwood@nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 17-Mar-2021 , 17-Mar-2022 , 17-Mar-2023

Synopsis | This Funding Opportunity Announcement (FOA) invites applications from investigators who strive to expand their research trajectories through the acquisition of new knowledge and skills in the areas of basic psychological processes, sociological processes, and/or biomedical pathways—expertise that is beyond and enhances their current areas of expertise. The program will support career development experiences and a small-scale research project that will provide experienced investigators with the scientific competencies required to conduct independent research projects that more thoroughly investigate interrelationships among behavioral, biological, endocrine, epigenetic, immune, inflammatory, neurological, psychological, and/or social processes. Applicants may propose research that involves non-human animals, secondary data analyses, or other career development projects that do not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants are permitted to propose research experience within a clinical trial led by a mentor or co-mentor. Eligible candidates are independent investigators at mid-career faculty rank or level. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants proposing Basic Experimental Studies with Humans (BESH) should apply to the companion FOA PAR-20-226. .

096446	Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19 (R01 -	National Institutes of Health/DHHS	PAR-20-243	02-Mar-2021	2,250,000 USD
--------	--	------------------------------------	------------	-------------	---------------

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

[Clinical Trial Optional](#)

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Adam Haim, Ph.D. Haima@mail.nih.gov Link to program URL 02-Mar-2021 This Funding Opportunity Announcement (FOA) aims to support research to strengthen the healthcare response to Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and future public health emergencies, including pandemics. While research related to the direct clinical effects of COVID-19 are supported by other funding opportunities, the purpose of this funding opportunity is to focus on the role and impact of digital health interventions [e.g., mobile health (mhealth), telemedicine and telehealth, health information technology (IT), and wearable devices] to address access, reach, delivery, effectiveness, scalability and sustainability of health assessments and interventions for secondary effects (e.g., behavioral health or self-management of chronic conditions) that are utilized during and following the pandemic, particularly in populations who experience health disparities and vulnerable populations.
--	---

089643	National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders, Substance Use Disorders, or Alcohol Use Disorder (U19 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-20-119	25-Mar-2021	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Linda Brady, Ph.D., Director 301-443-3563 lbrady@mail.nih.gov Link to program URL 25-Mar-2021 , 26-Jul-2021 , 26-Nov-2021 , 25-Mar-2022 The purpose of this FOA is to: accelerate innovative drug and device discovery; develop pharmacologic and neuromodulatory tools for basic and clinical research on mental health, substance use disorders (SUDs) or alcohol use disorder (AUD); develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative new candidates for mental disorders, SUDs or AUD; and support early-stage human studies to rapidly assess the safety,
--	---

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or Investigational Device Exemption (IDE)-ready devices for the treatment of mental disorders, SUDs or AUD. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders, SUDs or AUD, and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged. This FOA supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach. Projects seeking support for a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies should consider the companion FOA at PAR-20-118.

089640	National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental or Substance Use Disorders or Alcohol Disorder (U01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-20-118	25-Mar-2021	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Linda Brady, Ph.D., Director
Contact Telephone	301-443-3563
Contact Email	lbrady@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	25-Mar-2021 , 26-Jul-2021 , 26-Nov-2021 , 25-Mar-2022
Synopsis	<p>The purpose of this Funding Opportunity Announcement is to accelerate innovative drug and device therapies translation from discovery to early human studies. Studies appropriate for this FOA will develop pharmacologic and neuromodulatory tools for basic and clinical research on mental health disorders, substance use disorders (SUDs) or alcohol addiction; develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative new candidates for mental disorders; and support early-stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or Investigational Device Exemption (IDE)-ready devices for the treatment of mental disorders, SUDs or alcohol addiction. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders or SUDs or alcohol addiction, and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged. Projects seeking support for a research program of multiple projects directed toward a specific major objective, basic theme or program goal,</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

requiring a broadly based, multidisciplinary and often long-term approach should consider the companion FOA at PAR-20-119 . This FOA supports a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies.

100700	Notice of Special Interest (NOSI): Administrative Supplement for Research and Capacity Building Efforts Related to Bioethical Issues (Admin Supp Clinical Trial Optional)	National Institutes of Health/DHHS	NOT-OD-21-020	05-Mar-2021	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name	Shari Feirman, PhD
Contact Telephone	301-435-6350
Contact Email	shari.feirman@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Mar-2021
Synopsis	The NIH Office of Science Policy (OSP) within the Office of the Director (OD) announces the availability of administrative supplements to support 1) research on bioethical issues to develop or support the development of an evidence base that may inform future policy directions, and/or 2) certain efforts to develop or augment bioethics research capacity. Applicants may propose to supplement parent awards focused on bioethics or to add a component related to bioethics to a parent award in which bioethics was not the focus. Note that applications must be within the general scope of the parent award.

100484	RFA-NS-21-008 -- Treatments for Lewy Body Dementias--Exploratory Clinical Trial (U01 Clinical Trial Required)	National Institutes of Health/DHHS	RFA-NS-21-008	02-Feb-2021 [Optional][LOI/Pre-App]	Not Specified
--------	---	------------------------------------	---------------	-------------------------------------	---------------

Contact Name	Debra Babcock, PhD, MD
Contact Telephone	301-496-9964
Contact Email	dbabcock@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	02-Feb-2021 [Optional][LOI/Pre-App], 02-Mar-2021
Synopsis	This Funding Opportunity Announcement invites applications from investigators seeking to conduct exploratory clinical trials designed to test new treatments for patients with Lewy Body Dementia (LBD). Applicants may propose to conduct either Phase I or Phase II clinical trials depending on the developmental stage of the potential therapeutic, but all trials must include

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		patients with LBD. Proposed therapies may include novel medications or devices, or existing treatments that are potentially beneficial but not currently approved for use in patients with LBD. Treatments intended to prevent or delay disease progression in LBD patients, as well as therapies to alleviate existing motor or non-motor clinical symptoms, are of interest.			
100349	RFA-AI-20-076 -- New Technologies for the In vivo Delivery of Gene Therapeutics for an HIV Cure (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-AI-20-076	15-Feb-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name: Betty Poon, Ph.D.</p> <p>Contact Telephone: 240-669-5024</p> <p>Contact Email: poonb@niaid.nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 15-Feb-2021 [Optional][LOI/Pre-App], 17-Mar-2021, 15-Feb-2022 [Optional][LOI/Pre-App], 17-Mar-2022, 15-Feb-2023 [Optional][LOI/Pre-App], 17-Mar-2023</p> <p>Synopsis: The purpose of this Funding Opportunity Announcement (FOA) is to support research on the development and validation of innovative strategies to deliver anti-HIV gene therapies efficiently to specific target cells in vivo.</p>				
100956	RFA-HL-22-009 -- Summer Institute for Research Education in Biostatistics and Data Science (R25 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-HL-22-009	08-Feb-2021 [Optional][LOI/Pre-App]	1,195,000 USD
	<p>Contact Name: Sean Coady</p> <p>Contact Telephone: 301-435-1289</p> <p>Contact Email: coadys@nhlbi.nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 08-Feb-2021 [Optional][LOI/Pre-App], 08-Mar-2021</p> <p>Synopsis: National Heart, Lung, and Blood Institute (NHLBI) invites applications for research education activities in the mission areas of the NIH. The over-arching goal of this NHLBI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development. This FOA will use the NIH R25 Education Projects award mechanism.</p>				
101558	RFA-DA-21-020 -- HEAL Initiative: HEALthy Brain and Child Development	National Institutes of	RFA-DA-	01-Mar-2021	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Study (Collaborative U01- Clinical Trial Not Allowed)	Health/DHHS	21-020	[Optional][LOI/Pre-App]	Specified
	<p>Contact Name Minki Chatterji</p> <p>Contact Telephone 301-827-5435</p> <p>Contact Email minki.chatterji@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Mar-2021 [Optional][LOI/Pre-App], 31-Mar-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to seek applications for linked Research Project Sites for the HEALTHy Brain and Child Development (HBCD) Study using the cooperative agreement award mechanism. This FOA runs in parallel with companion FOAs that seek applications for single, unlinked Research Project Sites (RFA-DA-21-021), a single Consortium Administrative Core (RFA-DA-21-022) and a single Data Coordinating Center (RFA-DA-21-023). It is expected that investigators, upon funding, will work jointly with NIH scientific staff to assist, guide, coordinate, or participate in project activities. This FOA seeks applications to create a consortium of research sites in service of the nationwide, multi-site, multi-modal, longitudinal cohort HBCD Study to prospectively examine brain and behavioral development from birth through childhood, including an emphasis on understanding the impact of in utero substance exposure on outcomes. Research sites will enroll pregnant women and collect data from them and their children using methodologies that include neuroimaging, neurophysiology, behavioral and cognitive assessments and collection of biospecimens.</p>				
101569	RFA-DA-21-022 -- HEAL Initiative: HEALTHy Brain and Child Development Consortium Administrative Core (U24 - Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-DA-21-022	01-Mar-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Minki Chatterji</p> <p>Contact Telephone 301-827-5435</p> <p>Contact Email minki.chatterji@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Mar-2021 [Optional][LOI/Pre-App], 31-Mar-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to seek applications for a Consortium Administrative Core for the HEALTHy Brain and Child Development (HBCD) Study. This FOA runs in parallel with companion FOAs that seek applications for linked (RFA-DA-21-020) and unlinked (RFA-DA-21-021) research sites and a single Data Coordinating Center (RFA-DA-21-023). It is expected that investigators, upon funding, will work jointly with NIH scientific staff to assist, guide,</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
101570	RFA-DA-21-023 -- HEAL Initiative: HEALthy Brain and Child Development Data Coordinating Center (U24)	National Institutes of Health/DHHS	RFA-DA-21-023	01-Mar-2021 [Optional][LOI/Pre-App]	Not Specified

coordinate, or participate in project activities. The HBCD Consortium Administrative Core (HCAC) will be responsible for providing the organizational framework for the management, direction, and overall coordination of the national multi-site consortium. It will coordinate the interactions of the individual Research Project Sites and the HBCD Data Coordinating Center. The Consortium Administrative Core will include Administrative and Project Management Plans, and will also be responsible for managing collaborative activities such as the functions of an Expert Scientific Board and oversight of an internal Steering Committee. See Section I (Funding Opportunity Description) below for more information.

Contact Name | Minki Chatterji
 Contact Telephone | 301-827-5435
 Contact Email | minki.chatterji@nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 01-Mar-2021 [Optional][LOI/Pre-App], 31-Mar-2021

Synopsis | The purpose of this Funding Opportunity Announcement (FOA) is to seek applications for a Data Coordinating Center for the HEALthy Brain and Child Development Study. This FOA runs in parallel with companion FOAs that solicit applications for linked (RFA-DA-21-020) and unlinked (RFA-DA-21-021) research sites and a single Consortium Administrative Core (RFA-DA-21-022). It is expected that investigators, upon funding, will work jointly with NIH scientific staff to assist, guide, coordinate, and participate in project data collection and harmonization activities of HBCD research sites. The HBCD Data Coordinating Center (HDCC) will develop (and revise as necessary) the procedures for collection of the core neuroimaging, neuropsychological, and other phenotypic assessment data in a manner that will maximize comparability across the individual research sites of the consortium for the HBCD longitudinal study. The center will perform quality control, data curation, and analysis for the measures collected from the research sites as well as provide data informatics tools for sites and NIH program staff to monitor consortium progress and performance and explore the curated data. The HDCC will facilitate cross-site pooling of data, create a database across assessment modalities, and harmonize with existing large-scale neurodevelopmental research efforts. The successful applicant will propose a secure bioinformatics platform for data storage, harmonization and sharing that enables effective communication of detailed research data, tools for data access and analysis, supporting documentation and necessary training materials. The HDCC should include a director (or co-directors) and one or more associate directors to ensure that the wide scope of activities -- functions of supporting the HBCD Study consortium data and informatics enterprise and acting as a resource center to the scientific community at large -- are seamlessly coordinated.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
101573	RFA-DA-21-029 -- HEAL Initiative: Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR): Coordination and Dissemination Center (R24 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-DA-21-029	26-Mar-2021	2,875,000 USD
	<p>Contact Name Shelley Su, Ph.D.</p> <p>Contact Telephone 301-402-3869</p> <p>Contact Email IMPOWR@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 26-Mar-2021</p> <p>Synopsis The National Institutes of Health (NIH) intends to establish an Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR) network consisting of clinical research centers, which will be supported by a single Coordination and Dissemination center. This network is intended to create multidisciplinary team science collaborations to develop effective interventions, best models of care for delivery of services, and sustainable implementation strategies for access to quality care for complex patients with chronic pain (CP) and opioid use disorder (OUD) or opioid misuse. The network will be part of the NIH's Helping to End Addiction Long-term (HEAL)SM Initiative to speed the development and implementation of scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative will bolster research across NIH to (1) improve treatment and prevention of opioid misuse and opioid use disorder and (2) enhance pain management. This FOA seeks applications for a single Coordination and Dissemination Center for the IMPOWR network. Key responsibilities include coordination and communication to support the research centers within this network and other HEAL funded projects of relevance to CP and OUD/misuse, data harmonization on common data elements, providing educational infrastructure, stakeholder and patient engagement and information dissemination, and creating novel tool assessments. This FOA runs in parallel with a companion FOA that seeks applications to develop collaborative research projects on approaches, models, delivery, and implementation of care for co-occurring chronic non-cancer pain and OUD/misuse (RFA-DA-21-030).</p>				
101490	RFA-HL-21-014 -- Understanding and Reducing Cardiovascular Disease in Type 1 Diabetes Mellitus (R01 – Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-HL-21-014	13-Feb-2021 [Optional][LOI/Pre-App]	2,500,000 USD
	<p>Contact Name Nicole Redmond, MD, PhD, MPH</p> <p>Contact Telephone 301-435-0379</p> <p>Contact Email nicole.redmond@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 13-Feb-2021 [Optional][LOI/Pre-App], 15-Mar-2021 , 15-Sep-2021 [Optional][LOI/Pre-App], 15-Oct-2021</p> <p>Synopsis This funding opportunity is intended to support research that enhances the understanding of the pathophysiology and epidemiology of cardiovascular disease among individuals with Type 1 Diabetes Mellitus (T1DM) and advances the development of interventions to reduce CVD risk among these individuals. The overall goal is to develop evidence-based guidelines to prevent or reduce CVD complications of T1DM across the lifespan. This funding opportunity will support epidemiologic studies to refine risk assessment, mechanistic trials to enhance understanding of the pathophysiology of CVD in T1DM, and small clinical trials that could inform the future development of larger trials focused on preventing or reducing the CVD complications of T1DM.</p>				
101561	RFA-DA-21-021 -- HEAL Initiative: HEALthy Brain and Child Development Study (U01 - Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-DA-21-021	01-Mar-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Minki Chatterji</p> <p>Contact Telephone 301-827-5435</p> <p>Contact Email minki.chatterji@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Mar-2021 [Optional][LOI/Pre-App], 31-Mar-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to seek applications for unlinked Research Project Sites for the HEALthy Brain and Child Development (HBCD) Study using the cooperative agreement award mechanism. This FOA runs in parallel with companion FOAs that seek applications for linked Research Project Sites (RFA-DA-21-020), a single Consortium Administrative Core (RFA-DA-21-022) and a single Data Coordinating Center (RFA-DA-21-023). It is expected that investigators, upon funding, will work jointly with NIH scientific staff to assist, guide, coordinate, or participate in project activities. This FOA seeks applications to create a consortium of research sites in service of the nationwide, multi-site, multi-modal, longitudinal cohort HBCD Study to prospectively examine brain and behavioral development from birth through childhood, including an emphasis on understanding the impact of in utero substance exposure on outcomes. Research sites will enroll pregnant women and collect data from them and their children using methodologies that include neuroimaging, neurophysiology, behavioral and cognitive assessments and collection of biospecimens.</p>				
101577	RFA-MH-21-145 -- HEAL Initiative: Optimizing Multi-Component Service Delivery Interventions for People with Opioid Use Disorder, Co-Occurring Conditions, and/or Suicide Risk (R01 Clinical Trials Optional)	National Institutes of Health/DHHS	RFA-MH-21-145	18-Feb-2021 [Optional][LOI/Pre-App]	8,000,000 USD
	<p>Contact Name Michael C. Freed, Ph.D.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-443-3747</p> <p>Contact Email michael.freed@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 18-Feb-2021 [Optional][LOI/Pre-App], 18-Mar-2021</p> <p>Synopsis In April 2018, the National Institutes of Health (NIH) launched the HEAL (Helping to End Addiction Long-term) Initiative, an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis. In response to this initiative, the National Institute of Mental Health (NIMH), in partnership with other NIH Institutes, Centers, and Offices, invites research that will optimize multi-component service delivery interventions for people with opioid use disorder (OUD) and co-occurring conditions, to include mental disorders and/or suicide risk. The purpose of the initiative is to support studies that will (1) test the overall effectiveness of multi-component interventions for OUD and co-occurring conditions and (2) examine the relative contribution of constituent components to overall effectiveness. This research will streamline service packages so they only include components that drive clinical improvements for complex conditions. The content of this RFA complements research stemming from RFA-DA-21-029 and RFA-DA-21-030.</p>				
101453	<p>International Research Scientist Development Award (IRSDA) (K01) Independent Clinical Trial Not Allowed</p>	National Institutes of Health/DHHS	PAR-21-104	09-Mar-2021	700,000 USD
	<p>Contact Name Christine Jessup, Ph.D.</p> <p>Contact Telephone 301-496-1653</p> <p>Contact Email Christine.Jessup@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Mar-2021 , 09-Mar-2022 , 08-Mar-2023</p> <p>Synopsis The purpose of the International Research Scientist Development Award (IRSDA) is to provide support and protected time (three to five years) to advanced postdoctoral U.S. research scientists and recently-appointed U.S. junior faculty (applicants must be at least two years beyond conferral of doctoral degree) for an intensive, mentored research career development experience in a low- or middle-income country (LMIC), as defined by the World Bank (http://data.worldbank.org/about/country-classifications/country-and-lending-groups), including "low-income," "lower-middle-income," and "upper-middle-income" countries) leading to an independently-funded research career focused on global health. This Funding Opportunity Announcement (FOA) invites applications from postdoctoral research scientists and junior faculty from any health-related discipline who propose career development activities and a research project that is</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>relevant to the health priorities of the LMIC under the mentorship of LMIC and U.S. mentors. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator should apply to the companion FOA (PAR-21-105).</p>			
101641	RFA-DK-21-001 -- Biomarkers for Diabetic Foot Ulcers through the Diabetic Foot Consortium (R61/R33 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-DK-21-001	22-Mar-2021 [Optional][LOI/Pre-App]	1,300,000 USD
	Contact Name	Teresa L.Z. Jones, MD			
	Contact Telephone	301-435-2996			
	Contact Email	teresa.jones@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	22-Mar-2021 [Optional][LOI/Pre-App], 22-Apr-2021 , 03-Oct-2021 [Optional][LOI/Pre-App], 03-Nov-2021			
	Synopsis	<p>The purpose of this Funding Opportunity Announcement is to promote the development of prognostic, monitoring, and diagnostic biomarkers for diabetic foot ulcers that can be used in clinical trials and patient care. This initiative will support early analytical and clinical validation of biomarkers through a phased award to encourage innovative research. The initiative will leverage the resources of the Diabetic Foot Consortium to facilitate the access to well-characterized patients and high-quality human samples. The goal of this initiative is to deliver candidate biomarkers that are ready for definitive analytical and clinical validation studies through the Diabetic Foot Consortium.</p>			
101571	RFA-DA-21-030 -- HEAL Initiative: Integrative Management of Chronic Pain and OUD for Whole Recovery (IMPOWR): Research Centers (RM1 Clinical Trial Required)	National Institutes of Health/DHHS	RFA-DA-21-030	26-Mar-2021	8,750,000 USD
	Contact Name	Shelley Su, Ph.D.			
	Contact Telephone	301-402-3869			
	Contact Email	IMPOWR@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	26-Mar-2021			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
101454	International Research Scientist Development Award (IRSDA) (K01) Independent Clinical Trial Required	National Institutes of Health/DHHS	PAR-21-105	09-Mar-2021	700,000 USD

Synopsis The National Institutes of Health (NIH) intends to establish an Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR) network consisting of clinical research centers, which will be supported by a single Coordination and Dissemination center. This network is intended to create multidisciplinary team science collaborations to develop effective interventions, best models of care for delivery of services, and sustainable implementation strategies for access to quality care for complex patients with chronic pain (CP) and opioid use disorder (OUD) or opioid misuse. The network will be part of the NIH's Helping to End Addiction Long-term (HEAL)SM Initiative to speed the development and implementation of scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative will bolster research across NIH to (1) improve treatment and prevention of opioid misuse and opioid use disorder and (2) enhance pain management. This FOA seeks research center applications to develop approaches, models, delivery, and implementation of care for co-occurring chronic non-cancer pain and OUD/misuse, which will be supported by a single Coordination and Dissemination Center (RFA-DA-21-029).

Contact Name | Christine Jessup, Ph.D.
 Contact Telephone | 301-496-1653
 Contact Email | Christine.Jessup@nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 09-Mar-2021 , 09-Mar-2022 , 08-Mar-2023

Synopsis The purpose of the International Research Scientist Development Award (IRSDA) is to provide support and protected time (three to five years) to advanced postdoctoral U.S. research scientists and recently-appointed U.S. junior faculty (applicants must be at least two years beyond conferral of doctoral degree) for an intensive, mentored research career development experience in a low- or middle-income country (LMIC), as defined by the World Bank (<http://data.worldbank.org/about/country-classifications/country-and-lending-groups>), including "low-income," "lower-middle-income," and "upper-middle-income" countries) leading to an independently-funded research career focused on global health. This Funding Opportunity Announcement (FOA) invites applications from postdoctoral research scientists and junior faculty from any health-related discipline who propose career development activities and a research project that is relevant to the health priorities of the LMIC under the mentorship of LMIC and U.S. mentors. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

led by another investigator, must apply to companion FOA (PAR-21-104).

085931	Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Basic Experimental Studies with Humans Required)	Office of Behavioral and Social Sciences Research/NIH/DHHS	PAR-19-384	17-Mar-2021	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name	William Elwood, PhD
Contact Telephone	301-402-0116
Contact Email	william.elwood@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	17-Mar-2021
Synopsis	This funding opportunity announcement (FOA) solicits research projects that seek to explain the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in human health, illness, recovery, and overall wellbeing. Types of projects submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical and/or behavioral outcomes in humans to understand fundamental aspects of phenomena related to social connectedness and isolatedness. NIH considers such studies as “prospective basic science studies involving human participants” that meet the NIH definition of basic research and fall within the NIH definition of a clinical trials (see, e.g., NOT-OD-19-024) Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind.

085930	Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Clinical Trials Not Allowed)	Office of Behavioral and Social Sciences Research/NIH/DHHS	PAR-19-373	17-Mar-2021	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name	William Elwood, PhD
Contact Telephone	301-402-0116
Contact Email	william.elwood@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	17-Mar-2021 , 17-Mar-2021

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis | This funding opportunity announcement (FOA) solicits research projects that seek to model the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in health, illness, recovery, and overall wellbeing. Both animal and human subjects research projects are welcome. Researchers proposing basic science experimental studies involving human participants should consider this FOA's companion for basic experimental studies with humans.

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
101054	Mid-scale Research Infrastructure-2 (Mid-scale RI-2)	National Science Foundation	21-537	03-Feb-2021 [LOI/Pre-App]	100,000,000 USD
	<p>Contact Name Brian Midson</p> <p>Contact Telephone 703-292-8145</p> <p>Contact Email bmidson@nsf.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-Feb-2021 [LOI/Pre-App], 05-Mar-2021 [LOI/Pre-App], 20-Sep-2021</p> <p>Synopsis NSF-supported science and engineering research increasingly relies on cutting-edge infrastructure. With its Major Research Instrumentation (MRI) program and Major Multi-user Research Facility projects (Major Facilities), NSF supports infrastructure projects at the lower and higher ends of infrastructure scales across science and engineering research disciplines. The Mid-scale Research Infrastructure Big Idea is intended to provide NSF with an agile, Foundation-wide process to fund experimental research capabilities in the mid-scale range between the MRI and Major Facilities thresholds. NSF defines Research Infrastructure (RI) as any combination of facilities, equipment, instrumentation, or computational hardware or software, and the necessary human capital in support of the same. Major facilities and mid-scale projects are subsets of research infrastructure. The NSF Mid-scale Research Infrastructure-2 Program (Mid-scale RI-2) supports the implementation of unique and compelling RI projects. Mid-scale RI-2 projects may include any combination of equipment, instrumentation, cyberinfrastructure, broadly used large-scale data sets, and the commissioning and/or personnel needed to successfully complete the project. Mid-scale RI-2 projects should fill a research community-defined scientific need, or address an identified national research priority, that enables current and next-generation U.S. researchers and a diverse STEM workforce to remain competitive in a global research environment. The total cost for Mid-scale RI-2 projects ranges from \$20 million to below the threshold for a Major Facilities Project, currently \$100 million. Mid-scale RI-2 projects will directly enable advances in any of the research domains supported by NSF, including STEM education research. Projects may also include upgrades to existing research infrastructure. The Mid-scale RI-2 Program emphasizes projects that have strong scientific merit, respond to an identified need of the research community, demonstrate technical and managerial readiness for implementation, include a well-developed plan for student training in the design and implementation of mid-scale research infrastructure, and involve a diverse workforce in mid-scale facility development, and/or associated data management. Training of students in design and implementation, not just in scientific exploitation of the infrastructure, is essential.</p>				
100442	NSF/CASIS Collaboration on Tissue Engineering and Mechanobiology on the International Space Station (ISS) to Benefit Life on Earth	National Science Foundation	21-520	01-Mar-2021	400,000 USD

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Laurel C. Kuxhaus</p> <p>Contact Telephone 703-292-4465</p> <p>Contact Email lkuxhaus@nsf.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Mar-2021</p> <p>Synopsis The Divisions of Chemical, Bioengineering and Environmental Transport (CBET) and Civil, Mechanical, and Manufacturing Infrastructure (CMMI) in the Engineering Directorate of the National Science Foundation (NSF) are partnering with The Center for the Advancement of Science in Space (CASIS) to solicit research projects in the general fields of tissue engineering and mechanobiology that can utilize the International Space Station (ISS) National Lab to conduct research that will benefit life on Earth. For utilization of the ISS National Lab through this solicitation, entities must qualify as "U.S. Persons" under 22 U.S. Code §6010: "'United States person' means any United States citizen or alien admitted for permanent residence in the United States, and any corporation, partnership, or other organization organized under the laws of the United States."</p>				
100721	NSF/CASIS Collaboration on Transport Phenomena Research on the International Space Station (ISS) to Benefit Life on Earth	National Science Foundation	21-525	02-Mar-2021	400,000 USD
	<p>Contact Name Ronald Joslin</p> <p>Contact Telephone 703-292-7030</p> <p>Contact Email rjoslin@nsf.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 02-Mar-2021</p> <p>Synopsis The Division of Chemical, Bioengineering and Environmental Transport (CBET) in the Engineering Directorate of the National Science Foundation (NSF) is partnering with The Center for the Advancement of Science in Space (CASIS) to solicit research projects in the general field of fluid dynamics, particulate and multiphase processes, combustion and fire systems, thermal transport processes, and nanoscale interactions that can utilize the International Space Station (ISS) National Lab to conduct research that will benefit life on Earth. Only entities that qualify as "U.S. Persons" under 22 U.S. Code §6010, including academic investigators, non-profit independent research laboratories and academic-commercial teams are eligible to apply.</p>				
100333	EarthCube: Developing a Community-Driven Data and Knowledge Environment for the	National Science	21-515	02-Mar-2021	Not Specified

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Geosciences	Foundation			
	<p>Contact Name Eva Zanzerkia</p> <p>Contact Telephone 703-292-4734</p> <p>Contact Email ezanzerk@nsf.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 02-Mar-2021</p> <p>Synopsis EarthCube is a community-driven activity sponsored through a partnership between the NSF Directorate for Geosciences (GEO) and the Office of Advanced Cyberinfrastructure (OAC) within the Directorate for Computer & Information Science & Engineering (CISE) to transform research in the academic geosciences community. EarthCube aims to create a well-connected and facile environment to share data and knowledge in an open, transparent, and inclusive manner, thus accelerating our ability to understand and predict the Earth system. Achieving EarthCube will require a long-term dialog between NSF and the interested scientific communities to develop cyberinfrastructure that is thoughtfully and systematically built to meet the current and future requirements of geoscientists. New avenues will be supported to gather community requirements and priorities for the elements of EarthCube, and to capture the best technologies to meet these current and future needs. The EarthCube portfolio will consist of interconnected projects and activities that engage the geosciences, cyberinfrastructure, computer science, and associated communities. The portfolio of activities and funding opportunities will evolve over time depending on the status of the EarthCube effort and the scientific and cultural needs of the geosciences community.</p>				
100697	Navigating the New Arctic (NNA)	National Science Foundation	21-524	05-Mar-2021	3,000,000 USD
	<p>Contact Name </p> <p>Contact Telephone 703-292-8030</p> <p>Contact Email nna@nsf.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Mar-2021</p> <p>Synopsis Arctic temperatures are warming faster than nearly everywhere else on Earth, with some models predicting that continued warming could produce an ice-free Arctic Ocean by mid-century. The rapid and wide-scale changes occurring in response to</p>				

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

this warming portend new opportunities and unprecedented risks to natural systems; social and cultural systems; economic, political and legal systems; and built environments of the Arctic and across the globe. Gaps in scientific observations and the prevalence of interdependent social, natural, and built systems in the Arctic make it challenging to predict the region's future. Understanding and adapting to a changing Arctic will require creative new directions for Arctic-related research, education, workforce development, and leveraging of science, engineering, and technology advances from outside the Arctic. Navigating the New Arctic (NNA), one of NSF's 10 Big Ideas, embodies the Foundation's forward-looking response to these profound challenges and opportunities. NNA seeks innovations in fundamental convergence research across the social, natural, environmental, and computing and information sciences, and engineering that address the interactions or connections between natural and built environments and social systems and how these connections inform our understanding of Arctic change and its local and global effects. NNA promotes initiatives that empower new research communities, diversify the next generation of Arctic researchers, integrate the co-production of knowledge, and engage partnerships, particularly among international stakeholders. NNA also strongly encourages projects with components that advance science, technology, engineering, and mathematics (STEM) education; public understanding of the changing Arctic to benefit both citizens and policy makers; and workforce development objectives. NSF recognizes the inherently international nature of the Arctic region, and that impacts of Arctic changes span geographic and political boundaries, and encourages proposals that include significant international components.

101047	Spectrum and Wireless Innovation enabled by Future Technologies (SWIFT)	National Science Foundation	21-539	05-Mar-2021	750,000 USD
--------	---	-----------------------------	--------	-------------	-------------

Contact Name	Mohammad Ali
Contact Telephone	703-292-4632
Contact Email	moali@nsf.gov
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	05-Mar-2021
Synopsis	The National Science Foundation's Directorates for Engineering (ENG), Computer and Information Science and Engineering (CISE), Mathematical & Physical Sciences (MPS), and Geosciences (GEO) are coordinating efforts to identify new concepts and ideas on Spectrum and Wireless Innovation enabled by Future Technologies (SWIFT). A key aspect of the SWIFT program, now in its second year, is its focus on effective spectrum utilization and/or coexistence techniques, especially with passive uses, which have received less attention from researchers. Coexistence is when two or more applications use the same frequency band at the same time and/or at the same location, yet do not adversely affect one another. Coexistence is

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
	<p>especially difficult when at least one of the spectrum users is passive, i.e., not transmitting any radio frequency (RF) energy. Examples of coexisting systems may include passive and active systems (e.g., radio astronomy and wireless broadband communication systems) or two active systems (e.g., weather radar and Wi-Fi). Breakthrough innovations are sought on both the wireless communication hardware and the algorithmic/protocol fronts through synergistic teamwork. The goal of these research projects may be the creation of new technology or significant enhancements to existing wireless infrastructure, with an aim to benefit society by improving spectrum utilization, beyond mere spectrum efficiency. The SWIFT program seeks to fund collaborative team research that transcends the traditional boundaries of individual disciplines.</p>																		
094021	Industry/University Cooperative Research Centers	National Science Foundation	20-570	10-Mar-2021 [LOI/Pre-App]	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Prakash Balan</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>703-292-5341</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>pbalan@nsf.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>10-Mar-2021 [LOI/Pre-App], 09-Jun-2021 , 08-Sep-2021 [LOI/Pre-App], 08-Dec-2021</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The IUCRC program catalyzes breakthrough pre-competitive research by enabling close and sustained engagement between industry innovators, world-class academic teams, and government agencies. IUCRCs help industry partners and government agencies connect directly and efficiently with university researchers to achieve three primary objectives: 1) Conduct high-impact research to meet shared and critical industrial needs in companies of all sizes; 2) Enhance U.S. global leadership in driving innovative technology development, and 3) Identify, mentor and develop a diverse, highly skilled science and engineering workforce.</td> </tr> </table>					Contact Name	Prakash Balan	Contact Telephone	703-292-5341	Contact Email	pbalan@nsf.gov	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	10-Mar-2021 [LOI/Pre-App], 09-Jun-2021 , 08-Sep-2021 [LOI/Pre-App], 08-Dec-2021	Synopsis	The IUCRC program catalyzes breakthrough pre-competitive research by enabling close and sustained engagement between industry innovators, world-class academic teams, and government agencies. IUCRCs help industry partners and government agencies connect directly and efficiently with university researchers to achieve three primary objectives: 1) Conduct high-impact research to meet shared and critical industrial needs in companies of all sizes; 2) Enhance U.S. global leadership in driving innovative technology development, and 3) Identify, mentor and develop a diverse, highly skilled science and engineering workforce.
Contact Name	Prakash Balan																		
Contact Telephone	703-292-5341																		
Contact Email	pbalan@nsf.gov																		
Sponsor Website	Link to sponsor website																		
Program URL	Link to program URL																		
Deadline Dates (ALL)	10-Mar-2021 [LOI/Pre-App], 09-Jun-2021 , 08-Sep-2021 [LOI/Pre-App], 08-Dec-2021																		
Synopsis	The IUCRC program catalyzes breakthrough pre-competitive research by enabling close and sustained engagement between industry innovators, world-class academic teams, and government agencies. IUCRCs help industry partners and government agencies connect directly and efficiently with university researchers to achieve three primary objectives: 1) Conduct high-impact research to meet shared and critical industrial needs in companies of all sizes; 2) Enhance U.S. global leadership in driving innovative technology development, and 3) Identify, mentor and develop a diverse, highly skilled science and engineering workforce.																		
101440	Dear Colleague Letter: Catalyzing Industry-University Collaboration in Chemical Research through Industry/University Cooperative Research Centers (IUCRCs)	National Science Foundation	NSF 21-036	10-Mar-2021 [LOI/Pre-App]	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Ken Moloy</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>703-292-8441</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>kmoloy@nsf.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> </table>					Contact Name	Ken Moloy	Contact Telephone	703-292-8441	Contact Email	kmoloy@nsf.gov	Sponsor Website		Program URL	Link to program URL				
Contact Name	Ken Moloy																		
Contact Telephone	703-292-8441																		
Contact Email	kmoloy@nsf.gov																		
Sponsor Website																			
Program URL	Link to program URL																		

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 10-Mar-2021 [LOI/Pre-App]</p> <p>Synopsis The Industry/University Cooperative Research Centers (IUCRC) program strives to build long-term partnerships among industry, academe, and government. Leveraging the IUCRC model, the Mathematical and Physical Sciences (MPS) Directorate through the Division of Chemistry (CHE) and the Engineering Directorate (ENG) through the Division of Industrial Innovation and Partnerships (IIP) at NSF are coordinating efforts to promote productive research in cutting-edge areas of chemistry of particular interest to a cadre of allied industrial partners. With this DCL, CHE is encouraging submissions of Planning or Phase I proposals to build a portfolio of CHE-centered IUCRCs in response to the recent release of the new IUCRC solicitation (NSF 20-570). All CHE-supported research areas are encouraged, with special emphasis on research foci that align with the Industries of the Future (IoF) topics, such as Advanced Manufacturing (including Sustainable Chemistry), Artificial Intelligence, Biotechnology, and Quantum Information Science.</p>				
101263	Enabling Discovery through GENomics (EDGE)	National Science Foundation	21-546	16-Mar-2021	1,200,000 USD
	<p>Contact Name Edda (Floh) Thiels</p> <p>Contact Telephone 703-292-8167</p> <p>Contact Email ethiels@nsf.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Mar-2021 , 17-Feb-2022</p> <p>Synopsis Through the Enabling Discovery through GENomics (EDGE) program, the National Science Foundation (NSF) and the National Institutes for Health (NIH) support research to advance understanding of comparative and functional genomics. The EDGE program supports the development of innovative tools, technologies, resources, and infrastructure that advance biological research focused on the identification of the causal mechanisms connecting genes and phenotypes. The EDGE program also supports functional genomic research that addresses the mechanistic basis of complex traits in diverse organisms within the context (environmental, developmental, social, and/or genomic) in which they function. These goals are essential to uncovering the rules that underlie genomes-to-phenomes relationships and predict phenotype, an area relevant to Understanding the Rules of Life: Predicting Phenotype, one of the 10 Big Ideas for NSF investment. The goals also support the NHGRI priority to establish the roles and relationships of all genes and regulatory elements in pathways, networks, and phenotypes.</p>				
101434	Future of Work at the Human-Technology Frontier: Core Research (FW-HTF)	National Science	21-548	23-Mar-2021	Not Specified

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Foundation					
	<p>Contact Name Balakrishnan (Prabha) Prabhakaran</p> <p>Contact Telephone 703-292-4847</p> <p>Contact Email fwhtf-contacts@nsf.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 23-Mar-2021</p> <p>Synopsis The overarching vision of this program is to support multi-disciplinary research to sustain economic competitiveness, to promote worker well-being, lifelong and pervasive learning, and quality of life, and to illuminate the emerging social and economic context and drivers of innovations that are shaping the future of jobs and work. For the purposes of this solicitation, work is defined as mental or physical activity to achieve tangible benefit such as income, profit, or community welfare. A proposal for a research grant in this program must focus on advancing fundamental understanding of future work and work outcomes for workers and society.</p>	National Science Foundation	NSF 20-132	31-Mar-2021	300,000 USD
100097	Dear Colleague Letter: Future of International Research Collaboration Post COVID-19				
	<p>Contact Name Cassandra Dudka</p> <p>Contact Telephone</p> <p>Contact Email cdudka@nsf.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-Mar-2021</p> <p>Synopsis The NSF Office of International Science and Engineering (OISE) seeks to understand the nature and scope of COVID-19 impacts on international collaboration in research and education. OISE further seeks to encourage creative efforts to leverage the unique moment to enable more robust, resilient and sustainable collaborations. OISE anticipates that documenting and sharing lessons will strengthen future international collaboration efforts.</p>	National Science Foundation	20-562	31-Mar-2021	1,000,000 USD
092037	Civic Innovation Challenge				

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	David Corman 703-292-8754 dcorman@nsf.gov Link to sponsor website Link to program URL 31-Mar-2021 The Civic Innovation Challenge (CIVIC) is a research and action competition in the Smart and Connected Communities (S&CC) domain designed to build a more cohesive research-to-innovation pipeline and foster a collaborative spirit. Building on the NSF S&CC program and the extensive S&CC ecosystem, CIVIC aims to accelerate the impact of S&CC research, and deepen cooperation and information sharing across sectors and regions. CIVIC will lay a foundation for a broader and more fluid exchange of research interests and civic priorities that will create new instances of collaboration and introduce new areas of technical and social scientific discovery. CIVIC will fund projects that can produce significant community impact within 12 months (following a four-month planning phase) — in contrast to many community-university partnerships that take years to provide tangible benefits to communities — and have the potential for lasting impact beyond the period of the CIVIC award.
--	---

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
101327	The Kevin and Avonte Program: Reducing Injury and Death of Missing Individuals with Dementia and Developmental Disabilities	Bureau of Justice Assistance/Department of Justice	O-BJA-2021-44004	17-Feb-2021	150,000 USD
	Contact Name				
	Contact Telephone	800-851-3420			
	Contact Email	grants@ncjrs.gov			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	17-Feb-2021 , 03-Mar-2021			
	Synopsis	The Reducing Injury and Death of Missing Individuals with Dementia and Developmental Disabilities Program supports local jurisdictions' efforts to reduce the number of deaths and injuries of individuals with forms of dementia, such as Alzheimer's Disease, or developmental disabilities, such as autism, who due to their condition wander from safe environments. It provides funding to law enforcement and public safety agencies to implement locative technologies to track missing individuals; and to such agencies and partnering nonprofit organizations to develop or operate programs to prevent wandering, increase individuals' safety, and facilitate rescues.			
101600	Provide Comprehensive Packages of HIV Prevention, Care, and Treatment Services for Key Populations in South Africa under the President's Emergency Plan for AIDS Relief (PEPFAR)	Center for Global Health/CDC/DHHS	CDC-RFA-GH21-2127	12-Mar-2021	11,000,000 USD
	Contact Name	Romel Lacson, Project Officer			
	Contact Telephone				
	Contact Email	rnl3@cdc.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Mar-2021			
	Synopsis	This NOFO will focus on delivery of a comprehensive and targeted package of HIV prevention, testing, and treatment among key populations (KPs) including sex workers (SWs), men who have sex with men (MSM), transgender people (TG), and people who inject drugs (PWID). Activities will take place over a period of five years and will focus on the provision of prevention, testing or screening, and treatment of HIV and related diseases including TB, sexually transmitted infections (STIs), and viral hepatitis. Complementary services (e.g., sexual and reproductive health, opioid substitution therapy (OST)) should be provided as necessary. The SW program will operate in 5 to 9 districts (i.e., eThekweni and uMgungundlovu in KwaZuluNatal,			

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>OR Tambo in Eastern Cape, Dr. Kenneth Kaunda and Ngaka Modiri Molema in North West and Nkangala, Gert Sibande, and Ehlanzeni in Mpumalanga). The MSM/TG program will operate in 5 districts (i.e., eThekweni and uMgungundlovu in KwaZulu-Natal, Tshwane and Ekurhuleni in Gauteng, and Ehlanzeni in Mpumalanga). The PWID program will operate in 2 districts in South Africa (i.e., Tshwane in Gauteng and Ehlanzeni in Mpumalanga). There is a possibility of later expansion depending on epidemic need and PEPFAR prioritization.</p>			
101544	Comprehensive Access to HIV/AIDS Care and Treatment, and Prevention Services for Key Populations in Haiti under the President's Emergency Plan for AIDS Relief (PEPFAR)	Center for Global Health/CDC/DHHS	CDC-RFA-GH21-2111	09-Mar-2021	4,000,000 USD
	<p>Contact Name Kathy Grooms, Project Officer</p> <p>Contact Telephone ; 011-509-3452-1952</p> <p>Contact Email kwg1@cdc.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Mar-2021</p> <p>Synopsis This notice of funding opportunity announcement (NOFO) will support Haiti's capacity to deliver comprehensive, high-impact HIV prevention, care and treatment programs for key populations (KP) [commercial sex workers (CSW), transgender (TG), men who have sex with men (MSM)] and adolescent girls and young women (AGYW). The goal of this NOFO is to improve KP condom and pre-exposure prophylaxis (PrEP) use for prevention, case identification, linkage to and retention in care, adherence to antiretroviral therapy (ART) and viral suppression. The recipient will capacitate health care workers (HCWs) and community outreach workers in quality assurance (QA) and quality improvement (QI) activities. Stigma-free service delivery will be implemented utilizing client-centered approaches in collaboration with local KP associations. Programs and services will be implemented in selected communes of all 10 administrative departments. These geographic prioritizations may change over the course of the performance period based on the burden of disease.</p>				
101601	Strengthen Capacity of South African Government's Department of Health and Implementing Partners to Deliver Quality Differentiated, Advanced Clinical Care (ACC) for Unstable HIV and TB/HIV Patients in the Republic of South Africa (SA) under PEPFAR	Center for Global Health/CDC/DHHS	CDC-RFA-GH21-2122	12-Mar-2021	10,000,000 USD
	<p>Contact Name Philippe Chiliade, Project Officer</p> <p>Contact Telephone </p>				

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email pkc6@cdc.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Mar-2021</p> <p>Synopsis In SA, it is estimated that 20% of patients newly initiating anti-retroviral therapy (ART) present late and 10-15% of patients on first line ART are failing treatment, leading to poor retention, especially in the first 12 months of treatment. This NOFO seeks to decrease morbidity and mortality, improve treatment retention and viral load (VL) suppression of HIV and TB/HIV coinfecting patients through the use of innovative capacity building approaches for health service providers to better manage complicated and unstable HIV and TB/HIV co-infected patients. Activities under this NOFO must include but are not limited to: building in-country capacity through in-person and other innovative capacity-building approaches in ACC to effectively manage complicated HIV and TB/HIV co-infected patients; building a cadre of local expertise through a Train the Trainer model; and using existing virtual platforms and technological tools to provide technical assistance (TA) to facility-based staff on management of complicated HIV and TB/HIV patients. Expected NOFO outcomes must include but are not limited to: increased competencies among health workers in providing appropriate services to manage complicated HIV and TB/HIV patients; improved quality of ACC services offered by the trained health care providers; and improved referral for genotypic testing services for eligible clients with VL failure.</p>				
101588	<p>Achieving and Sustaining Epidemic Control Through Comprehensive HIV/AIDS Prevention, Care and Treatment Services in Machakos, Makueni and Kitui Counties in Kenya under the President's Emergency Plan for AIDS Relief (PEPFAR)</p>	Center for Global Health/CDC/DHHS	CDC-RFA-GH21-2116	09-Mar-2021	8,800,000 USD
	<p>Contact Name Lucy Nganga, Project Officer</p> <p>Contact Telephone</p> <p>Contact Email hon5@cdc.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Mar-2021</p> <p>Synopsis This NOFO will support implementation of sustainable, high quality, comprehensive HIV prevention and treatment programs in the Eastern region of Kenya, in collaboration with the County governments of Machakos, Makueni and Kitui counties. A key focus will be county capacity strengthening towards a Kenya-owned, and funded HIV program including HIV testing services (HTS); pediatric and adult HIV treatment; TB/HIV prevention, diagnosis and treatment; Prevention of Mother-to-Child</p>				

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>Transmission (PMTCT); orphans and vulnerable children (OVC) services; HIV prevention and treatment for Key Populations (KP) (Female Sex Workers (FSW), Men who have Sex with Men (MSM), Transgender (TG) and People Who Inject Drugs (PWID)); HIV prevention for adolescent girls and young women (AGYW); associated laboratory services and strategic information; and county systems strengthening. This NOFO aligns with UNAIDS, PEPFAR and Kenya’s goal of ending AIDS by 2030. Expected outcomes include strengthened county health systems as evidenced by increased resource allocation, enhanced leadership and implementation of the HIV program by the county government, improved coverage and quality of HIV services for all populations, resulting in reduced HIV incidence and improved health outcomes, and reduced morbidity and mortality among people living with HIV (PLHIV) including those with TB and elimination of mother-to-child transmission of HIV (eMTCT).</p>			
101584	Supporting the Sustainable Implementation of Comprehensive High-Quality HIV Prevention, Care and Treatment Programs in the Western Region of the Republic of Kenya under the President's Emergency Plan for AIDS Relief (PEPFAR)	Center for Global Health/CDC/DHHS	CDC-RFA-GH21-2119	09-Mar-2021	48,500,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p>	<p>Hellen Muttai, Project Officer</p> <p></p> <p>hoz1@cdc.gov</p> <p></p> <p>Link to program URL</p> <p>09-Mar-2021</p>			
	Synopsis	<p>This NOFO will support the implementation of comprehensive HIV prevention and treatment programs in Homa Bay, Kisumu, Siaya, Migori, and Kisii counties; with the goal of achieving HIV epidemic control and building the county governments’ capacity to own, manage and implement integrated HIV services for sustainability. The integrated model will include: HIV Testing Services (HTS); pediatric and adult HIV treatment; TB/HIV prevention, diagnosis, and treatment; Prevention of Mother-to-Child Transmission (PMTCT); Voluntary Medical Male Circumcision (VMMC); HIV prevention and treatment for Key Populations (KP) [Female Sex Workers (FSW), Men having Sex with Men (MSM), People Who Inject Drugs (PWID) and Transgender] and Priority Populations (PP) [fisherfolk, prisoners, etc.]; HIV prevention for adolescent girls and young women (AGYW); orphans and vulnerable children (OVC) services; HIV Pre-exposure Prophylaxis (PrEP); gender-based violence (GBV) services; laboratory services; and strategic information. Expected outcomes include improved coverage of quality HIV services for all populations; reduced HIV incidence; reduced morbidity and mortality among People Living with HIV (PLHIV) including those with TB; elimination of mother to child transmission of HIV (eMTCT); and strengthened county health systems, evidenced by increased resource allocation, enhanced leadership, and implementation of HIV services by the county</p>			

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		governments.			
101675	Scaling Up Comprehensive Facility and Community HIV Prevention, Care and Treatment Programs for Key and Vulnerable Populations, and People Living with HIV (PLHIV) in Tanzania under the President's Emergency Plan for AIDS Relief (PEPFAR)	Center for Global Health/CDC/DHHS	CDC-RFA-GH21-2135	15-Mar-2021	35,000,000 USD
	Contact Name	Gbolahan Cole, Project Officer			
	Contact Telephone				
	Contact Email	yka7@cdc.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Mar-2021			
	Synopsis	<p>Progress has been made towards reaching the UNAIDS 95-95-95 targets, through enhanced HIV-prevention and antiretroviral therapy (ART) services to both the general population of PLHIV and those in most need: key and vulnerable populations (KVP) and Adolescent Girls and Young Women (AGYW). Meeting the needs of diverse populations requires advanced differentiated service delivery (DSD) models on comprehensive HIV prevention services, case identification, linkages, retention of known PLHIV on life-long ART, adherence to ART, and viral suppression. Recipient(s) will scale-up innovative and targeted HIV-case identification services including index testing, HIV-self testing (HIVST), risk screening for testing, and promote prevention services for all populations, with particular emphasis on KVP and AGYW. Positives identified will be linked and retained in Care and Treatment. Comprehensive service delivery models will support integration of pre-exposure prophylaxis (PrEP), TB/HIV, prevention of mother to child transmission of HIV (PMTCT), and access to medication assisted therapy (MAT). Initial focus will be in Tanzania's high burden regions of Mwanza, Kagera, Geita, and Dar es Salaam. This may shift from CDC-supported region to region based on performance, epidemiological data, specific type of KVP focus changing, or changes in where KVPs are concentrated. Recipient(s) may be awarded for community activities, facility activities, or both for specific region(s).</p>			
051296	RFP -- AMENDMENT -- Aerospace Medicine, Clinical Research, Human Performance Research, and Expeditionary Medicine	Department of the Air Force	BAA-AFRL-RQKHC-2016-0009	01-Mar-2021	Not Specified
	Contact Name	Charles Dean			
	Contact Telephone	210-536-3374			

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email charles.dean@us.af.mil</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Mar-2021</p> <p>Synopsis A -- Aerospace Medicine, Clinical Research, Human Performance Research, and Expeditionary Medicine SOL BAA-AFRL-RQKHC-2016-0009 Charles Dean, Program Manager, Phone (210) 536-3374, Email charles.dean@us.af.mil - Kimberly Cerney, Contract Specialist, Phone (937) 713-9922, Email kimberly.cerney@us.af.mil The 711th Human Performance Wing intends to solicit White Papers under this announcement for Aerospace Medicine, Clinical Research, Human Performance Research, and Expeditionary Medicine for innovative and state-of-the-art research to enhance the following fields of En Route Care, Expeditionary Medicine, Force Health Protection, Human Performance and Systems Integration, and Operational Medicine. CITE: https://www.fbo.gov/spg/USAF/AFMC/AFRLWRS/BAA-AFRL-RQKHC-2016-0009/listing.html Grants.gov (03/02/16)</p>				
101519	Breast Cancer Research Program--Breakthrough Award Level 4	Department of the Army	W81XWH-21-BCRP-BTA4	12-Mar-2021 [LOI/Pre-App]	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 301-682-5507</p> <p>Contact Email help@eBRAP.org</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Mar-2021 [LOI/Pre-App], 23-Jun-2021</p> <p>Synopsis The BCRP challenges the scientific community to design research that will address the urgency of ending breast cancer. Specifically the BCRP seeks to accelerate high-impact research with clinical relevance, encourage innovation and stimulate creativity, and facilitate productive collaborations. The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are: Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must move beyond a minor advancement and have the potential to lead to a new approach that is fundamentally better than interventions already approved or in clinical development. Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research. Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. It is the responsibility of the Principal Investigator (PI) to select the level</p>				

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<p>that aligns with the scope of the proposed research. The funding level should be selected based on the research scope defined in the Program Announcement, and not on the amount of the budget.</p>					
101521	Breast Cancer Research Program--Innovator Awards	Department of the Army	W81XWH-21-BCRP-INNOV	12-Mar-2021 [LOI/Pre-App]	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 301-682-5507</p> <p>Contact Email help@eBRAP.org</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Mar-2021 [LOI/Pre-App], 23-Jun-2021 , 25-Jun-2021</p> <p>Synopsis The BCRP challenges the scientific community to design research that will address the urgency of ending breast cancer. Specifically, the BCRP seeks to accelerate high-impact research with clinical relevance, encourage innovation and stimulate creativity, and facilitate productive collaborations. The Innovator Award supports visionary individuals who have demonstrated exceptional creativity, innovative work, and paradigm-shifting leadership in any field including, but not limited to, breast cancer. The Innovator Award will provide these individuals with the funding and freedom to pursue their most novel, visionary, high-risk ideas that could accelerate progress to ending breast cancer.</p>				
101520	Breast Cancer Research Program--Era of Hope Scholar Award	Department of the Army	W81XWH-21-BCRP-EOHS	11-Mar-2021 [LOI/Pre-App]	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 301-682-5507</p> <p>Contact Email help@eBRAP.org</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Mar-2021 [LOI/Pre-App], 25-Mar-2021 , 29-Mar-2021</p> <p>Synopsis The Era of Hope Scholar Award supports individuals early in their careers who have demonstrated significant potential to effect meaningful change in breast cancer. These individuals should be exceptionally talented scientists who have shown that they are the “best and brightest” in their field(s) through extraordinary creativity, vision, innovation, and productivity. They should have demonstrated experience in forming effective partnerships and collaborations and must exhibit strong potential</p>				

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
	for future leadership in breast cancer research.																		
101514	Breast Cancer Research Program--Breakthrough Award Level 3	Department of the Army	W81XWH-21-BCRP-BTA3	12-Mar-2021 [LOI/Pre-App]	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%;">Contact Name</td> <td></td> </tr> <tr> <td>Contact Telephone</td> <td>301-682-5507</td> </tr> <tr> <td>Contact Email</td> <td>help@eBRAP.org</td> </tr> <tr> <td>Sponsor Website</td> <td></td> </tr> <tr> <td>Program URL</td> <td>Link to program URL</td> </tr> <tr> <td>Deadline Dates (ALL)</td> <td>12-Mar-2021 [LOI/Pre-App], 23-Jun-2021</td> </tr> <tr> <td>Synopsis</td> <td>The BCRP challenges the scientific community to design research that will address the urgency of ending breast cancer. Specifically, the BCRP seeks to accelerate high-impact research with clinical relevance, encourage innovation and stimulate creativity, and facilitate productive collaborations. The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are: Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must move beyond a minor advancement and have the potential to lead to a new approach that is fundamentally better than interventions already approved or in clinical development. Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research. Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. It is the responsibility of the Principal Investigator (PI) to select the level that aligns with the scope of the proposed research. The funding level should be selected based on the research scope defined in the Program Announcement, and not on the amount of the budget.</td> </tr> </table>					Contact Name		Contact Telephone	301-682-5507	Contact Email	help@eBRAP.org	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	12-Mar-2021 [LOI/Pre-App], 23-Jun-2021	Synopsis	The BCRP challenges the scientific community to design research that will address the urgency of ending breast cancer. Specifically, the BCRP seeks to accelerate high-impact research with clinical relevance, encourage innovation and stimulate creativity, and facilitate productive collaborations. The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are: Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must move beyond a minor advancement and have the potential to lead to a new approach that is fundamentally better than interventions already approved or in clinical development. Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research. Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. It is the responsibility of the Principal Investigator (PI) to select the level that aligns with the scope of the proposed research. The funding level should be selected based on the research scope defined in the Program Announcement, and not on the amount of the budget.
Contact Name																			
Contact Telephone	301-682-5507																		
Contact Email	help@eBRAP.org																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	12-Mar-2021 [LOI/Pre-App], 23-Jun-2021																		
Synopsis	The BCRP challenges the scientific community to design research that will address the urgency of ending breast cancer. Specifically, the BCRP seeks to accelerate high-impact research with clinical relevance, encourage innovation and stimulate creativity, and facilitate productive collaborations. The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are: Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must move beyond a minor advancement and have the potential to lead to a new approach that is fundamentally better than interventions already approved or in clinical development. Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research. Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. It is the responsibility of the Principal Investigator (PI) to select the level that aligns with the scope of the proposed research. The funding level should be selected based on the research scope defined in the Program Announcement, and not on the amount of the budget.																		
101606	Human Papillomavirus (HPV) Roundtable: Supporting a National Network of Partners to Promote Cancer Prevention through Human Papillomavirus Vaccination	National Center for Immunization and Respiratory Diseases/CDC/DHHS	CDC-RFA-IP21-2105	22-Mar-2021	2,250,000 USD														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%;">Contact Name</td> <td>Jonathan Hill, Project Officer</td> </tr> <tr> <td>Contact Telephone</td> <td>404-639-4744</td> </tr> <tr> <td>Contact Email</td> <td>hws1@cdc.gov</td> </tr> <tr> <td>Sponsor Website</td> <td></td> </tr> </table>					Contact Name	Jonathan Hill, Project Officer	Contact Telephone	404-639-4744	Contact Email	hws1@cdc.gov	Sponsor Website							
Contact Name	Jonathan Hill, Project Officer																		
Contact Telephone	404-639-4744																		
Contact Email	hws1@cdc.gov																		
Sponsor Website																			

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 22-Mar-2021</p> <p>Synopsis CDC announces the availability of funds to advance a national network of cancer-prevention and immunization stakeholders by creating and supporting a planning committee that prioritizes network activities, updates and disseminates educational resources, and expands the diversity of stakeholders represented within the network that positively impact human papillomavirus (HPV) vaccination rates; convene at least one national meeting of network members to provide technical assistance and catalyze their support of efforts to increase HPV vaccine uptake; and create and support task groups, forums or councils to address priority areas identified by the national network, initiate high-priority pilot projects to reduce barriers to HPV vaccine uptake, and share lessons learned. By working toward these goals, the network can provide channels of education, outreach, and training structured for the public and health care providers. The network, through its engagement and coordination with stakeholders, will be equipped to increase public and provider understanding of the burden of HPV-associated cancers that can be prevented by HPV vaccination and to accelerate the full implementation of HPV vaccination to prevent HPV-associated cancers.</p>				
085930	Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Clinical Trials Not Allowed)	Office of Behavioral and Social Sciences Research/NIH/DHHS	PAR-19-373	17-Mar-2021	Not Specified
	<p>Contact Name William Elwood, PhD</p> <p>Contact Telephone 301-402-0116</p> <p>Contact Email william.elwood@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Mar-2021 , 17-Mar-2021</p> <p>Synopsis This funding opportunity announcement (FOA) solicits research projects that seek to model the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in health, illness, recovery, and overall wellbeing. Both animal and human subjects research projects are welcome. Researchers proposing basic science experimental studies involving human participants should consider this FOA's companion for basic experimental studies with humans.</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
002780	Post Doctoral Fellowship	A-T Children's Project		01-Mar-2021	80,000 USD
	Contact Name				
	Contact Telephone	954-481-6611			
	Contact Email	grants@atcp.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Mar-2021 , 01-Jul-2021 [LOI/Pre-App], 07-Sep-2021			
	Synopsis	The Post Doctoral Fellowship Award provides competitive support for clinical and translational research related to A-T.			
012744	Fellowship Program Grants	Abbott Laboratories Fund		01-Mar-2021	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	abbottgrants@abbott.com			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Mar-2021			
	Synopsis	Abbott provides funding for medical institutions to administer their own fellowship programs in the areas of cardiovascular disease, cardiac arrhythmia, electrophysiology, heart failure and structural heart therapies.			
067831	Research Grants	Alpha-1 Foundation		15-Mar-2021	200,000 USD
	Contact Name	David Fernandez			
	Contact Telephone	877-228-7321 x242			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Email	dfernandez@alpha1.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	15-Mar-2021
Synopsis	This grant provides funds to encourage the development of new information that contributes to the understanding of the basic biology of AAT expression, and the pathogenesis/management of AAT Deficiency.

067828	Pilot and Feasibility Grants	Alpha-1 Foundation		15-Mar-2021	75,000 USD
--------	--	--------------------	--	-------------	------------

Contact Name	David Fernandez
Contact Telephone	877-228-7321 x242
Contact Email	dfernandez@alpha1.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	15-Mar-2021
Synopsis	This grant provides funds to encourage the development and testing of new hypotheses and/or new methods in research areas relevant to AAT Deficiency.

089995	Alzheimer's Association Research Grant to Promote Diversity - New to the Field (AARG-D-NTF)	Alzheimer's Association		31-Mar-2021	150,000 USD
--------	---	-------------------------	--	-------------	-------------

Contact Name	
Contact Telephone	312-335-5747
Contact Email	grantsapp@alz.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	31-Mar-2021			
	Synopsis	The Research Grant to Promote Diversity - New to the Field award is up to three years (minimum two years) to increase the number of scientists from underrepresented groups at academic institutions in Alzheimer's and all dementia research.			
089994	Alzheimer's Association Research Grant - New to the Field (AARG-NTF)	Alzheimer's Association		31-Mar-2021	150,000 USD
	Contact Name				
	Contact Telephone	312-335-5747			
	Contact Email	grantsapp@alz.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	31-Mar-2021			
	Synopsis	The Research Grant aims to fund investigators who are new to Alzheimer's or other dementias field of research. The purpose of this program is to provide independent investigators with unique expertise and apply their knowledge to Alzheimer's and all dementias.			
071372	Treat FTD Fund – Funding for Innovative Clinical Trials for Frontotemporal Degeneration	Alzheimer's Drug Discovery Foundation		05-Feb-2021 [LOI/Pre-App]	2,000,000 USD
	Contact Name	Meriel Owen, PhD, Assistant Director, ADDF			
	Contact Telephone	212-901-8000			
	Contact Email	mowen@alzdiscovery.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021 [LOI/Pre-App], 19-Mar-2021			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis | Leveraging scientific advances in FTD research to develop effective medications has proven challenging. The Treat FTD Fund, a major new funding opportunity initiated by AFTD in partnership with ADDF, seeks to accelerate FTD drug development by focusing exclusively on clinical trials of FTD therapeutics. Over the next 10 years, The Treat FTD Fund will award \$10 million to support clinical trials of novel or repurposed drugs to treat FTD symptoms or target disease mechanisms.

051829	Charles River Prize	American Association for Laboratory Animal Science		01-Mar-2021	2,500 USD
--------	-------------------------------------	--	--	-------------	-----------

Contact Name	
Contact Telephone	901-754-8620
Contact Email	awards@aalas.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	01-Mar-2021
Synopsis	The Charles River Prize is awarded to a veterinarian in recognition of his/her outstanding contributions to laboratory animal science and medicine. The recipient is awarded a plaque and a \$2,500 honorarium.

064841	Anatomy Training Program	American Association of Anatomists		01-Mar-2021	Not Specified
--------	--	------------------------------------	--	-------------	---------------

Contact Name	
Contact Telephone	301-634-7910
Contact Email	info@anatomy.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	01-Mar-2021

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The Anatomy Training Program (co-sponsored by AAA & The Anatomical Society) is intended to provide vocational training to those involved in teaching anatomy but who have not had much exposure to either human anatomy or clinical experience.			
051613	President's Research Initiative Awards	American Neuromuscular Foundation		15-Mar-2021	500 USD
	Contact Name				
	Contact Telephone	507-288-0100			
	Contact Email	meeting@aanem.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Mar-2021			
	Synopsis	Each year the AANEM President chooses a topic for research for the AANEM annual meeting. Up to 10 abstracts submitted to the annual meeting on this topic may receive the President's Research Initiative Award. Award winners must be the first and presenting author.			
051611	Best Abstract Award	American Neuromuscular Foundation		15-Mar-2021	Not Specified
	Contact Name				
	Contact Telephone	507-288-0100			
	Contact Email	meeting@aanem.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Mar-2021			
	Synopsis	The AANEM's Best Abstract Award is given each year to the first and presenting author of the best abstract submitted to the AANEM Annual meeting.			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
086312	AAA Graduate Education Scholarships	American Australian Association		15-Mar-2021	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; vertical-align: top;">Contact Name</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>212-338-6860 x304</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>scholarships@aaanyc.org</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>15-Mar-2021 , 15-Oct-2021</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The AAA Graduate Education Scholarships support American and Australian individuals undertaking or planning to undertake full-time Graduate level study (Masters, Ph.D. or Postdoctoral Research) at an accredited institution in the country of the other, for a minimum of one year. The scholarships will provide support of up to US \$40,000 to those in the specialty fields of Science, Technology, Engineering, Mathematics, Health, Medicine and Sustainability. Scholarship funds may be used toward travel, living, tuition and other associated educational costs.</td> </tr> </table>					Contact Name		Contact Telephone	212-338-6860 x304	Contact Email	scholarships@aaanyc.org	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	15-Mar-2021 , 15-Oct-2021	Synopsis	The AAA Graduate Education Scholarships support American and Australian individuals undertaking or planning to undertake full-time Graduate level study (Masters, Ph.D. or Postdoctoral Research) at an accredited institution in the country of the other, for a minimum of one year. The scholarships will provide support of up to US \$40,000 to those in the specialty fields of Science, Technology, Engineering, Mathematics, Health, Medicine and Sustainability. Scholarship funds may be used toward travel, living, tuition and other associated educational costs.
Contact Name																			
Contact Telephone	212-338-6860 x304																		
Contact Email	scholarships@aaanyc.org																		
Sponsor Website	Link to sponsor website																		
Program URL	Link to program URL																		
Deadline Dates (ALL)	15-Mar-2021 , 15-Oct-2021																		
Synopsis	The AAA Graduate Education Scholarships support American and Australian individuals undertaking or planning to undertake full-time Graduate level study (Masters, Ph.D. or Postdoctoral Research) at an accredited institution in the country of the other, for a minimum of one year. The scholarships will provide support of up to US \$40,000 to those in the specialty fields of Science, Technology, Engineering, Mathematics, Health, Medicine and Sustainability. Scholarship funds may be used toward travel, living, tuition and other associated educational costs.																		
030860	Discovery Grants	American Brain Tumor Association		24-Mar-2021	50,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; vertical-align: top;">Contact Name</td> <td>Jen Chang, Science Manager</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>773-577-8742</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>jchang@abta.org</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>24-Mar-2021</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The mission of the American Brain Tumor Association is to advance the understanding and treatment of brain tumors with the goals of improving, extending and, ultimately, saving the lives of those impacted by a brain tumor diagnosis. Discovery Grants are one-year, \$50,000 grants for high risk, high impact research with the potential to change current diagnostic or treatment models.</td> </tr> </table>					Contact Name	Jen Chang, Science Manager	Contact Telephone	773-577-8742	Contact Email	jchang@abta.org	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	24-Mar-2021	Synopsis	The mission of the American Brain Tumor Association is to advance the understanding and treatment of brain tumors with the goals of improving, extending and, ultimately, saving the lives of those impacted by a brain tumor diagnosis. Discovery Grants are one-year, \$50,000 grants for high risk, high impact research with the potential to change current diagnostic or treatment models.
Contact Name	Jen Chang, Science Manager																		
Contact Telephone	773-577-8742																		
Contact Email	jchang@abta.org																		
Sponsor Website	Link to sponsor website																		
Program URL	Link to program URL																		
Deadline Dates (ALL)	24-Mar-2021																		
Synopsis	The mission of the American Brain Tumor Association is to advance the understanding and treatment of brain tumors with the goals of improving, extending and, ultimately, saving the lives of those impacted by a brain tumor diagnosis. Discovery Grants are one-year, \$50,000 grants for high risk, high impact research with the potential to change current diagnostic or treatment models.																		

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
046410	Seed Grant Program	American Epilepsy Society		24-Mar-2021	20,000 USD
	Contact Name				
	Contact Telephone	312-883-3800			
	Contact Email	grants@aesnet.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	24-Mar-2021			
	Synopsis	AES offers seed funding to help established investigators launch new lines of research, collaborations, and/or research methods in epilepsy research. Seed grants provide up to \$20,000 for one year, to be used to cover direct costs to fund preliminary investigation that will help researchers compete for larger grants that cover the full cost of research. They may not be renewed.			
070069	Century Scholarship	American Library Association		01-Mar-2021	2,500 USD
	Contact Name	Kimberly L. Redd			
	Contact Telephone	312-280-4279			
	Contact Email	klredd@ala.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Mar-2021			
	Synopsis	The Century Scholarship An annual scholarship of \$2,500 that funds services or accommodation for a library school student(s) with disabilities admitted to an ALA-accredited library school.			
055942	ANS Research Grant Award	American Neurotology Society		01-Mar-2021	25,000 USD
	Contact Name	Dr. Ronna Hertzano, Chair of the American Neurotology Society Research Committee			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone 217-638-0801 Contact Email RHertzano@som.umaryland.edu Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 01-Mar-2021 Synopsis The purpose of the ANS Research Grant is to encourage and support academic research in sciences related to the investigation of otology and neurotology.				
064003	Post-Doctoral Fellowship	American Parkinson Disease Association		12-Mar-2021	50,000 USD
	Contact Name Contact Telephone 800-223-2732 Contact Email apda@apdaparkinson.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 12-Mar-2021 Synopsis Post-Doctoral fellowships are awarded to support post-doctoral scientists whose research training holds promise into new insights of geriatric psychology, pathophysiology, etiology and treatment of Parkinson's disease.				
087777	Society for Health Psychology (Division 38) -- Award for Excellence in Health Psychology Research	American Psychological Association		31-Mar-2021	500 USD
	Contact Name Contact Telephone 804-752-4987 Contact Email apadiv38@verizon.net Sponsor Website Link to sponsor website				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL Link to program URL Deadline Dates (ALL) 31-Mar-2021 Synopsis The Award for Excellence in Health Psychology Research highlights the accomplishments of psychologists who have made significant contributions to the body of academic literature, demonstrating the value of psychological science and inquiry toward the betterment of health and healthcare.				
087778	Society for Health Psychology (Division 38) -- Award for Excellence in Health Psychology Research by an Early Career Professional	American Psychological Association		31-Mar-2021	500 USD
	Contact Name Contact Telephone 804-752-4987 Contact Email apadiv38@verizon.net Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 31-Mar-2021 Synopsis The Award for Excellence in Health Psychology Research by an Early Career Professional highlights the accomplishments of early career psychologists who have made significant contributions to the body of academic literature, demonstrating the value of psychological science and inquiry toward the betterment of health and healthcare.				
059738	Clinical Grants	American Society for Surgery of the Hand		01-Feb-2021 [LOI/Pre-App]	40,000 USD
	Contact Name Contact Telephone 312-880-1900 Contact Email afsh@assh.org				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2021 [LOI/Pre-App], 29-Mar-2021</p> <p>Synopsis The American Society for Surgery of the Hand (ASSH) and the American Foundation for Surgery of the Hand (AFSH) have established grant funding to encourage young investigators to perform clinical research studies. The goal is to enable investigators to initiate pilot projects that will lead to subsequent funding from other sources such as the National Institutes of Health (NIH). The AFSH is committed to excellence in clinical research while maintaining the highest academic integrity and fiscal responsibility.</p>				
059739	Basic Science Grants	American Society for Surgery of the Hand		01-Feb-2021 [LOI/Pre-App]	20,000 USD
	<p>Contact Name</p> <p>Contact Telephone 312-880-1900</p> <p>Contact Email afsh@assh.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2021 [LOI/Pre-App], 29-Mar-2021</p> <p>Synopsis These grants function similarly to the NIH Exploratory/Developmental Research Grant Program (R21). The R21 grant mechanism is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development.</p>				
080139	Career Development Grant	American Society of Colon and Rectal Surgeons		01-Mar-2021	150,000 USD
	<p>Contact Name</p> <p>Contact Telephone 847-956-1846</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email rf@fascrs.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 01-Mar-2021 Synopsis The Career Development Award provides support for young staff for initiating and developing academic careers in the field of diseases of the colon, rectum and anus.				
000814	Medical Student Research Initiation Grant	American Society of Colon and Rectal Surgeons		01-Mar-2021	4,000 USD
	Contact Name Contact Telephone 847-956-1846 Contact Email rf@fascrs.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 01-Mar-2021 Synopsis The Medical Student Research Initiation Grant provides opportunities for Medical Students to participate in clinical or laboratory-based research focused on diseases of the colon, rectum and anus.				
032663	Clinical Research Training Institute (CRTI) Program	American Society of Hematology		31-Mar-2021	Not Specified
	Contact Name Contact Telephone 202-776-0544 Contact Email training@hematology.org Sponsor Website Link to sponsor website Program URL Link to program URL				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 31-Mar-2021</p> <p>Synopsis The ASH Clinical Research Training Institute (CRTI) is a unique, year-long education and mentoring program for hematology fellows and junior faculty at academic medical centers. CRTI offers a broad education on clinical research methods, research collaborations, statistical analysis, and managing the demands of family and career. The goal of the program is to produce leaders armed with ideas for clinical hematology research and the tools and resources to make their ideas a reality.</p>				
041497	Annual Cerebrovascular Research Grant Awards	Aneurysm and AVM Foundation (TAAF)		05-Mar-2021	25,000 USD
	<p>Contact Name</p> <p>Contact Telephone 510-464-4540</p> <p>Contact Email research@taafonline.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Mar-2021</p> <p>Synopsis The Aneurysm and AVM Foundation (TAAF) seeks applications for scientific research projects that will significantly move the field forward toward effective understanding of the mechanisms of cerebrovascular disease as they relate to aneurysms, AVMs and complex vascular malformations. The Aneurysm and AVM Foundation Grants respond to the cerebrovascular community's need for projects that highlight innovative research strategies that will support the development of novel therapies, clinical management and recovery for adult and/or pediatric patients. Awards will be granted at a maximum of \$25,000. Funds will not be granted for indirect costs. The award is open to all levels of investigators. Grant recipients will present their research at TAAF's Annual Meeting (which historically has been TAAF's Annual Aneurysm and AVM Awareness Walk held the first Sunday of May). The specific meeting date and location will be announced later. Grant awardees or an appropriate representative must attend the Annual Meeting and present results of funded research.</p>				
100967	Special Call for Research to Address Gastrointestinal Complications	Angelman Syndrome Foundation, Inc.		15-Mar-2021	100,000 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Stormy Chamberlain, PhD</p> <p>Contact Telephone 800-432-6435</p> <p>Contact Email research@angelman.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Mar-2021</p> <p>Synopsis The Angelman Syndrome Foundation announces the availability of funds to be awarded in support of research on Angelman syndrome. This is a special call for research focused on gastrointestinal complications in Angelman syndrome.</p>				
023279	Short-Term Research/Training Fellowship	Asian Pacific Society of Respiriology		31-Mar-2021	Not Specified
	<p>Contact Name </p> <p>Contact Telephone +81-3-5684-3370</p> <p>Contact Email apsrinfo@theapsr.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-Mar-2021 , 31-Jul-2021 , 30-Nov-2021</p> <p>Synopsis The APSR is funding a scholarship programme with the aims of: promoting science and research in respiratory medicine in the APSR region; supporting the exchange in the APSR region of young scientists and clinicians actively involved in respiratory medicine; and contributing to the development of research and science of respiratory medicine in the APSR region.</p>				
101609	Grants Program	Association for Surgical Education		01-Mar-2021	Not Specified

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Lois Ehrlich</p> <p>Contact Telephone 310-215-1226</p> <p>Contact Email lois@surgicaleducation.com</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Mar-2021</p> <p>Synopsis The Association for Surgical Education Foundation (ASEF) recognizes the importance of advancing education research in the surgical fields and the difficult financial climate due to the on-going Covid pandemic. Therefore, ASEF is offering a series of education research grants to start July 1, 2021. Grant proposals that focus on the theme of virtual (either synchronous or asynchronous) instruction or assessment topics will receive special priority.</p>				
053890	Innovative Use of Technology Award	Association of Diabetes Care & Education Specialists		01-Mar-2021	Not Specified
	<p>Contact Name </p> <p>Contact Telephone 800-338-3633</p> <p>Contact Email </p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Mar-2021</p> <p>Synopsis This award supports the innovative use and integration of software and/or technology into practice. The project submitted should have significantly improved self-management among individual patient practices or broad diabetes populations.</p>				
044910	Veterinary Scholars Program - Veterinary Research Award for Graduate Veterinarians	Boehringer Ingelheim Veterinary		30-Mar-2021	2,500 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Akihiko Kusanagi, DVM, PhD</p> <p>Contact Telephone 678-638-3633</p> <p>Contact Email Akihiko.Kusanagi@Boehringer-Ingelheim.com</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 30-Mar-2021</p> <p>Synopsis This award is open to graduate veterinarians who will soon complete or have recently completed a PhD program in the biomedical sciences, or who are in the final 1 to 2 years of residency training in the field of veterinary pathology, medicine, surgery, radiology/imaging, or laboratory animal medicine.</p>				
057952	Fay/Frank Seed Grant Program	Brain Research Foundation		30-Mar-2021	80,000 USD
	<p>Contact Name </p> <p>Contact Telephone 312-759-5150</p> <p>Contact Email info@thebrf.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 30-Mar-2021</p> <p>Synopsis The Brain Research Foundation's Annual Seed Grant Program provides start-up monies for new research projects in the field of Neuroscience that will likely lead to extramural funding from the National Institutes of Health (NIH) or other outside funding sources.</p>				
058166	Career Guidance for Trainees (CGT) Program	Burroughs Wellcome Fund		12-Mar-2021	25,000 USD
	<p>Contact Name Victoria McGovern, PhD, Senior Program Officer</p> <p>Contact Telephone 919-991-5112</p> <p>Contact Email vmcgovern@bwfund.org</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 12-Mar-2021 Synopsis The Career Guidance for Trainees (CGT) program provides grants of \$15,000 to \$25,000 over a one-year period to support demonstration projects that will model affordable, transferable approaches to improving trainees' readiness for stable, fulfilling careers. This program does not support biomedical research projects proposed by individual investigators.				
059564	QuickStart Program	California Breast Cancer Research Program		18-Mar-2021	Not Specified
	Contact Name Contact Telephone 888-313-2277 Contact Email QuickStartTP@gmail.com Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 18-Mar-2021 Synopsis QuickStart is an innovative three-month program for both newly forming and experienced collaborative community-academic research partnerships. The full QuickStart program is scheduled for May 2021 to October 2021. The optional grant preparation and mock review is scheduled to take place between October 2021 to January 2022. This schedule may change as it is determined whether or not in-person sessions will be offered, or whether those sessions will be spread over a combination of in-person and online sessions, or whether those 4-days-worth of session will be completely online, or some other approach.				
058489	Technology Impact Award	Cancer Research Institute, Inc.		15-Mar-2021	200,000 USD
	Contact Name				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 212-688-7515</p> <p>Contact Email grants@cancerresearch.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Mar-2021</p> <p>Synopsis The Cancer Research Institute Technology Impact Award provides seed funding of up to \$200,000 to be used over 12 to 24 months to address the gap between technology development and clinical application of cancer immunotherapies.</p>				
061423	CAMs Summer Research Fellowship Scholarship	Chinese American Medical Society		01-Mar-2021	5,000 USD
	<p>Contact Name Att: Scholarship Committee</p> <p>Contact Telephone 212-334-4760</p> <p>Contact Email scholarship@camsociety.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Mar-2021</p> <p>Synopsis The Chinese American Medical Society (CAMS) offers scholarships for medical students working on summer research projects. The research can be basic science or clinical in nature but must be completed in a ten week time frame. Preferences will be given to proposals studying problems related to health problems of the Chinese. At the conclusion of the project, a written report is expected.</p>				
030340	Robert D. Kruse Memorial Scholarship Fund for Allied Health Professionals	Cleveland Clinic Foundation		31-Mar-2021	5,000 USD
	<p>Contact Name </p> <p>Contact Telephone 216-444-4018</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email hrehocm@ccf.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-Mar-2021</p> <p>Synopsis The Robert D. Kruse Memorial Scholarship provides \$5,000 to eligible students enrolled in a health science program to help cover academic expenses such as tuition and fees.</p>				
009252	Bender Scientific Fund	Community Foundation for the Greater Capital Region		18-Mar-2021 [LOI/Pre-App]	12,500 USD
	<p>Contact Name Shelly Connolly, Program Officer</p> <p>Contact Telephone 518-446-9638</p> <p>Contact Email sconnolly@cfgcr.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 18-Mar-2021 [LOI/Pre-App], 05-Aug-2021 [LOI/Pre-App]</p> <p>Synopsis The Bender Scientific Fund was established for the exclusive purpose of making grants to support and promote discovery and development in medicine, science and technology in the Capital Region. Grants from this fund usually range between \$1,000 and \$12,500.</p>				
007739	Grants Program	Cummings (James H.) Foundation		20-Jan-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 716-874-0040</p> <p>Contact Email info@jameshcummings.com</p> <p>Sponsor Website Link to sponsor website</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 20-Jan-2021 , 24-Mar-2021 [LOI/Pre-App], 14-Apr-2021</p> <p>Synopsis The James H. Cummings Foundation provides support to nonprofit organizations in Buffalo, Toronto, and Hendersonville, North Carolina to advance medical research, science, and post-secondary medical education; to provide services for vulnerable children and children with disabilities; and to assist older adults and vulnerable adults with services that help them maintain independent, healthy, and active lifestyles.</p>				
033065	Clinical Pilot and Feasibility Awards	Cystic Fibrosis Foundation		19-Mar-2021 [LOI/Pre-App]	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 301-841-2614</p> <p>Contact Email grants@cff.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 19-Mar-2021 [LOI/Pre-App], 18-Aug-2021</p> <p>Synopsis The intent of the Clinical Pilot and Feasibility Award is to enable investigators to collect sufficient preliminary data to determine the best strategies and methods for approaching a major question that ultimately will require assessment through a larger scale research and/or multi-center, collaborative clinical trial.</p>				
043695	Clinical Fellowships (Second Year)	Cystic Fibrosis Foundation		03-Mar-2021	69,500 USD
	<p>Contact Name</p> <p>Contact Telephone 301-841-2614</p> <p>Contact Email grants@cff.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 03-Mar-2021</p> <p>Synopsis The Second Year Clinical Fellowship award is part of the Cystic Fibrosis Foundation’s Physician Training Program and is designed to support Second Year Clinical Fellows pursuing training in CF relevant subspecialties. The maximum award is \$69,500.</p>				
005450	Clinical Research Award	Cystic Fibrosis Foundation		25-Jan-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 301-841-2637</p> <p>Contact Email grants@cff.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-Jan-2021 , 19-Mar-2021 [LOI/Pre-App], 18-Aug-2021</p> <p>Synopsis Clinical Research Awards are offered to provide support for investigator-initiated clinical research projects that have the potential to make an important contribution to the CF Foundation’s mission. Research projects may address diagnosis, treatment, management of disease or symptom, or the pathophysiology of CF using clinical (observational/interventional), translational or epidemiologic study approaches. Applicants must demonstrate access to sufficient numbers of CF patients and appropriate controls. Applicants may request funding of up to \$150,000 per year, plus an additional twelve (12) percent indirect costs for single-center clinical studies; and up to \$350,000 per year, plus twelve (12) percent indirect costs for multi-center clinical studies.</p>				
061719	Seedcorn Funding Programme	Cystinosis Ireland		31-Mar-2021	10,000 USD
	<p>Contact Name</p> <p>Contact Telephone 01 828 0483</p> <p>Contact Email research@cystinosis.ie</p> <p>Sponsor Website Link to sponsor website</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-Mar-2021 , 31-Aug-2021 , 30-Nov-2021</p> <p>Synopsis The Cystinosis Seedcorn Funding Programme aims to provide researchers with the opportunity to generate solid preliminary data which would contribute to a sustainable, longer-term application for funding. Funding is available to research institutions worldwide.</p>				
020313	Sapere Aude: DFF- Starting Grant	Danish Agency for Science and Higher Education		26-Mar-2021	688,000 USD
	<p>Contact Name</p> <p>Contact Telephone (+45) 7231 8200</p> <p>Contact Email DFF-opslag@ufm.dk</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 26-Mar-2021</p> <p>Synopsis The Danish Council for Independent Research (DFF) offers Starting Grants to younger researchers who have achieved outstanding research results in the field of Medical Sciences and gives them an opportunity to develop and strengthen their research ideas. DFF expects that a Sapere Aude: DFF–Starting Grant will help to enable the applicant to apply for an ERC Starting Grant/Consolidator Grant/Advanced Grant, or corresponding international programmes.</p>				
093354	Scholarship Program	David (Dan) Foundation		10-Mar-2021	15,000 USD
	<p>Contact Name</p> <p>Contact Telephone 972-3-6406614</p> <p>Contact Email ddprize@tauex.tau.ac.il</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 10-Mar-2021</p> <p>Synopsis The Dan David Prize laureates annually donate twenty scholarships of US\$15,000 each to outstanding doctoral and post-doctoral students of exceptional promise in selected fields. Ten scholarships are awarded to doctoral and post-doctoral students at universities throughout the world and ten scholarships at Tel Aviv University.</p>				
016617	Post-Doctoral Fellowship Programme	de Duve (Christian) Institute of Cellular Pathology		15-Mar-2021	33,120 USD
	<p>Contact Name Mrs. Nathalie Krack</p> <p>Contact Telephone 32-0-2-764 75 50</p> <p>Contact Email nathalie.krack@uclouvain.be</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Mar-2021 , 15-Sep-2021</p> <p>Synopsis The de Duve Institute awards 1-year fellowships, which are renewable once, to young foreign scientists, who wish to carry out their post-doctoral research within one of the research groups in the Institute.</p>				
038247	Clinical Scientist Development Award	Duke (Doris) Charitable Foundation		12-Mar-2021	150,000 USD
	<p>Contact Name</p> <p>Contact Telephone 212-974-7000</p> <p>Contact Email ddcf@aibs.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Mar-2021</p> <p>Synopsis Approximately 12 to 18 grants of up to \$495,000 each over 3 years (\$150,000 direct cost and \$15,000 indirect costs)</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>per year) will be awarded to early-career physician scientists (MD, MD/PhD, DO or foreign equivalent degree) at the Instructor or Assistant Professor rank working at US degree-granting institutions to support clinical research that will enable their transition to independent research funding.</p>			
042707	Student Mobility Award	European Federation of Chemical Engineering		01-Mar-2021	2,400 USD
	Contact Name				
	Contact Telephone	+49-69-7564 143			
	Contact Email	ines.honndorf@dechema.de			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Mar-2021			
	Synopsis	The European Federation of Chemical Engineering (EFCE) offers the Student Mobility Award on a biennial basis to promote mobility among European chemical engineering students.			
006584	Crystal Cornea Award	Eye Bank Association of America		19-Mar-2021	Not Specified
	Contact Name				
	Contact Telephone	202-775-4999			
	Contact Email				
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	19-Mar-2021			
	Synopsis	The Crystal Cornea Award is presented to individuals or organizations whose work helps the eye bank community give the gift of sight. This award is presented during the EBAA Annual Meeting or another appropriate venue and is			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
	awarded to media organizations, lawmakers, or individuals for outstanding contributions through creative design, speaking, writing, publishing or airing information that advances cornea donation and the mission of EBAA.																		
073832	Summer Institute for Medical Students (SIMS)	Ford (Betty) Institute		01-Feb-2021	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 2px;">Contact Name</td> <td style="padding: 2px;"></td> </tr> <tr> <td style="padding: 2px;">Contact Telephone</td> <td style="padding: 2px;">760-773-4375</td> </tr> <tr> <td style="padding: 2px;">Contact Email</td> <td style="padding: 2px;">MPE@hazeldenbettyford.org</td> </tr> <tr> <td style="padding: 2px;">Sponsor Website</td> <td style="padding: 2px;">Link to sponsor website</td> </tr> <tr> <td style="padding: 2px;">Program URL</td> <td style="padding: 2px;">Link to program URL</td> </tr> <tr> <td style="padding: 2px;">Deadline Dates (ALL)</td> <td style="padding: 2px;">01-Feb-2021 , 01-Mar-2021</td> </tr> <tr> <td style="padding: 2px;">Synopsis</td> <td style="padding: 2px;">The Summer Institute for Medical Students program provides an inside look at the dynamics of addiction and the process of healing.</td> </tr> </table>					Contact Name		Contact Telephone	760-773-4375	Contact Email	MPE@hazeldenbettyford.org	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	01-Feb-2021 , 01-Mar-2021	Synopsis	The Summer Institute for Medical Students program provides an inside look at the dynamics of addiction and the process of healing.
Contact Name																			
Contact Telephone	760-773-4375																		
Contact Email	MPE@hazeldenbettyford.org																		
Sponsor Website	Link to sponsor website																		
Program URL	Link to program URL																		
Deadline Dates (ALL)	01-Feb-2021 , 01-Mar-2021																		
Synopsis	The Summer Institute for Medical Students program provides an inside look at the dynamics of addiction and the process of healing.																		
010950	General Request for Applications (RFA)	Foundation for Prader-Willi Research		05-Mar-2021 [LOI/Pre-App]	100,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 2px;">Contact Name</td> <td style="padding: 2px;">Jessica Bohonowych</td> </tr> <tr> <td style="padding: 2px;">Contact Telephone</td> <td style="padding: 2px;">888-322-5487</td> </tr> <tr> <td style="padding: 2px;">Contact Email</td> <td style="padding: 2px;">jessica.bohonowych@fpwr.org</td> </tr> <tr> <td style="padding: 2px;">Sponsor Website</td> <td style="padding: 2px;">Link to sponsor website</td> </tr> <tr> <td style="padding: 2px;">Program URL</td> <td style="padding: 2px;">Link to program URL</td> </tr> <tr> <td style="padding: 2px;">Deadline Dates (ALL)</td> <td style="padding: 2px;">05-Mar-2021 [LOI/Pre-App], 21-May-2021</td> </tr> <tr> <td style="padding: 2px;">Synopsis</td> <td style="padding: 2px;">The Foundation for Prader-Willi Research (FPWR), a nonprofit organization dedicated to supporting research to advance the understanding and treatment of Prader-Willi syndrome (PWS), announces the availability of funds to support innovative PWS research. FPWR is particularly interested in supporting projects that will lead to new</td> </tr> </table>					Contact Name	Jessica Bohonowych	Contact Telephone	888-322-5487	Contact Email	jessica.bohonowych@fpwr.org	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	05-Mar-2021 [LOI/Pre-App], 21-May-2021	Synopsis	The Foundation for Prader-Willi Research (FPWR), a nonprofit organization dedicated to supporting research to advance the understanding and treatment of Prader-Willi syndrome (PWS), announces the availability of funds to support innovative PWS research. FPWR is particularly interested in supporting projects that will lead to new
Contact Name	Jessica Bohonowych																		
Contact Telephone	888-322-5487																		
Contact Email	jessica.bohonowych@fpwr.org																		
Sponsor Website	Link to sponsor website																		
Program URL	Link to program URL																		
Deadline Dates (ALL)	05-Mar-2021 [LOI/Pre-App], 21-May-2021																		
Synopsis	The Foundation for Prader-Willi Research (FPWR), a nonprofit organization dedicated to supporting research to advance the understanding and treatment of Prader-Willi syndrome (PWS), announces the availability of funds to support innovative PWS research. FPWR is particularly interested in supporting projects that will lead to new																		

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		treatments to alleviate the symptoms associated with PWS.			
099806	Development and Validation of Improved Outcome Measures	Fox (Michael J.) Foundation for Parkinson's Research		18-Mar-2021	750,000 USD
	Contact Name				
	Contact Telephone	800-708-7644			
	Contact Email	grants@michaeljfox.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	18-Mar-2021			
	Synopsis	The Michael J. Fox Foundation (MJFF) seeks applications to develop objective biomarkers that can support therapeutic development in Parkinson's. These may include biomarkers that improve definitive diagnosis, objectively track disease progression, enrich for subject populations, or more precisely detect a treatment response or target engagement. The availability of these types of biomarkers would transform clinical trial design and assist in the interpretation of trial results. The award amount is up to \$750,000.			
051545	Target Advancement Program	Fox (Michael J.) Foundation for Parkinson's Research		18-Mar-2021	150,000 USD
	Contact Name				
	Contact Telephone	800-708-7644			
	Contact Email	grants@michaeljfox.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	18-Mar-2021			
	Synopsis	The Michael J. Fox Foundation seeks applications that leverage and translate basic research to enable therapeutic			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

development.

099827	PIPETTE: 4R Tau and Alpha-Synuclein PET Tracer Development	Fox (Michael J.) Foundation for Parkinson's Research		18-Mar-2021	1,000,000 USD
--------	--	--	--	-------------	---------------

Contact Name
 Contact Telephone 1-800-708-7644
 Contact Email grants@michaeljfox.org
 Sponsor Website [Link to sponsor website](#)
 Program URL [Link to program URL](#)
 Deadline Dates (ALL) 18-Mar-2021

Synopsis The partnership's goal is to support the development of novel positron emission tomography (PET) tracers for tau and alpha-synuclein. As a collaborative effort of leading non-profit organizations, the PIPETTE Consortium seeks to pool ideas, expertise, and resources to enable improved diagnosis and treatment of multiple disorders. The PIPETTE 4R Tau and Alpha-synuclein PET Tracer Development program seeks to accelerate the development of selective 4R tau and alpha-synuclein PET tracers. The ability to image brain neurofilaments of 4R tau, the predominant tau isoform associated with progressive supranuclear palsy and related disorders, would be a game-changing achievement for the field.

030560	Therapeutic Pipeline Program	Fox (Michael J.) Foundation for Parkinson's Research		18-Mar-2021	Not Specified
--------	--	--	--	-------------	---------------

Contact Name
 Contact Telephone 800-708-7644
 Contact Email grants@michaeljfox.org
 Sponsor Website [Link to sponsor website](#)
 Program URL [Link to program URL](#)

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 18-Mar-2021</p> <p>Synopsis The Therapeutic Pipeline Program seeks to speed the development of Parkinson’s disease therapeutics with potential for fundamentally altering disease course or significantly improving treatment or management of non-motor or motor symptoms beyond current standards of care. Proposals should focus on strategies with clear impact for people with Parkinson’s and well-defined development plans. Programs developing novel approaches as well as those seeking to repurpose or reposition approved or clinically safe therapies from other disease indications are appropriate for this RFA. MJFF will prioritize clinical and pre-clinical approaches built on strong scientific and biological rationale for targeting fundamental processes underlying Parkinson’s cause, progression and/or non-motor and motor symptom expression.</p>				
099762	Analysis of Patient-Reported Outcomes from Fox Insight	Fox (Michael J.) Foundation for Parkinson's Research		18-Mar-2021	100,000 USD
	<p>Contact Name</p> <p>Contact Telephone 800-708-7644</p> <p>Contact Email grants@michaeljfox.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 18-Mar-2021</p> <p>Synopsis This Request for Applications (RFA) seeks to fund analyses of the patient-reported outcomes (PROs) and genetic data collected through the Fox Insight study.</p>				
007116	Postdoctoral Fellowships	French Muscular Dystrophy Association		19-Jan-2021	Not Specified
	<p>Contact Name Laurence TIENNOT-HERMENT</p> <p>Contact Telephone + 33 1 69 47 28 28</p> <p>Contact Email spcsafm@afm.genethon.fr</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 19-Jan-2021 , 30-Mar-2021 Synopsis The Association Francaise contre les Myopathies provides Postdoctoral Fellowships for for one year, renewable for a second year, for research of neuromuscular diseases and rare genetic diseases.				
036254	Keith Michael Andrus Memorial Award	Friedreich's Ataxia Research Alliance		01-Mar-2021	300,000 USD
	Contact Name Contact Telephone 484-879-6160 Contact Email info@cureFA.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 01-Mar-2021 Synopsis The Keith Michael Andrus Cardiac Research Award was made in honor of its namesake to remember Keith's legacy and to help advanced our understanding and treatment of the cardiomyopathy associated with FA. Proposals for this award should focus on advancing understanding and/or treatment of the cardiac involvement in FA.				
065344	Joseph T. Freeman Award	Gerontological Society of America		31-Mar-2021	Not Specified
	Contact Name Contact Telephone 202-842-1275 Contact Email awards@geron.org Sponsor Website Link to sponsor website Program URL Link to program URL				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	31-Mar-2021			
	Synopsis	The Joseph T. Freeman Award is a lectureship in geriatrics and is awarded to a prominent physician in the field of aging, both in research and practice.			
063403	Research Grant Program	Glaucoma Foundation		05-Mar-2021	60,000 USD
	Contact Name	Andrea Steele, Director of Operations			
	Contact Telephone	212-651-2509			
	Contact Email	asteel@glaucomafoundation.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Mar-2021 , 08-Mar-2021			
	Synopsis	The Glaucoma Foundation (TGF) offers one-year, renewable grants to researchers striving to improve the lives of glaucoma patients through novel innovations and scientific advances.			
013935	Premier's Science Fellowship Program	Government of Western Australia		02-Mar-2021	Not Specified
	Contact Name	Dr Ros Dilworth			
	Contact Telephone	61 8 6552 6080			
	Contact Email	ros.dilworth@jtsi.wa.gov.au			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	02-Mar-2021			
	Synopsis	The Premier's Science Fellowship Program aims to attract Premier's Science Fellows (distinguished researchers and leaders of international prominence) and Premier's Early to Mid-Career Fellows (supporting early to mid-career researchers) to Western Australia.			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
066296	Walter A. Rosenblith New Investigator Award	Health Effects Institute	RFA 19-2	24-Mar-2021	500,000 USD
	Contact Name	Dan Crouse			
	Contact Telephone	617-488-2322			
	Contact Email	dcrouse@healtheffects.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	24-Mar-2021 , 01-Sep-2021			
	Synopsis	The Walter A. Rosenblith New Investigator Award supports creative junior investigators, at Assistant Professor or equivalent level, with outstanding promise who are interested in the health effects of air pollution. RFA 20-2 provides funding for a project relevant to HEI's research interests, as outlined in the HEI Strategic Plan 2020-2025. Each award will be a maximum of \$500,000 for three years in total costs to support a research project.			
057817	Charles A. King Trust Postdoctoral Research Fellowship Program	Health Resources in Action		03-Mar-2021	Not Specified
	Contact Name	Lindsey Carver, MA - Grants Officer			
	Contact Telephone	617-451-0049			
	Contact Email	lcarver@hria.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	03-Mar-2021			
	Synopsis	The Charles A. King Trust Postdoctoral Research Fellowship Program is designed to support postdoctoral scientists in non-profit academic, medical or research institutions in Massachusetts. Two-year grants ranging from \$109,408 to \$127,600, inclusive of a \$2,000 expense allowance, will be awarded October 1.			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
002797	Fellowship Program	Heed Ophthalmic Foundation		01-Mar-2021	10,000 USD
	Contact Name	c/o Lisa Brown			
	Contact Telephone	415-447-0249			
	Contact Email	heed@ao.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Mar-2021			
	Synopsis	The Heed Ophthalmic Foundation provides fellowships to assist young men and women in pursuing postgraduate studies in ophthalmology.			
057155	Grants Program	Hofmann (Kent Richard) Foundation		05-Mar-2021 [LOI/Pre-App]	Not Specified
	Contact Name				
	Contact Telephone	917-573-0486			
	Contact Email	krhofmann@gmail.com			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Mar-2021 [LOI/Pre-App], 01-Apr-2021 , 05-Aug-2021 [LOI/Pre-App], 03-Sep-2021			
	Synopsis	The Kent Richard Hofmann Foundation is a small, private foundation dedicated to the fight against HIV and AIDS. Grants are made semi-annually, to non-profit organizations, in support of Care and direct services; Education; and Research.			
081163	SWOG/Hope Foundation Impact Award	Hope Foundation for Cancer Research		15-Mar-2021	250,000 USD
	Contact Name	Johanna Horn, President & CEO			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 734-998-7150</p> <p>Contact Email jo@thehopefoundation.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Mar-2021 , 01-Jul-2021 [LOI/Pre-App], 01-Sep-2021</p> <p>Synopsis The SWOG/Hope Foundation Impact Award is a funding program that encourages novel and innovative SWOG research by supporting early and conceptual stages of these projects. The work proposed should use resources from completed SWOG trials or be directly translatable to future clinical trials in SWOG and the National Clinical Trials Network (NCTN). These studies may involve scientific risk but potentially lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on cancer research. It is expected that support via this mechanism will lead to subsequent extramural support from other sources, and will be a metric of success for this grant program. In addition, publications citing SWOG and The Hope Foundation will be further metrics for success.</p>				
059770	Berman/Topper HD Career Development Fellowship	Huntington's Disease Society of America, Inc.		19-Mar-2021	240,000 USD
	<p>Contact Name George Yohrling, PhD, HDSA Senior Director, Mission and Scientific Affairs</p> <p>Contact Telephone 212-242-1968 x211</p> <p>Contact Email gyohrling@hdsa.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 19-Mar-2021</p> <p>Synopsis A stagnant NIH budget and lack of career development mechanisms for young HD researchers has led to an environment where the funding opportunities for young HD researchers are limited. The Huntington's Disease Society of America (HDSA) believes we must ensure that the pipeline of passionate and bright HD scientists and clinicians</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

remains full, a vision that is shared by the Berman and Topper families. With that in mind and with their support, HDSA is interested in sponsoring innovative lines of scientific inquiry into HD biology by young researchers with a desire in making HD part of their career plan. The HDSA Berman/Topper Family HD Career Development Fellowship will be provided as salary and research support (up to \$80,000/year) for new clinical, translational or basic HD biology research projects for a potential of \$240,000 per three year award.

072205	IADR Lion Dental Research Award	International Association for Dental Research		01-Mar-2021	2,000 USD
--------	---	---	--	-------------	-----------

Contact Name	Anthony Jones, Awards, Fellowships and Grants Coordinator
Contact Telephone	703-548-0066
Contact Email	ajones@iadr.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	01-Mar-2021
Synopsis	The Lion Dental Research Award is intended to support improvements in oral health sciences through the stimulation of junior researchers.

072193	IADR Colgate Research in Prevention Travel Awards	International Association for Dental Research		01-Mar-2021	2,000 USD
--------	---	---	--	-------------	-----------

Contact Name	Anthony Jones, Awards, Fellowships and Grants Coordinator
Contact Telephone	703-548-0066
Contact Email	ajones@iadr.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	01-Mar-2021

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The IADR is inviting applications from young investigators who have submitted an abstract which has a preventive component for a travel award to support their attendance at the IADR General Session.			
049954	Kulzer Travel Award	International Association for Dental Research		01-Mar-2021	2,500 USD
	Contact Name	Anthony Jones; Awards, Fellowships and Grants Coordinator			
	Contact Telephone				
	Contact Email	ajones@iadr.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Mar-2021			
	Synopsis	The IADR is inviting applications from young investigators who have submitted an abstract which has a dental materials component for a travel award to support their attendance at the IADR General Session. The winner of each award will receive US \$2,500 for expenses to attend the IADR General Session & Exhibition.			
049993	Periodontal Research Group Past Presidents' Travel Award	International Association for Dental Research		01-Mar-2021	3,000 USD
	Contact Name	Panos N. Papapanou, DDS, PhD; Chair, Section of Oral and Diagnostic Sciences			
	Contact Telephone	+1.703.548.0066			
	Contact Email	pp192@cumc.columbia.edu			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Mar-2021			
	Synopsis	In honor of the PRG's Past Presidents, the Group is offering the PRG Presidents' Travel Award in line with its focus on enhancing research and attracting junior researchers into academia.			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
049984	Microbiology/Immunology Travel Awards	International Association for Dental Research		01-Mar-2021	1,000 USD
	<p>Contact Name Hansel Fletcher</p> <p>Contact Telephone 1-703-548-0066</p> <p>Contact Email Hfletcher@llu.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Mar-2021</p> <p>Synopsis The IADR Microbiology/Immunology Group is offering travel awards. One is in honor of Dr. Susan Kinder Haake, and another in honor of Dr. Arnold Bleiweis, to enhance research and attract early career researchers into the field of oral microbiology and immunology. The group also provides additional travel awards for outstanding research by deserving students and postdoctoral fellows. Up to four travel grants are awarded per year.</p>				
049995	IADR/Philips Oral Healthcare Young Investigator Research Grant	International Association for Dental Research		31-Mar-2021	10,000 USD
	<p>Contact Name Iain L. C. Chapple, Head of the School of Dentistry, Professor of Periodontology</p> <p>Contact Telephone 703-548-0066</p> <p>Contact Email I.L.C.Chapple@bham.ac.uk</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-Mar-2021</p> <p>Synopsis Philips Oral Healthcare offers a research grant on a competitive basis annually through the IADR Periodontal Research Group. The objective is to provide seed funding for a post-doctoral student/staff that is within 12-months of successfully completing a Ph.D. at the time of the submission deadline, and wishes to establish an independent program of research.</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
006210	Annual Balzan Prizes	International Balzan Prize Foundation		15-Mar-2021	Not Specified
	Contact Name Contact Telephone 39-02-7600-2212 Contact Email balzan@balzan.it Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 15-Mar-2021 Synopsis The Balzan Prizes are chosen by the General Prize Committee in two general subject areas: Literature, Moral Sciences and the Arts; and the Physical, Mathematical and Natural Sciences and Medicine. The four Balzan Prizes, two per category, are awarded to scholars, artists and scientists who have distinguished themselves in their fields on an international level. The subject areas in which the awards are granted are rotated, and this special characteristic of the Balzan Prize ensures the promotion and recognition of new or emerging fields of study or research that may have been overlooked by other international awards. In 2001, the Articles of the Balzan Foundation made a stipulation that prizewinners must destine half of the prize to finance research projects that are preferably carried out by young scholars or scientists.				
078587	Innovator Awards	International OCD Foundation		01-Mar-2021	300,000 USD
	Contact Name Contact Telephone 617-973-5801 Contact Email research@iocdf.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 01-Mar-2021				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<p>Synopsis</p>		<p>International OCD Foundation offers \$300,000 grants for senior researchers investigating OCD. The goal of these awards is to support research with the potential to revolutionize scientific understanding of OCD, accelerate progress toward new and more effective treatments, and discover ways to prevent OCD from taking hold in the first place.</p>			
015167	Postdoctoral Scholar Awards	International Retinal Research Foundation, Inc.		15-Mar-2021	35,000 USD
<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>		<p>Ms. Sandra Blackwood, MPA, Executive Director</p> <p>205-325-8103</p> <p>sblackwood@irrfonline.org</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>15-Mar-2021</p> <p>Three IRRF Scholar Awards have been designated in honor of individuals who played a critical role in the development of the International Retinal Research Foundation and are meant to serve as a memorial to their efforts. Three awards are given: The Alston Callahan, MD Scholar Award; The Charles D. Kelman, MD Scholar Award; and the Loris and David Rich Scholar Award. The IRRF Postdoctoral Scholar Awards were established to provide salary and research support in the amount of \$35,000 per year for a postdoctoral scholar nearing the end of his/her training.</p>			
018976	ISSLS Clinical Travelling Fellowship	International Society for the Study of the Lumbar Spine		15-Mar-2021	5,000 USD
<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p>		<p></p> <p>+46-31-786 44 36</p> <p>fiona.strain@issls.org</p> <p>Link to sponsor website</p> <p>Link to program URL</p>			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 15-Mar-2021</p> <p>Synopsis ISSLS announces a call for applications for its 2021 Clinical Travelling Fellowship. The sponsor invites junior faculty members (in practice for fewer than 10 years) from any country or part of the world to apply. The Fellowship Committee will decide upon the awardee at the ISSLS Annual Meeting in Milan, Italy in May/June 2021. Applications will be judged on merit and qualifications, with an emphasis on scholarly activities and clinical experience.</p>				
095169	Educational Grants -- Infectious Diseases (HIV/AIDS)	Janssen Biotech, Inc.		15-Mar-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email jtgrantinfo@its.jnj.com</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Mar-2021 , 15-May-2021</p> <p>Synopsis Janssen provides grants to support educational activities for healthcare providers, allied healthcare providers and patients. Priority is given for activities within Janssen’s areas of scientific interest that contribute to improved knowledge, practice and performance for healthcare providers and improved health outcomes for patients, including in the area of Infectious Diseases. Grants are available for: Continuing Medical Education (CE)/Non-Accredited Continuing Education (NCE); Fellowships; and Patient Education.</p>				
081724	Therapeutic Area Contributions - Infectious Diseases Program	Janssen Pharmaceuticals, Inc.		31-Jan-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 908-218-6095</p> <p>Contact Email</p> <p>Sponsor Website Link to sponsor website</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-Jan-2021 , 31-Mar-2021 , 31-May-2021 , 31-Jul-2021 , 30-Sep-2021 , 15-Nov-2021</p> <p>Synopsis Janssen Pharmaceuticals, Inc. makes charitable contributions to support therapeutic area initiatives. Applications are evaluated competitively with emphasis given to innovative programs with measurable outcomes that address disparities or unmet needs. The Infectious Diseases area of interest supports the following disease states: Hepatitis B; HIV / AIDS; Respiratory Infections; and Vaccines.</p>				
095455	King Faisal International Prize - Medicine	King Faisal Foundation		31-Mar-2021	195,000 USD
	<p>Contact Name</p> <p>Contact Telephone +(966-1) 465 2255</p> <p>Contact Email nominations@kingfaisalprize.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-Mar-2021</p> <p>Synopsis The General Secretariat of King Faisal International Prize is accepting nominations for the year 2022 Prize for Medicine on the topic of: Gene Editing Technologies.</p>				
100175	MIT Aging Brain Initiative "la Caixa" Foundation Postdoctoral Fellowships	la Caixa Foundation		01-Mar-2021	195,000 USD
	<p>Contact Name Abby Reynolds</p> <p>Contact Telephone</p> <p>Contact Email areynol2@mit.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 01-Mar-2021</p> <p>Synopsis "la Caixa" Foundation offers three postdoctoral fellowships for up to three years in Aging Brain Initiative laboratories across MIT to the most talented PhD graduates. Preference will be given graduates from institutions in Spain or Portugal who have a strong record of academic excellence, outstanding PhD research, proven scientific productivity, and evidence of potential in their research paths.</p>				
044094	Research Grants	McGovern (Jack) Coats Disease Foundation (JMCDF)		01-Mar-2021	25,000 USD
	<p>Contact Name Deborah Marron</p> <p>Contact Telephone 888-314-8853</p> <p>Contact Email deborahmarron@curecoats.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Mar-2021</p> <p>Synopsis The Jack McGovern Coats' Disease Foundation supports medical research specific to Coats' Disease and other retinal diseases which may lead to a cure for, or improve treatment for, Coats' Disease. The Foundation encourages research and, when applicable, collaboration between researchers who are working in the area of Coats' Disease.</p>				
061235	Merck MISP Oncology Grant	Merck		19-Jan-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 267-305-3871</p> <p>Contact Email oncmisp@msd.com</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 19-Jan-2021 , 10-Mar-2021</p> <p>Synopsis The Investigator Studies Program aims to advance science and improve patient care by supporting, through the provision of drug/vaccine and/or total/partial funding, high-quality research that is initiated, designed, implemented and sponsored by external investigators. Results will be generated and properly disseminated in peer-reviewed publications.</p>				
034636	Ron Mardigian Biotechnology Teaching Award	National Association of Biology Teachers		15-Mar-2021	500 USD
	<p>Contact Name </p> <p>Contact Telephone 703-264-9696</p> <p>Contact Email office@nabt.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Mar-2021</p> <p>Synopsis The Ron Mardigian Biotechnology Teaching Award, recognizes a teacher who demonstrates outstanding and creative teaching of biotechnology in the classroom.</p>				
017219	Graduate Scholarship Program	National Environmental Health Association		31-Mar-2021	2,500 USD
	<p>Contact Name Jonna Ashley, NEHA Scholarship Liaison</p> <p>Contact Telephone 303-756-9090 x336</p> <p>Contact Email jashley@neha.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-Mar-2021</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The NEHA offers a scholarship program to stimulate past and present graduates to pursue postgraduate studies in environmental health sciences.			
017114	Department of Neurology - Neuromuscular Medicine Fellowship	Northwestern University Feinberg School of Medicine		01-Mar-2021	Not Specified
	Contact Name	Erin van Bladel, Fellowship Coordinator			
	Contact Telephone	312-503-2849			
	Contact Email	e-vanbladel@northwestern.edu			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Mar-2021			
	Synopsis	<p>The McGaw Medical Center of Northwestern University offers a one-year, ACGME-accredited Neuromuscular Medicine fellowship that provides comprehensive training in electrodiagnosis (EMG), muscle and nerve biopsy and inpatient/outpatient management. The Neuromuscular Medicine Fellowship Program is a structured, 12-month educational experience combining electrophysiology, muscle and nerve pathology and clinical exposure to wide variety of neuromuscular disorders in adult and children. Teaching occurs through didactic programs and through direct supervision of residents in the Electrodiagnostic laboratory and with every patient encounter, whether it is in the inpatient or outpatient setting. Full-time clinical faculty at the program sites supervises all aspects of the program. There is a graded progression of the resident responsibilities. Fellows interact with neurology and physical medicine and rehabilitation residents during testing and clinical activities and also have the opportunity to give didactic lectures to the neurology residents. The aim of the fellowship is to provide neuromuscular disorder specialists with specialized knowledge in the science, clinical evaluation and clinical management of disorders of anterior horn cell, peripheral nerve, neuromuscular junction and muscle. This includes knowledge of the pathophysiology, pathology, diagnosis and treatment of these disorders at a level that is significantly beyond the training and knowledge expected of a general neurologist. Educational Goals Prepare the trainee for the independent evaluation and management of patients with neuromuscular disorders Prepare the trainee for the acquisition of specialized skills required for the diagnosis of neuromuscular disorders like performing and interpreting Electrodiagnostic studies and muscle and nerve biopsies</p>			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
018980	Department of Radiology - Neuroradiology Fellowship	Northwestern University Feinberg School of Medicine		01-Mar-2021	Not Specified

Understand the indications for Electrodiagnostic studies and for nerve and muscle biopsies and the role of these procedures in the diagnosis and management of patients with neuromuscular diseases Provide the foundation in basic science of neuromuscular disorders Assure increasing level of responsibility for patient management in a supervised environment Provide foundation for the scholarly activity These objectives will be achieved by developing competence in the following areas: professionalism, patient care, medical knowledge, interpersonal and communication skills, system-based practice and practice learning and improvement.

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Margie Szymanskyj, Program Coordinator</p> <p>312-695-1292</p> <p>mszyman2@nm.org</p> <p>Link to sponsor website</p> <p></p> <p>01-Mar-2021</p> <p>The Neuroradiology Fellowship training program at McGaw Medical Center of Northwestern University is an ACGME-approved, one-year program based at Northwestern Memorial Hospital (NMH) and the main campus of Northwestern University Feinberg School of Medicine in the heart of Chicago. Fellows also rotate at the Ann & Robert H. Lurie Children’s Hospital of Chicago. The program is offered to physicians who have completed their radiology residency and are American Board of Radiology board-certified/eligible. A total of six positions are available. The program trains fellows in all aspects of diagnostic neuroradiology with an emphasis on advanced imaging techniques, minimally invasive diagnostic and therapeutic spine procedures and catheter angiography. Fellows will gain experience in therapeutic neuroendovascular techniques through participation in that service and will be supported in pursuing academic interests. A second-year Advanced Diagnostic Neuroradiology Fellowship program is also available for those who want to focus on advanced imaging techniques and have already completed an initial one year ACGME-approved Diagnostic Neuroradiology Fellowship.</p>
---	---

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
086556	PFF Scholars Program	Pulmonary Fibrosis Foundation		15-Mar-2021	50,000 USD
	Contact Name	Zoe Bubany, VP of Board and External Relations			
	Contact Telephone	888-733-6741			
	Contact Email	zbubany@pulmonaryfibrosis.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Mar-2021			
	Synopsis	The PFF Scholars Program is designed to support early stage researchers and provide career development opportunities to future leaders in the field of pulmonary fibrosis. An award of up to \$50,000 USD to be given over a two-year period to encourage early stage investigators (individuals must be post-doctoral trainees, instructors, or Assistant professors) to support them as they seek “K” or “R”-level funding.			
001723	Clinical Research Proposals	ResMed Foundation		15-Mar-2021	250,000 USD
	Contact Name	Kristi Burlingame, Executive Director			
	Contact Telephone	858-361-0755			
	Contact Email	kristib@resmedfoundation.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Mar-2021 , 15-Sep-2021			
	Synopsis	The Foundation's key mission is to promote novel research as well as public and physician awareness of sleep disordered breathing (SDB), with a primary focus on positive airway pressure therapies and ventilation-based treatments. The Foundation will consider proposals focused on the evaluation, diagnosis, treatment and management of SDB and other respiratory disorders. Research areas of interest are also other morbidities that are associated with SDB which include cardiovascular disease, metabolic syndrome, diabetes and morbid obesity. In the cardiovascular			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>area, there is a particular emphasis on hypertension, coronary artery disease, heart failure, and atrial fibrillation. Other areas of focus are: SDB in conjunction with occupational health safety, asthma and anesthesiology; chronic obstructive pulmonary disease; and, pregnancy/preeclampsia. Specific focus is on outcomes that can influence clinical practice in the near term.</p>				
036955	Hoebel Prize for Creativity	Society for the Study of Ingestive Behavior		31-Mar-2021	750 USD
	<p>Contact Name</p> <p>Contact Telephone 847-807-4924</p> <p>Contact Email info@ssib.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-Mar-2021</p> <p>Synopsis This award honors a SSIB member, at any stage of their career, for an exceptional level of creativity and excellence in his or her research on ingestive behavior.</p>				
020728	Alan N. Epstein Research Award	Society for the Study of Ingestive Behavior		31-Mar-2021	750 USD
	<p>Contact Name</p> <p>Contact Telephone 847-807-4924</p> <p>Contact Email info@ssib.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-Mar-2021</p> <p>Synopsis This award honors an individual for a specific research discovery that has advanced the understanding of ingestive</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		behavior.			
020497	Distinguished Career Award	Society for the Study of Ingestive Behavior		31-Mar-2021	1,500 USD
	Contact Name				
	Contact Telephone	847-807-4924			
	Contact Email	info@ssib.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	31-Mar-2021			
	Synopsis	The award honors an individual for his or her accomplishments in and contributions to the understanding of ingestive behavior.			
020729	New Investigator Travel Award	Society for the Study of Ingestive Behavior		22-Mar-2021	Not Specified
	Contact Name				
	Contact Telephone	847-807-4924			
	Contact Email	ssib@ssib.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	22-Mar-2021			
	Synopsis	Travel awards are available for students and postdoctoral fellows (until five years after receiving doctoral degree). These awards are competitive, and are made based on scientific merit and abstract quality, as assessed by the NITA selection committee.			
019649	Clinical Research Seed Grants	Society for Vascular Surgery		01-Mar-2021	25,000 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 800-258-7188</p> <p>Contact Email svsfoundation@vascularsociety.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Mar-2021</p> <p>Synopsis The Society for Vascular Surgery provides Clinical Research Seed Grants in recognition of the importance of clinical investigation in vascular disease.</p>				
010948	E.J. Wylie Traveling Fellowship	Society for Vascular Surgery		01-Mar-2021	12,000 USD
	<p>Contact Name</p> <p>Contact Telephone 800-258-7188</p> <p>Contact Email SVSFoundation@vascularsociety.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Mar-2021</p> <p>Synopsis The primary purpose of the E.J. Wylie Traveling Fellowship is to provide the recipient with the opportunity to visit a number of excellent vascular surgery centers worldwide. The E.J. Wylie Traveling Fellowship of the SVS Foundation pays up to US\$12,000 for expenses of travel, research, and clerical help.</p>				
091670	Medal for Innovation in Vascular Surgery	Society for Vascular Surgery		01-Mar-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 312-334-2300</p> <p>Contact Email vascular@vascularsociety.org</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 01-Mar-2021 Synopsis The SVS Medal for Innovation in Vascular Surgery honors individuals whose contribution has had a transforming impact on the practice or science of vascular surgery. An individual may be nominated on a singular innovation or a body of work. If two or more individuals have contributed to the advance, the award will be made to both individuals.				
066625	Barrington Moore Memorial Award	Society of American Foresters		15-Mar-2021	1,000 USD
	Contact Name Contact Telephone 301-897-8720 Contact Email membership@safnet.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 15-Mar-2021 Synopsis The Barrington Moore Memorial Award recognizes outstanding achievement in biological research leading to the advancement of forestry. Biological research includes such fields as forest ecology, fire ecology, forest soil science, forest hydrology, forest wildlife or fish ecology, forest or tree physiology, forest genetics, forest pathology, forest entomology, forest carbon cycle science, and ecological aspects of managerial or quantitative fields like silviculture, agroforestry, or biometrics. The award consists includes a \$1,000 honorarium, one complimentary SAF convention registration, and up to \$500 to offset travel expenses. The award is presented at the SAF national convention.				
037524	Robert E. Henkin Government Relations Fellowship	Society of Nuclear Medicine and Molecular Imaging Education and Research Foundation		01-Mar-2021	1,000 USD
	Contact Name Contact Telephone 703-708-9000				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email grants&awards@snmmi.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Mar-2021</p> <p>Synopsis The Robert E. Henkin Fellowship is designed to provide early-career professionals in nuclear medicine and molecular imaging direct personal exposure to government relations activities of the SNMMI as well as the state and federal legislative and regulatory processes. The Fellow receives a \$1,000 stipend, in addition to all-expense paid travel to the Washington DC area.</p>				
091400	Early Career Awards	Thrasher Research Fund		16-Mar-2021	25,000 USD
	<p>Contact Name</p> <p>Contact Telephone 801-240-4753</p> <p>Contact Email</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Mar-2021 , 07-May-2021 , 14-Sep-2021 , 05-Nov-2021</p> <p>Synopsis The Fund recognizes that young investigators may find it difficult to remain in pediatric research because of a lack of funding. Therefore, the purpose of this program is to encourage the development of medical research in child health by awarding small grants to new researchers, helping them gain a foothold in this important area. The goal is to fund applicants who will go on to be independent investigators. The Fund will make up to 30 awards total with two funding cycles (15 awards each).</p>				
079439	Biomedical Research Advances for Space Health (BRASH) 2101	Translational Research Institute for Space Health	TRISHRFA1802PD	30-Mar-2021	1,000,000 USD
	Contact Name Kristin Fabre, Ph.D.				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 713-357-1038</p> <p>Contact Email SpaceHealth-Info@bcm.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 30-Mar-2021</p> <p>Synopsis TRISH is seeking and funding emerging scientific and Biomedical Research Advances for Space Health (BRASH), disruptive technologies, therapies, and new approaches that reduce risks to human health and performance during deep space exploration. The annual budget is capped at \$500K per year for up to two years (direct plus indirect costs). The 10% cost-sharing minimum must be added on top of the maximum budget of \$500K per year.</p>				

026175	Autism Research Postdoctoral Training Program	UC Davis MIND Institute		01-Mar-2021	Not Specified
--------	---	-------------------------	--	-------------	---------------

	<p>Contact Name Diane Larzelere</p> <p>Contact Telephone 916-703-0280</p> <p>Contact Email larzelere@ucdavis.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Mar-2021</p> <p>Synopsis The UC Davis MIND Institute offers a postdoctoral training program to prepare Ph.D. and M.D. fellows for careers in autism research. The goal of this program is to train truly interdisciplinary autism research scientists. The MIND Institute and UC Davis provide a unique environment for conducting postdoctoral research on multiple aspects of autism.</p>				
--	--	--	--	--	--

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
059714	Ara Parseghian Medical Research Fund (APMRF) at Notre Dame (ND) Research Grants	University of Notre Dame		01-Mar-2021 [LOI/Pre-App]	Not Specified
	Contact Name				
	Contact Telephone	574-631-4689			
	Contact Email	skassen@nd.edu			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Mar-2021 [LOI/Pre-App], 01-May-2021			
	Synopsis	The mission of the APMRF is to promote research that furthers understanding of the molecular basis of Niemann Pick Type C (NPC) disease and targets development of novel strategies to treat and/or cure the disease. For more information please read the rest of the RFP including the General Information section.			
091395	Wylie Scholar Program	Vascular Cures		01-Mar-2021	150,000 USD
	Contact Name				
	Contact Telephone	650-368-6022			
	Contact Email	info@vascularcures.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Mar-2021			
	Synopsis	Vascular Cures' Wylie Scholar Program is building a pipeline of innovators in vascular health. The sponsor provides 3-year career development grants to outstanding young vascular surgeon-scientists who combine active patient care with academic research. The award supports crucial research that enables them to compete for future research funding. Wylie Scholars become North America's world-class vascular surgeon-scientists; many are now chiefs at major academic centers, prominent leaders in the field, and play a key role in programs.			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
059991	Grants Program	World Diabetes Foundation		01-Mar-2021	Not Specified
	Contact Name				
	Contact Telephone	+45 44 42 25 56			
	Contact Email	contact@worlddiabetesfoundation.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Mar-2021 , 01-Sep-2021			
	Synopsis	The World Diabetes Foundation (WDF) funds projects devoted to improving diabetes care and prevention in low- and middle income countries.			
024768	Collaborative Research Grants	Zoos Victoria		19-Mar-2021	Not Specified
	Contact Name	Dr Michael Magrath, Senior Research Manager, Wildlife Conservation & Science			
	Contact Telephone	+61-3 9340 2752			
	Contact Email	research@zoo.org.au			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	19-Mar-2021 , 21-May-2021 , 23-Jul-2021 , 17-Sep-2021 , 12-Nov-2021			
	Synopsis	Zoos Victoria welcomes collaborative research proposals. These could involve the use of Zoos Victoria resources, active collaboration with Zoos Victoria staff or independent research at one of Zoos Victoria's three properties: Melbourne Zoo, Werribee Open Range Zoo or Healesville Sanctuary.			